Surface marker modification of fibroblasts to target cells to specific tissue and organs for therapeutic use

Abstract

The present disclosure concerns genetic modification of fibroblasts or fibroblast-derived materials (including of the fibroblasts from which the fibroblast-derived materials are derived). In specific aspects, they are modified such that they may express one or more surface markers that allow targeting to a tissue and / or organ of interest. In some aspects, they are modified such that they may lose one or more surface markers that then allow targeting to a tissue and / or organ of interest. In certain aspects, one or more surface markers are modified that then allows targeting to a tissue and / or organ of interest.

Description

SURFACE MARKER MODIFICATION OF FIBROBLASTS TO TARGET CELLS TO SPECIFIC TISSUE AND ORGANS FOR THERAPEUTIC USECROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of priority to U.S. Provisional Patent Application Serial No. 63 / 707,129, filed 14 October 2024, the contents of which are hereby incorporated by reference in their entirety.TECHNICAL FIELD

[0002] Aspects of the disclosure concern at least the fields of cell biology, molecular biology, immunology, and medicine.BACKGROUND

[0003] Fibroblasts are no longer considered as mere structural components of organs but as dynamic participants in cell differentiation, tissue regeneration, immune modulation, and maintenance of stem cell niches in multiple organs[l-8],

[0004] Since its identification and characterization, CRISPR / Cas and similar gene editing technologies have become an invaluable tool in inserting, deleting, and / or modifying nucleotides, including entire genes, as a tool in treating diseases, diagnostics, and generating knock-out and knock-in animal models for use in pre-clinical studies[9], as examples.

[0005] One of the most prevalent issues with the currently approved small molecule and antibody -based therapeutics has been the off-target effects leading to significant side effects and long-term, short-term health, and quality of life impact. As far as tissue regeneration is concerned, the invasive modes of stem cell administration have been a major hurdle in patient compliance and utilization.

[0006] The present disclosure concerns solutions for long-felt needs in the art of tissue regeneration and targeting of cells to specific tissues or organs.1299833684.1BRIEF SUMMARY

[0007] Aspects of the disclosure encompass modifying one or more surface markers (including proteins, glycoproteins, and / or lipoproteins of fibroblasts and / or or stem cells (of any kind) or stem-cell derived products, and / or fibroblast-derived materials. In specific aspects, the modification allows targeting fibroblasts and / or stem cells and / or fibroblast-derived materials to a specific location or organ of interestfl 0-12], including in an individual. In particular aspects, there are methods and compositions that encompass the targeting of tissues and / or organs of interest, such as for immune modulation, tissue repair, regeneration, and / or stem cell niche activation and / or migration, as examples. In certain aspects, the modified (the term “modified” may be used interchangeably herein with the term “engineered”) cells / cell-derived products allow for targeted administration of modified single cell fibroblasts, fibroblast spheroids, exosomes (such as from fibroblasts), apoptotic cells (of fibroblast origin), conditioned media (such as from culture of fibroblasts), lysate (such as from fibroblasts), apoptotic bodies (such as from fibroblasts) and / or fibroblast-derived products of any kind. In specific aspects, the modified single cell fibroblasts, modified fibroblast spheroids, exosomes from fibroblasts, apoptotic cells from fibroblasts, lysate from fibroblasts, conditioned medium from fibroblasts and / or any other fibroblast-derived products target directly towards a tissue of interest and, in specific aspects only, may be administered subcutaneously or intravenously. Although the engineering of the noted products may be by any suitable method, in specific aspects it is by using CRISPR / CAS9, novel Cas Nucleases (NCN), CasMINI, Cas-CLOVER, Prokaryotic Argonautes (NgAgo), Zinc Finger Nucleases (ZFNs), and / or Transcription activator-Like Effector Nucleases (TALENs), as examples.

[0008] Aspects of the disclosure encompass compositions, methods, and systems for using any type of gene modification for the modification or introduction of one or more surface markers on single cell fibroblasts, fibroblast spheroids, exosomes, apoptotic cells, and so forth. In particular aspects, engineering can be used to add, delete, and / or modify one or more fibroblast cell surface markers that results in the targeting of the products to a specific organ or tissue of interest. In particular aspects, there is engineering of a tissue-specific antigen to the membranebound portion of a surface marker such that the tissue-specific or organ-specific antigencomprising surface marker is able to target to a specific tissue or organ, respectively, when the modified fibroblasts (or fibroblast-derived materials) are administered to an individual. The2299833684.1administering may occur by any manner, including topically, intravenously, subcutaneously, intraperitoneally, or intrathecally, as examples only. In particular aspects, the disclosure concerns interaction of a first type of cells with a second type of cells and / or certain agent(s) and includes modification(s) to the first and / or second type of cells as a result of the interaction. In specific aspects, the disclosure includes compositions, methods, and systems in which the modified fibroblasts may be further modified upon exposure to certain cells and / or one or more of a combination of certain agent(s), including nucleic acids, cytokines, chemokines, and / or growth factors. Introduction of these modified fibroblasts into an individual in need can then target specific tissues or organs for tissue repair, regeneration, immune modulation, and / or recruitment of stem cells or other type of cells into the tissue or organ of interest, in specific aspects.

[0009] Aspects of the disclosure include differentiation at a tissue and / or organ of interest following introduction of modified single cell fibroblasts, fibroblast spheroids, exosomes from fibroblasts, lysates from fibroblasts, apoptotic cells from fibroblasts and / or other fibroblast- derived materials of any kind, and in some aspects, the introduction to the individual is topically, intravenously, subcutaneously, intraperitoneally, and / or intrathecally. Aspects of the disclosure encompass epigenetic reprogramming of senescent or pathogenic fibroblasts, keratinocytes, epithelial cells, and / or immune cells (such as macrophages, neutrophils, T cells NK cells, and / or B cells), such as through indirect or direct contact with the modified or unmodified single cell fibroblasts, fibroblast spheroids, and / or other fibroblast-derived materials. Aspects of the disclosure include reprogramming or activating by-products (e.g., microsomes, exosomes, apoptotic bodies, growth factors, cytokines, chemokines) excreted from the modified or unmodified single cell fibroblasts, fibroblast spheroids, and / or other fibroblast-derived materials in the targeted tissue and / or organ microenvironment. Aspects of the disclosure include tissuespecific and / or organ-specific recruitment, activation, and / or differentiation of local stem cells into active tissue-specific or organ-specific fibroblasts, and / or tissue- or organ-specific cells, such as through the direct or indirect action of the delivered and targeted modified or unmodified single cell fibroblasts, fibroblast spheroids, exosomes from fibroblasts, lysates from fibroblasts, apoptotic cells from fibroblasts and / or fibroblast-derived materials from the modified or unmodified fibroblasts.3299833684.1

[0010] Aspects of the disclosure encompass modulation of the immune system upon administration of single cell fibroblasts, fibroblast spheroids, exosomes from fibroblasts, apoptotic cells from fibroblasts, and / or other fibroblast-derived materials to control the expansion and localization of pathogenic immune cells, including of their expression of pathogenic level of cytokine, chemokines, and / or growth factors, including those associated with inflammation. In specific aspects, these or related compositions control the expansion and localization of pathogenic immune cells, such as T cells, dendritic cells macrophages, and / or neutrophils, or any cells that expressing pathogenic levels of chemokines, cytokines, and / or growth factors. Any compositions of the disclosure may be administered topically, intravenously, subcutaneously, intraperitoneally, and / or intrathecally, in specific aspects.

[0011] In specific aspects, the disclosure concerns compositions, methods, and systems in which certain cells are modified upon exposure to fibroblasts and / or exposure to certain agent(s) excreted from fibroblasts. In particular aspects, the interaction of fibroblasts with one or more other types of cells (and in some aspects that interaction also includes one or more certain agent(s)) results in modification of the fibroblasts and / or other type(s) of cells. In specific aspects, the other types of cells include at least immune cells of any kind.

[0012] In specific aspects, methods of the disclosure occur ex vivo, such as all of the modification of the fibroblasts using CRISPR / CAS9, novel Cas Nucleases (NCN), CasMINI, Cas-CLOVER, Prokaryotic Argonautes (NgAgo), Zinc Finger Nucleases (ZFNs), and / or Transcription activator-Like Effector Nucleases (TALENs), including in a culture, although in some aspects part or all methods may also occur in vivo or in vitro. In particular cases, the methods of the disclosure occur by the hand of man and do not encompass ordinary or random occurrences in a body. The methods of the disclosure are non-natural, in particular aspects. In specific aspects, the concentrations of cells used in any method encompassed herein, including of exposing one type of cells to another type of cells, does not occur in nature and does not happen randomly in nature. In specific aspects, the concentrations of cells used in any method encompassed herein, including of exposing one type of cells to another type of cells, occurs at a rate greater than would occur in nature or randomly occur in nature. In specific aspects, the concentration of one or more agents used in a method of exposing one or more agents to one or more types of cells does not occur in nature and does not happen randomly in nature. In specific aspects, the concentration of one or more agents used in a method of exposing one or more agents4299833684.1to one or more types of cells occurs at a rate greater than would occur in nature or randomly occur in nature. The modification of any types of cells encompassed by the disclosure that occurs ex vivo or in vitro does not occur in vivo naturally in the same manner. In such an aspect, tissue biopsy from a donor may be used to isolate, characterize (if necessary), activate, expand, modify, and / or reintroduce back into the donor one or a combination of the cells or cellular products for any purpose, including for the purpose of modulating the immune system, reprogramming local keratinocytes, fibroblasts, and / or epithelial cells.

[0013] In at least some cases, the single cell fibroblasts, fibroblast spheroids, or other fibroblast-derived materials have been modified prior to their exposure to immune cells and / or other cells of any kind, such as found in the blood and / or skin tissue. Such modification may be chemically, physically, or epigenetically activated, and / or exposed to conditions that are not normally found in the body. The disclosure encompasses therapeutic uses of cells, including epithelial cells, keratinocytes, epithelial cells, dendritic cells, macrophages, B lymphocytes, T lymphocytes, myeloid cells, endothelial cells, fibroblasts, immune cells, or mixtures thereof. In other cases, immune cells, or their derivatives, have been modified, such as activated, prior to their exposure to fibroblasts.

[0014] Aspects of the disclosure provide means of utilizing fibroblasts as allogeneic, autologous (or xenogeneic or syngeneic) therapeutic cells, such as through modification of culture conditions. In one aspect of the disclosure, fibroblasts are extracted from sources with lower immunogenicity (e.g., placental fibroblasts, omental tissue derived fibroblasts, cord blood derived fibroblasts, foreskin fibroblasts, etc.) and utilized.

[0015] In one aspect of the disclosure, single cell fibroblasts, and / or fibroblast-derived materials (including spheroids) are cultured in vitro, such as for preserving viability and proliferative ability of fibroblasts. In some aspects, the disclosure provides for the modification of known culture techniques to decrease recognition of fibroblasts by the recipient immune system. In one aspect, fibroblasts and / or fibroblast spheroids are cultured in conditions that lack xenogeneic components, such as xenogeneic-free medium; in some cases, for example, the media is free of fetal calf serum. In specific aspects, the disclosure encompasses the substitution of fetal calf serum with one or more other agents, such as those that facilitate reduction of immunogenicity of fibroblasts, for example, human platelet rich plasma, platelet lysate, umbilical cord blood serum, autologous serum, and / or one or more defined cytokines, such as5299833684.1one or a combination of fibroblast growth factor, epidermal growth factor, leukemia inhibitory factor, insulin like growth factor, angiopoietin, and vascular endothelial growth factor.

[0016] In one aspect of the disclosure, effective amounts of single cell fibroblasts, fibroblast spheroids, or any fibroblast-derived materials as prepared in methods encompassed by the disclosure are administered to an individual for a therapy or prevention of one or more medical conditions. In specific aspects, the fibroblasts and / or fibroblast-derived materials are administered to improve keratinocyte, epithelial, fibroblast, and / or tissue- or organ-specific resident immune cell responsiveness, modulation of immune cell activity, and / or cell differentiation. In such cases, the administration of the fibroblasts and / or fibroblast-derived materials results in the amelioration of at least one symptom of a medical condition.

[0017] Aspects of the disclosure provide methods for co-administration of universal donor single cell fibroblasts, fibroblast spheroids, or fibroblast-derived materials with one or more agents that modulate immune cell activity in a desired tissue or organ microenvironment. In a specific aspect of the disclosure, methods are provided for co-administration of universal donor single cell fibroblasts, fibroblast spheroids, or other fibroblast-derived materials with one or combination of growth factors, chemokines, and / or cytokines. In one aspect of the disclosure, universal donor fibroblasts derived from fibroblasts that have been treated under conditions to reduce immunogenicity and / or modified as described elsewhere herein to target specific tissues and / or organs of interest are utilized to stimulate vascular endothelial growth factor (VEGF) production by the introduced modified / unmodified fibroblasts or from endogenous cells under the regulatory control of nerve growth factor (NGF) of the individual, thereby leading to tissue regeneration and / or revascularization of a damaged tissue or organ of interest of any kind.

[0018] Aspects of the disclosure provide methods of reducing immunogenicity of particular types of fibroblasts. Single cell fibroblasts, fibroblast spheroids, exosomes from fibroblasts, lysates from fibroblasts, conditioned media from fibroblasts, apoptotic cells from fibroblasts or other fibroblast-derived materials may be obtained from one or more tissues or organs, including, but not limited to skin, heart, blood vessels, bone marrow, skeletal muscle, liver, pancreas, brain, foreskin, kidney, placenta, intestine, cartilage, lung, thymus, adipose tissue, which may be obtained by biopsy (where appropriate) or upon autopsy. In some aspects, the cells comprise fibroblasts, which can be from a fetal, neonatal, adult origin, or a combination thereof.6299833684.1

[0019] Single cell fibroblasts, fibroblast spheroids, exosomes from fibroblasts, lysates from fibroblasts, conditioned media from fibroblasts, apoptotic cells from fibroblasts, or other fibroblast-derived materials or products for use in any methods of the disclosure may be exposed to certain medium component(s), in specific aspects.

[0020] Aspects of the disclosure encompass methods of engineering fibroblasts, fibroblastlike cells, fibroblast-derived materials, stem cells, or stem cell-derived materials, comprising the step of adding, removing, and / or modifying one or more surface markers, or tissue-specific antigen bound thereto, on the respective fibroblasts, fibroblast-like cells, fibroblast-derived materials or fibroblast fragments, stem cells, or stem cell-derived materials, said markers selected from the group consisting of the markers in Marker List I, to thereby migrate to or target one or more specific tissues and / or one or more organs of interest with the engineered fibroblasts, fibroblast-like cells, fibroblast-derived materials, stem cells, or stem cell-derived materials. In specific aspects, one or more markers are removed from the fibroblasts, fibroblast-like cells, fibroblast-derived materials, stem cells, or stem cell-derived materials. In some aspects, one or more markers are added to the fibroblasts, fibroblast-like cells, fibroblast-derived materials, stem cells, or stem cell-derived materials. In certain aspects, one or more markers of the fibroblasts, fibroblast-like cells, fibroblast-derived materials, stem cells, or stem cell-derived materials are modified. The engineering may be by any manner, but in specific aspects the engineering step comprises use of CRISPR / CAS9, novel Cas Nucleases (NCN), CasMINI, Cas-CLOVER, Prokaryotic Argonautes (NgAgo), Zinc Finger Nucleases (ZFNs), and / or Transcription activator-Like Effector Nucleases (TALENs). The engineering process may be in vivo, ex vivo, and / or in vitro.

[0021] In some aspects, disclosed is one or more engineered fibroblasts, one or more engineered fibroblast-like cells, one or more engineered fibroblast-derived materials, one or more engineered stem cells, or one or more engineered stem cell-derived materials, produced according one or more methods of the disclosure.

[0022] The fibroblasts, fibroblast-like cells, fibroblast-derived materials, stem cells, or stem cell-derived materials may be autologous, allogeneic, xenogeneic, or syngenetic with respect to an individual. In some aspects, disclosed is a composition comprising a population of fibroblasts, fibroblast-like cells, fibroblast-derived materials, stem cells, and / or stem cell-derived materials of the disclosure. In some aspects, the population comprises at least 70%, 71%, 72%, 73%, 74%,7299833684.175%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100% of fibroblasts, fibroblast-like cells, fibroblast-derived materials, stem cells, and / or stem cell-derived materials of the disclosure.

[0023] In certain aspects of the method, wherein the fibroblast-derived material comprises exosomes from fibroblasts, including exosomes derive from the engineered fibroblasts. The method may further comprise the step of collecting exosomes from the engineered fibroblasts. In some aspects, disclosed is a composition comprising fibroblast-derived material comprises exosomes from fibroblasts, including exosomes derive from the engineered fibroblasts, wherein the composition comprises less than 30%, 29%, 28%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% of cells of any kind.

[0024] In some aspects, the fibroblast-derived material comprises organoids comprising fibroblasts, optionally wherein the organoids are spheroids. In some aspects, the fibroblast- derived material comprises organoids comprising the engineered fibroblasts, optionally wherein the organoids are spheroids. The method may further comprise the step of generating organoids from the engineered fibroblasts. In specific aspects, the fibroblast-derived material comprises fibroblast cells separated from organoids comprising fibroblasts. In some aspects, the organoids are generated from the engineered fibroblasts. The method may comprise the step of generating the organoids from the engineered fibroblasts.

[0025] In certain aspects, the fibroblast-derived material comprises lysate from fibroblasts, including lysate from the engineered fibroblasts. The method may comprise the step of generating the lysate from the engineered fibroblasts. In some aspects, disclosed is a composition comprising lysate from fibroblasts, including lysate from the engineered fibroblasts, wherein the composition comprises less than 30%, 29%, 28%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% of cells of any kind.

[0026] In particular aspects, the fibroblast-derived material comprises conditioned media from culture of fibroblasts, such as conditioned media is from culture of the engineered fibroblasts. The method may further comprise the step of generating the conditioned media from the engineered fibroblasts. In some aspects, disclosed is a composition comprising conditioned media from culture of fibroblasts, such as conditioned media is from culture of the engineered8299833684.1fibroblasts, wherein the composition comprises less than 30%, 29%, 28%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% of cells of any kind.

[0027] In some aspects, the fibroblast-derived material comprises apoptotic bodies from fibroblasts, such as apoptotic bodies from the engineered fibroblasts. The method may comprise the step of generating the apoptotic bodies from the engineered fibroblasts. In some aspects, disclosed is a composition comprising apoptotic bodies from fibroblasts, such as apoptotic bodies from the engineered fibroblasts, wherein the composition comprises less than 30%, 29%, 28%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% of cells of any kind.

[0028] In particular aspects, the antigen and / or the one or more markers is associated with liver, lung, thymus, intestines, kidney, pancreas, bone marrow, skeletal muscle, heart, and / or brain tissue or organs.

[0029] Aspects of the methods may comprise administering the engineered fibroblasts, fibroblast-like cells, fibroblast-derived materials, stem cells, or stem cell-derived materials, or compositions of the disclosure to an individual in need thereof. Methods may comprise the step of administering one or more type of immune cells or derivative agents thereof or compositions of the disclosure to an individual in need thereof. Such immune cells may be T cells, natural killer cells, natural killer T cells, dendritic cells, macrophages, B cells, monocytes, or a mixture thereof. In specific aspects, the engineered fibroblasts, fibroblast-like cells, fibroblast-derived materials, stem cells, or stem cell-derived materials are administered topically, intravenously, subcutaneously, intraperitoneally, and / or intrathecally. The engineered fibroblasts, fibroblastlike cells, fibroblast-derived materials, stem cells, or stem cell-derived materials are administered into any tissue or organ of interest. The administering may be into the blood stream or tissue or organ of interest of the individual.

[0030] In at least some methods the engineered fibroblasts, fibroblast-like cells, fibroblast- derived materials, stem cells, or stem cell-derived materials may be administered locally, by injection, or systemically. The administering may result in direct or indirect modulation of the expansion and proliferation of pathogenic immune cells in the individual; direct or indirect modulation of expression of pathogenic levels of cytokines, chemokines, and / or growth factors; direct or indirect epigenetic reprogramming of localized fibroblasts and / or non-fibroblast cells9299833684.1associated with the targeted tissue or organ of interest; direct or indirect enabling of the activation and / or migration of localized stem cell niches to replace pathogenetic fibroblasts or other targeted tissue-specific or organ-specific cells; and / or directly or indirectly results in locally activate tissue regeneration.

[0031] In specific aspects, the administering is to a tissue or organ of interest of the individual using a biologic or other material-encapsulating device to assist in protection and / or dispersion of clinical benefits to the individual. The biologic or other material-encapsulating device may comprise organic biomaterial. The biologic or other material-encapsulating device may comprise alginate, agarose, collagen, and chitosan. The material-encapsulating device may comprises one or more synthetic polymers, such as polyethylene glycol (PEG), poly(lactic- glycolic acid) (PLGA), poly(lactic acid) (PLA), poly(glycolic acid (PGA), or a combination thereof.

[0032] In some aspects, the fibroblasts and / or fibroblast-derived materials are activated with one or more agents and optionally one or more types of immune cells or derivative agent(s) thereof. The fibroblasts and / or fibroblast-derived materials may be activated upon ex vivo treatment with one or more cytokines, one or more chemokines, one or more growth factors, one or more epigenetic modifiers, scRNA. microRNA, RNAi, or a combination thereof. In some aspects, the administering utilizes one or more adjuvants with the engineered fibroblasts, fibroblast-like cells, fibroblast-derived materials, stem cells, or stem cell-derived materials. The administering may directly or indirectly activate the immune system of the individual. The one or more adjuvants may be chemical-based, viral-based, or bacterial-based, including an adjuvant that is selected from the group consisting of a mineral adjuvant, emulsion adjuvant, polymeric adjuvant, saponin, derivative of the complement system, cytokine, a bacterial -derived adjuvant, and a combination thereof.

[0033] Any method encompassed herein may include administering encapsulated RNA, microRNA, and / or RNAi to the individual. The RNA, microRNA, or RNAi may be directed to a transcription factor, cytosolic protein, or nuclear protein. The encapsulation may be by lipids, nano-particles, glycolipids, membranes, or a combination thereof.

[0034] The foregoing has outlined rather broadly the features and technical advantages of the present disclosure in order that the detailed description of the disclosure that follows may be better understood. Additional features and advantages of the disclosure will be described10299833684.1hereinafter which form the subject of the claims of the disclosure. It should be appreciated by those skilled in the art that the conception and specific aspects disclosed may be readily utilized as a basis for modifying or designing other structures for carrying out the same purposes of the present disclosure. It should also be realized by those skilled in the art that such equivalent constructions do not depart from the spirit and scope of the disclosure as set forth in the appended claims. The novel features which are believed to be characteristic of aspects of the disclosure, both as to its organization and method of operation, together with further objects and advantages will be better understood from the following description when considered in connection with the accompanying figures. It is to be expressly understood, however, that each of the figures is provided for the purpose of illustration and description only and is not intended as a definition of the limits of the present embodiments of the disclosure.DETAILED DESCRIPTION

[0035] The illustrative aspects described at least in the detailed description and claims are not meant to be limiting. Other aspects may be utilized, and other changes may be made, without departing from the spirit or scope of the subject matter presented herein. It will be readily understood that the aspects of the present disclosure, as generally described herein, may be arranged, substituted, combined, separated, and designed in a wide variety of different configurations, all of which are explicitly contemplated herein.

[0036] The following description of various aspects is exemplary and explanatory only and is not to be construed as limiting or restrictive in any way. Other aspects, features, objects, and advantages of the present teachings will be apparent from the description and accompanying drawings, and from the claims.

[0037] The disclosure herein uses affirmative language to describe the numerous aspects. The disclosure also includes aspects in which subject matter is excluded, in full or in part, such as substances or materials, method steps and conditions, protocols, or procedures.

[0038] It should be understood that any use of subheadings herein are for organizational purposes, and should not be read to limit the application of those subheaded features to the various aspects herein. Each and every feature described herein is applicable and usable in all the various aspects discussed herein and that all features described herein can be used in any contemplated combination, regardless of the specific example aspects that are described herein.11299833684.1It should further be noted that exemplary description of specific features are used, largely for informational purposes, and not in any way to limit the design, subfeature, and functionality of the specifically described feature.

[0039] Particular aspects of this application are described herein. Variations on those particular aspects will become apparent to those of ordinary skill in the art upon reading the foregoing description. It is contemplated that skilled artisans can employ such variations as appropriate, and the application can be practiced otherwise than specifically described herein. Accordingly, many aspects of this application include all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the application unless otherwise indicated herein or otherwise clearly contradicted by context. The various methods and techniques described above provide a number of ways to carry out the disclosure. Of course, it is to be understood that not necessarily all objectives or advantages described can be achieved in accordance with any particular aspect described herein. Thus, for example, those skilled in the art will recognize that the methods can be performed in a manner that achieves or optimizes one advantage or group of advantages as taught herein without necessarily achieving other objectives or advantages as taught or suggested herein. A variety of alternatives are mentioned herein. It is to be understood that some particular aspects specifically include one, another, or several features, while others specifically exclude one, another, or several features, while still others mitigate a particular feature by inclusion of one, another, or several advantageous features.

[0040] Furthermore, the skilled artisan will recognize the applicability of various features from different aspects. Similarly, the various elements, features and steps discussed above, as well as other known equivalents for each such element, feature or step, can be employed in various combinations by one of ordinary skill in this art to perform methods in accordance with the principles described herein. Among the various elements, features, and steps some will be specifically included and others specifically excluded in diverse aspects.

[0041] Although the application has been disclosed in the context of certain aspects and examples, it will be understood by those skilled in the art that the aspects of the disclosure extend beyond the specifically disclosed aspects to other alternative aspects and / or uses and modifications and equivalents thereof.12299833684.1I. Examples of Definitions

[0042] Unless otherwise noted, terms are to be understood according to conventional usage by those of ordinary skill in the relevant art. For purposes of the present disclosure, the following terms are explained below.

[0043] In keeping with long-standing patent law convention, the words “a” and “an” when used in the present specification in concert with the word comprising, including the claims, denote “one or more.” Some aspects of the disclosure may consist of or consist essentially of one or more elements, method steps, and / or methods of the disclosure. It is contemplated that any method or composition described herein can be implemented with respect to any other method or composition described herein.

[0044] Furthermore, “and / or” where used herein is to be taken as specific disclosure of each of the specified features or components with or without the other. Thus, the term “and / or” as used in a phrase such as “A and / or B” herein is intended to include “A and B,” “A or B,” “A” (alone), and “B” (alone).

[0045] As used herein, the term “about” or “approximately” refers to a quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length that varies by as much as 30, 25, 20, 25, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 % to a reference quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length. In particular aspects, the terms “about” or “approximately” when preceding a numerical value indicates the value plus or minus a range of 15%, 10%, 5%, or 1%. With respect to biological systems or processes, the term can mean within an order of magnitude, such as within 5-fold, or such as within 2-fold, of a value. Unless otherwise stated, the term ' about' means within an acceptable error range for the particular value.

[0046] As used herein, the term “activated cells” refers to cells treated with one or more stimuli capable of inducing one or more alterations in the cell: metabolic, immunological, epigenetic, growth factor secreting, surface marker expression, and production and excretion of microvesicles.

[0047] The term “administered” or “administering”, as used herein, refers to any method of providing a composition to an individual such that the composition has its intended effect on the individual. For example, one method of administering is by an indirect mechanism using a medical device such as, but not limited to a catheter, applicator gun, syringe etc. A second13299833684.1exemplary method of administering is by a direct mechanism such as, local tissue administration, oral ingestion, transdermal patch, topical, inhalation, injection, suppository etc.

[0048] As used herein, “allogeneic” refers to tissues or cells from another body that in a natural setting are immunologically incompatible or capable of being immunologically incompatible, although from one or more individuals of the same species.

[0049] As used herein, “autologous” refers to tissues or cells that are derived or transferred from the same individual's body ( / .< ., autologous blood donation; an autologous bone marrow transplant).

[0050] As used herein, “agent” refers to nucleic acids, cytokines, chemokines, transcription factors, epigenetics factors, growth factors, or hormones.

[0051] As used herein, “xenogeneic” refers to tissues or cells from a species different from the patient.

[0052] Cell culture” is an artificial in vitro system containing viable cells, whether quiescent, senescent or (actively) dividing. In a cell culture, cells are grown and maintained at an appropriate temperature, typically a temperature of 37°C and under an atmosphere typically containing oxygen and CO2. Culture conditions may vary widely for each cell type though, and variation of conditions for a particular cell type can result in different phenotypes being expressed. The most commonly varied factor in culture systems is the growth medium. Growth media can vary in concentration of nutrients, growth factors, and the presence of other components. The growth factors used to supplement media are often derived from animal blood, such as calf serum.

[0053] The term “hypoxia” as used herein can refer to the culture of cells, including fibroblasts or modified fibroblasts, under conditions comprising less than 5%, 4%, 3%, 2%, 1% or any range or value derivable therebetween. Cell can be cultured in hypoxic conditions for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more minutes, hours, days, weeks, or months.

[0054] Throughout this specification, unless the context requires otherwise, the words “comprise”, “comprises” and “comprising” will be understood to imply the inclusion of a stated step or element or group of steps or elements but not the exclusion of any other step or element or group of steps or elements. By “consisting of’ is meant including, and limited to, whatever follows the phrase “consisting of.” Thus, the phrase “consisting of’ indicates that the listed14299833684.1elements are required or mandatory, and that no other elements may be present. By “consisting essentially of’ is meant including any elements listed after the phrase, and limited to other elements that do not interfere with or contribute to the activity or action specified in the disclosure for the listed elements. Thus, the phrase “consisting essentially of’ indicates that the listed elements are required or mandatory, but that no other elements are optional and may or may not be present depending upon whether or not they affect the activity or action of the listed elements.

[0055] The term “individual”, as used herein, refers to a human or animal that may or may not be housed in a medical facility and may be treated as an outpatient of a medical facility. The individual may be receiving one or more medical compositions via the internet. An individual may comprise any age of a human or non-human animal and therefore includes both adults and juveniles (z.e., children) and infants. It is not intended that the term “individual” connotes a need for medical treatment, therefore, an individual may voluntarily or involuntarily be part of experimentation whether clinical or in support of basic science studies. The term “subject” or “individual” may be used interchangeably and refers to any organism or animal subject that is an object of a method or material, including mammals, e.g., humans, laboratory animals (e.g., primates, rats, mice, rabbits), livestock (e.g., cows, sheep, goats, pigs, turkeys, and chickens), household pets (e.g., dogs, cats, and rodents), horses, and transgenic non-human animals.

[0056] As used herein, the term “engineered” refers to refers to an aspect of having been manipulated and altered by the hand of man. In particular, the term “engineered cell” refers to a cell that has been subjected to a manipulation, so that its genetic, epigenetic, functional, and / or phenotypic identity is altered relative to an appropriate reference cell such as otherwise identical cell that has not been so manipulated. In some aspects, the manipulation is or comprises a genetic manipulation, such as gene editing, base editing, and gene therapy. In some aspects, an engineered cell is one that has been manipulated so that it contains and / or expresses a particular agent of interest (e.g., a protein, a nucleic acid, and / or a particular form thereof) in an altered amount (such as increased or decreased) and / or according to altered timing relative to such an appropriate reference cell.

[0057] As used herein, the terms “genetically altered” or “genetically modified” refer to a cell in which a genomic DNA sequence has been deliberately modified by recombinant technology.15299833684.1

[0058] As used herein the term “disrupted expression” may encompass both functional and structural disruption. Disrupted expression may refer to the permanent alteration or inactivation of a specific gene's function or expression, typically achieved through the introduction of insertions or deletions, or point mutations, at targeted genomic locus / loci within the gene or outside. In an aspect, the disrupted expression may result in complete loss of expression of a gene (e.g., knockout). In an aspect, the disrupted expression may result in reduction in the level of the specific gene product. Thus the gene may be expressed at less than 90%, less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, less than 1% of its endogenous expression level in the cell.

[0059] The term “modulation of expression” can refer to increasing or decreasing the expression of a gene compared to a control cell or population of cells. A control may be a cell or population of cells before being modified, engineered, activated, or otherwise manipulated to modulate expression.

[0060] The terms “increased” or “increase” or “upregulated” or “upregulate” as used herein generally mean an increase by a statically significant or practical (e.g., for the purposes of characterization) amount relative to a reference. For avoidance of doubt, “increased” may mean an increase, statistically significant or otherwise, of at least 10% as compared to a reference level, including an increase of at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100% or more, including, for example at least 1.1- fold, at least 2-fold, at least 3 -fold, at least 4-fold, at least 5-fold, at least 10-fold increase or greater as compared to a reference level, or any value therebetween.

[0061] The term “reduced” or “reduce” or “decrease” or “decreased” or “downregulate” or “downregulated” as used herein generally means a decrease by a statistically significant or practical (e.g., for the purposes of characterization) amount relative to a reference. For avoidance of doubt, “reduced” may mean a decrease, statistically significant or otherwise, of at least 10% as compared to a reference level, for example a decrease by at least 20%, at least 30%, at least 40%, at least 50%, or at least 60%, or at least 70%, or at least 80%, at least 90% or more, up to and including a 100% decrease (i.e., absent level as compared to a reference sample), or any decrease between 10-100% as compared to a reference level, or any value therebetween.16299833684.1

[0062] The term “fibroblast-derived materials” as used herein refers at least to exosomes from fibroblasts, organoids comprising fibroblasts (including spheroids), fibroblast cells separating from fibroblast organoids / spheroids, lysate from fibroblasts, conditioned media from culture of fibroblasts, and / or apoptotic bodies from fibroblasts, etc.

[0063] Reference throughout this specification to “one aspect,” “an aspect,” “a particular aspect,” “a related aspect,” “a certain aspect,” “an additional aspect,” or “a further aspect” or combinations thereof means that a particular feature, structure or characteristic described in connection with the aspect is included in at least one aspect of the present disclosure. Thus, the appearances of the foregoing phrases in various places throughout this specification are not necessarily all referring to the same aspect. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more aspects.

[0064] The terms “reduce,” “inhibit,” “diminish,” “suppress,” “decrease,” “prevent” and grammatical equivalents (including “lower,” “smaller,” etc. when in reference to the expression of any symptom in an untreated subject relative to a treated subject, mean that the quantity and / or magnitude of the symptoms in the treated subject is lower than in the untreated subject by any amount that is recognized as clinically relevant by any medically trained personnel. In one aspect, the quantity and / or magnitude of the symptoms in the treated subject is at least 10% lower than, at least 25% lower than, at least 50% lower than, at least 75% lower than, and / or at least 90% lower than the quantity and / or magnitude of the symptoms in the untreated subject.

[0065] As used herein, the term “transplantation” refers to the process of taking living tissue or cells and implanting it in another part of the body or into another body.

[0066] Treatment,” “treat,” or “treating” means a method of reducing the effects of a disease or condition. Treatment can also refer to a method of reducing the disease or condition itself rather than just the symptoms. The treatment can be any reduction from pre-treatment levels and can be, but is not limited to, the complete ablation of the disease, condition, or the symptoms of the disease or condition. Therefore, in the disclosed methods, “treatment” can refer to a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% reduction in the severity of an established disease or the disease progression, including reduction in the severity of at least one symptom of the disease. For example, a disclosed method for reducing the immunogenicity of cells is considered to be a treatment if there is a detectable reduction in the immunogenicity of cells when compared to pre-treatment levels in the same subject or control subjects. Thus, the17299833684.1reduction can be a 10, 20, 30, 40, 50, 60, 70, 80, 90, 100%, or any amount of reduction in between as compared to native or control levels. It is understood and herein contemplated that “treatment” does not necessarily refer to a cure of the disease or condition, but an improvement in the outlook of a disease or condition. In specific aspects, treatment refers to the lessening in severity or extent of at least one symptom and may alternatively or in addition refer to a delay in the onset and / or severity of at least one symptom.

[0067] The term “therapeutically effective amount” refers to any amount of the fibroblasts and / or fibroblast-derived materials that, when used alone or in combination with one or more other therapeutic agents, protects a subject against the onset of a disease or promotes disease regression evidenced by a decrease in severity of one or more disease symptoms, an increase in frequency and duration of disease symptom-free periods, or a prevention of impairment or disability due to the disease affliction. The ability of a therapeutic agent to promote disease regression can be evaluated using a variety of methods known to the skilled practitioner, such as in human subjects during clinical trials, in animal model systems predictive of efficacy in humans, or by assaying the activity of the agent in in vitro assays.

[0068] The term “organoid” as used herein refers to self-organized, three-dimensional tissue cultures that are derived from cells that have key functional, structural, and biological complexity of an organ, in addition to self-renewal and differentiation capacities. In specific cases, the term applies to organoids having specific shapes or substantially similar to specific shapes, such as spheroids. In specific cases, the cells that have self-renewal and differentiation capacities are fibroblasts. In some aspects, the organoid is random in shape. In specific aspects, the organoid may be about 5 pm to 50,000 pm in size, or any value therebetween. In an aspect, the disclosed organoid may range in size from about 5 pm - 50 pm, about 50 pm - 60 pm, about 60 pm - 70 pm, about 70 pm - 80 pm, about 80 pm - 90 pm, about 90 pm - 100 pm, about 100 pm - 1,500 pm, about 1,500 pm - 2,000 pm, about 2,000 pm - 3,000 pm, about 3,000 pm - 4,000 pm, about 4,000 pm - 5,000 pm, about 5,000 pm - 6,000 pm, about 6,000 pm - 7,000 pm, about 7,000 pm - 8,000 pm, about 8,000 pm - 9,000 pm, about 9,000 pm - 10,000 pm, about 10,000 pm - 20, 000 pm, about 20,000 pm - 30,000 pm, about 30,000 pm - 40,000 pm, about 40,000 pm - 50,000 pm in size, or any value therebetween.

[0069] The term “spheroid” as used herein may comprise a spheroidal aggregate of one or more cell types including fibroblasts.18299833684.1

[0070] The term “marker” can refer to a characteristic of a molecule or cell that is detectable or is made detectable by a reporter, or which may be coexpressed with a reporter. For molecules, a marker can be particular constituents or moieties, such as restrictions sites or particular nucleic acid sequences in the case of polynucleotides. For cells, characteristics may include a protein, including enzyme, receptor and ligand proteins, saccharides, polynucleotides, and combinations thereof, or any biological material associated with a cell. The product of an enzymatic reaction may also be used as a marker. The marker may be directly or indirectly associated with the reporter or can itself be a reporter. Thus, a marker is generally a distinguishing feature of a molecule or cell, and a reporter is generally an agent which directly or indirectly identifies or permits measurement of a marker. Aspects of the Disclosure

[0071] In some aspects, a composition is used that comprises fibroblast cells and may in addition or alternative comprise one or more fibroblast-derived materials, stem cells, or stem cell-derived materials. In some aspects, a composition is used that comprises fibroblast-derived materials, including in some cases that may also comprise whole fibroblast cells. In some aspects, the one or more fibroblasts are engineered fibroblasts. In some aspects, the one or more fibroblasts are genetically altered fibroblasts. In some aspects, there are one or more fibroblasts, one or more extracellular vesicles, one or more exosomes, one or more microvesicles, and / or one or more apoptotic bodies in a composition.

[0072] Aspects of the disclosure include methods of engineering fibroblasts, fibroblast-like cells, fibroblast-derived materials, stem cells, or stem cell-derived materials. Aspects of the disclosure include methods of having engineered fibroblasts, fibroblast-like cells, fibroblast- derived materials, stem cells, or stem cell-derived materials migrate to or target one or more specific tissues and / or one or more organs of interest. The marker may itself provide migration or targeting activity to the cell. Examples include those in Marker List I. In some cases, an antigen on the surface of the cell or cell-derived product may provide for migration or targeting activity to the cell or cell-derived product. In certain aspects, the antigen is bound to a cell surface marker, and the antigen allows for migration or targeting activity to the cell or cell-derived product. Binding of an antigen to another entity may be by electrostatic bond, hydrogen bond, or Van der Waals forces, as examples.19299833684.1

[0073] With respect to fibroblast-derived materials, the fibroblast-derived materials may derive from fibroblasts that themselves have been engineered and / or the fibroblast-derived materials may themselves be engineered.

[0074] In some aspects, the engineered fibroblasts or fibroblast-derived materials encode and / or overexpress at least one gene product, optionally an exogenous gene product. In some aspects, at least one gene product comprises one or more of Notch ligands, one or more nucleic acids, one or more cytokines, one or more chemokines, one or more transcription factors, one or more epigenetic factors, one or more growth factors, one or more hormones, one or more antigens, one or more antigen presenting molecules, one or more co-stimulatory receptors, one or more inhibitory receptors, any fragment, or any derivative thereof, and any combination thereof. In some aspects, at least one gene product comprises G-CSF, GM-CSF, survivin, CXCR4, SCF, VEGF, BMP4, bFGF, TPO, EPO, IL-3, IL-6, IL-15, SDF-1, Hox genes, DLL4, DLL1, DLL3, X-delta 2, JAG1, JAG2, FOXN1, IL-7, FOXP3, FLT-3L, CCL25, CXCL12, CXCL19, Lymphotoxin-alpha / beta, insulin-growth factor-1 / 2, fibroblast growth factor-7 / 10, HoxAl, Eyal, Pax9, Sixl, Tbxl, Ripply 3, E2F3, myc, miR-181a, Leptin receptor, ghrelin receptor, IL-22, fetal hemoglobin, hemoglobin, chimeric antigen receptor, or a fragment thereof, or a derivative thereof, or any combination thereof.

[0075] In some aspects, the engineered fibroblast or genetically altered fibroblast has a disrupted expression of one or more endogenous genes. In some aspects, the one or more endogenous gene is of one or more of HLA-I, HLA-II, Beta-2 microglobulin, T cell receptor, CD52, dCK, CD7, 4-1BB Ligand, CIITA, CD155 prostaglandin E2, CD26, androgen receptors (selected from Pgr, Nrli2, Ar, Esrl, Esr2, Gperl, Nr3cl, Nr3c2, and a combination thereof), or any combination thereof.

[0076] In some aspects, the one or more of any second cell type other than fibroblasts is an engineered cell. In some aspects, a second cell type can be immune cell, immune cell precursor, and / or blood cell. In some aspects, an immune cell, immune cell precursor, or blood cell is a T cell, B cell, natural killer (NK) cell, NKT cell, macrophage, monocyte, neutrophil, platelet, red blood cell, myeloid derived suppressor cell, mast cell, eosinophil, basophil, and / or dendritic cell.

[0077] In some aspects, any engineered fibroblast cell and / or fibroblast-derived material expresses a gene product, including at least one exogenous gene product. In some aspects, the gene product is G-CSF, GM-CSF, survivin, CXCR4, SCF, VEGF, BMP4, bFGF, TPO, EPO,20299833684.1IL-3, IL-6, IL-15, SDF-1, Hox genes, DLL4, DLL1, DLL3, X-delta 2, JAG1, JAG2, FOXN1, IL-7, FOXP3, FLT-3L, CCL25, CXCL12, CXCL19, Lymphotoxin-alpha / beta, insulin-growth factor-1 / 2, fibroblast growth factor-7 / 10, HoxAl, Eyal, Pax9, Sixl, Tbxl, Ripply3, E2F3, myc, miR-181a, Leptin receptor, ghrelin receptor, IL-22, fetal hemoglobin, hemoglobin, chimeric antigen receptor, HLA-E, HLA-G, Siglec-7, Siglec-9 or a fragment thereof, or a derivative thereof.

[0078] In some aspects, the engineered cell has a disrupted expression of one or more endogenous genes. In some aspects, the one or more endogenous gene is of one or more of HLA- I, HLA-II, Beta-2 microglobulin, T cell receptor, CD52, dCK, CD7, 4- IBB Ligand, CIITA, CD 155 prostaglandin E2, CD26, androgen receptors (selected from Pgr, Nrli2, Ar, Esrl, Esr2, Gperl, Nr3cl, Nr3c2), or any combination thereof. In some aspects, the one or more endogenous gene comprises an immune checkpoint gene and the engineered cell is any kind of fibroblast. In some aspects, the immune checkpoint gene is selected from PD1, CTLA4, TIM3, TIGIT, CD96, BTLA, and / or LAG3.

[0079] In some aspects, an organoid comprises a population of cells the majority of which are fibroblasts, including engineered and / or non-engineered fibroblasts. In some aspects, there are a second type of cells other than fibroblasts that are comprised in the organoid. In some aspects, the ratio of the fibroblasts to the second cell type is in the range of about 0.0001 :1 to 10000:1, or any ratio therebetween.

[0080] In some aspects, the organoid has a size between 5um to 50,000um, or any value therebetween.

[0081] In some aspects, the one or more fibroblasts, the one or more of a second cell type, or any combination thereof, are autologous, allogeneic, xenogeneic, or syngenetic with respect to an individual.

[0082] In some aspects, the fibroblasts are derived from one or more of bone marrow fibroblasts, skin fibroblasts, fibroblasts of other regions of the body, embryonic stem cells, induced pluripotent stem cells, hematopoietic stem cells, and / or progenitor cells.

[0083] In some aspects, the methods other than including use of fibroblasts also include use of an immune cell, immune cell precursor, and / or blood cell. In some aspects, immune cell, immune cell precursor, or blood cell is a T cell, B cell, natural killer (NK) cell, NKT cell,21299833684.1macrophage, monocyte, neutrophil, platelet, red blood cell, myeloid derived suppressor cell, mast cell, eosinophil, basophil, and / or dendritic cell.

[0084] Some aspects of the disclosure relate to a pharmaceutical composition comprising any of the engineered fibroblasts and / or engineered fibroblast-derived materials encompassed herein.

[0085] In some aspects, an individual has any medical condition and is provided a therapeutically effective amount of engineered fibroblasts and / or fibroblast-derived materials of any kind. In some aspects, the individual has cancer, heart disease, hematopoietic cell disfunction or deficiency and / or immune cell disfunction or deficiency, stroke, COVID-19, chronic lower respiratory diseases, diabetes, Nephritis, nephrotic syndrome, and nephrosis, Alzheimer’s; Chronic liver disease and cirrhosis; and so forth.

[0086] In specific aspects, the individual is diagnosed with or is suspected of having a disease associated with hematopoietic cell disfunction or deficiency and / or immune cell disfunction or deficiency. In some aspects, the disease is selected from a malignancy (such as leukemia or lymphomas), bone marrow diseases (such as severe aplastic anemia, Fanconi anemia, paroxysmal nocturnal hemoglobinuria, pure red cell aplasia, megakaryocytes, congenital thrombocytopenia), immune deficiency (such as SCID, Wiskott-Aldrich syndrome), Hemoglobinopathies (such as beta thalassemia, sickle cell disease), Metabolic disorders (such as Krabbe disease, Hurler syndrome, adrenoleukodystrophy, metachromatic leukodystrophy), myelodysplastic syndrome, multiple myeloma, familial erythrophagocytic lymphohistiocytic disorders, age related immune deficiency, immune deficiency, bone marrow failure syndrome, Neuroblastoma, plasma cell disorders, POEMS syndrome, primary amyloidosis, autoimmune diseases, and / or the like.

[0087] In some aspects, the method further comprises administering to the subject at least one additional therapy other than the methods and / or compositions encompassed herein. In some aspects, the individual has cancer and the at least one additional therapy is chemotherapy, radiation therapy, androgen deprivation therapy, antibody therapeutics, cell therapies, immune activation therapy, checkpoint blockade therapy, immune suppression, leukoblative or myeloablative therapy, lymphodepletion therapy, immune tolerogenic therapy, and / or pain therapy. In some aspects, the disease is selected from a malignancy (such as leukemia or lymphomas), bone marrow diseases (such as severe aplastic anemia, Fanconi anemia,22299833684.1paroxysmal nocturnal hemoglobinuria, pure red cell aplasia, megakaryocytes, congenital thrombocytopenia), immune deficiency (such as SCID, Wiskott-Aldrich syndrome), Hemoglobinopathies (such as beta thalassemia, sickle cell disease), Metabolic disorders (such as Krabbe disease, Hurler syndrome, adrenoleukodystrophy, metachromatic leukodystrophy), myelodysplastic syndrome, multiple myeloma, familial erythrophagocytic lymphohistiocytic disorders, age related immune deficiency, immune deficiency, bone marrow failure syndrome, Neuroblastoma, plasma cell disorders, POEMS syndrome, primary amyloidosis, autoimmune diseases. Any individual may be administering androgen deprivation therapy, antibody therapeutics, cell therapies, immune activation therapy, checkpoint blockade therapy, immune suppression, leukoablative or myeloablative therapy, lymphodepletion therapy, immune tolerogenic therapy, or pain therapy to the individual. In some aspects, the method further comprises genetic editing of genes in cells other than fibroblasts, such as at least hematopoietic stem cells, lymphoid progenitors, or myeloid progenitors.

[0088] Some aspects of the disclosure relate to a kit comprising any compositions encompassed herein, including any population of fibroblast cells and / or fibroblast-derived materials disclosed herein or any of the pharmaceutical compositions disclosed herein in individual or bulk packaging. In some cases, the kit comprises fibroblast cells and / or fibroblast- derived materials comprised in a pharmaceutically acceptable carrier, whereas in other cases the fibroblast cells and / or fibroblast-derived materials and a pharmaceutically acceptable carrier are housed separately. The kit may alternatively or additionally comprise one or more reagents suitable for engineering the fibroblast cells and / or fibroblast-derived materials, such as reagents for performing CRISPR / CAS9, novel Cas Nucleases (NCN), CasMINI, Cas-CLOVER, Prokaryotic Argonautes (NgAgo), Zinc Finger Nucleases (ZFNs), and / or Transcription activator-Like Effector Nucleases (TALENs). In specific aspects, the kit comprises a guide RNA suitable for a gene and / or one or more RNA-guided genome editing enzymes, such as Cas9 and related variants. Some aspects of the disclosure relate to a kit comprising means for carrying out any of the methods disclosed herein. Specific aspects of the disclosure include kits that incorporate any composition to be used in the administration of the composition.

[0089] In some aspects, the fibroblasts, fibroblast-derived materials, and / or a second cell type that is not a fibroblast (such as an immune cell) are engineered using one or more of a biologic, chemical, or viral delivery method.23299833684.1

[0090] In aspects in which fibroblast cells and / or fibroblast-derived materials are to be delivered by injection, the excipients may be tailored to ensure optimal delivery and performance. Physiological saline solutions are frequently utilized as a vehicle for injections, maintaining tissue hydration and osmolarity while minimizing cellular stress. Buffered solutions, such as phosphate-buff ered saline (PBS), Plasma-lyte A, Ringers solution or HEPES-buffered saline, serve to stabilize pH levels and osmotic balance, which are useful for maintaining tissue integrity during the injection process.

[0091] In injection aspects, to enhance stability and efficacy stabilizers may be incorporated into injection formulations. Compounds like albumin or gelatin aid in preventing tissue aggregation or degradation, safeguarding the structural and functional integrity of injected tissues. The cell / organoid formulation may comprise albumin, including human albumin, with a specific formulation comprising 2.5% human albumin. Furthermore, penetration enhancers, such as surfactants or liposomes, may be included to facilitate tissue penetration and uptake of therapeutic agents, ensuring targeted delivery and efficacy.

[0092] In certain aspects, to further prevent or reduce potential innate or adaptive immune response, and prevent coagulation, the fibroblast cells and / or fibroblast-derived materials may be either pre-treated with heparin or administered along with heparin in order to block tissue factor receptor on cell surfaces or cell fragment surfaces of the fibroblast cells and / or fibroblast- derived materials.

[0093] As provided above, certain aspects of the method concern culturing the disclosed cells for incorporation into compositions and / or use in methods described herein. In some aspects, cells are grown and maintained at an appropriate temperature, typically a temperature of 37°C and under an atmosphere typically containing oxygen and CO2. Culture conditions may vary widely for each cell type though, and variation of conditions for a particular cell type can result in different phenotypes being expressed. The most commonly varied factor in culture systems is the growth medium. Growth media can vary in concentration of nutrients, growth factors, and the presence of other components. The growth factors used to supplement media are often derived from animal blood, such as calf serum.

[0094] In some aspects, cells may be cultured for at least between about 10 days and about 40 days, for at least between about 15 days and about 35 days, for at least between about 15 days and 21 days, such as for at least about 15, 16, 17, 18, 19 or 21 days. In some aspects, the cells of24299833684.1the disclosure may be cultured for no longer than 60 days, or no longer than 50 days, or no longer than 45 days. The cells may be cultured for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 days. The cells may be cultured in the presence of a liquid culture medium. Typically, the medium may comprise a basal medium formulation as known in the art. Many basal media formulations can be used to culture cells herein, including but not limited to Eagle's Minimum Essential Medium (MEM), Dulbecco's Modified Eagle's Medium (DMEM), alpha modified Minimum Essential Medium (alpha-MEM), Basal Medium Essential (BME), Iscove's Modified Dulbecco's Medium (IMDM), BGJb medium, F-12 Nutrient Mixture (Ham), Leibovitz L-15, DMEM / F-12, Essential Modified Eagle's Medium (EMEM), RPMI-1640, and modifications and / or combinations thereof. Compositions of the above basal media are generally known in the art, and it is within the skill of one in the art to modify or modulate concentrations of media and / or media supplements as necessary for the cells cultured. In some aspects, a culture medium formulation may be explants medium (CEM) which is composed of IMDM supplemented with 10% fetal bovine serum (FBS), 100 U / ml penicillin G, 100 pg / ml streptomycin and 2 mmol / L L-glutamine. Other aspects may employ further basal media formulations, such as chosen from the ones above.

[0095] Any medium capable of supporting cells in vitro may be used to culture the cells. Media formulations that can support the growth of cells include, but are not limited to, Dulbecco's Modified Eagle's Medium (DMEM), alpha modified Minimal Essential Medium (aMEM), and Roswell Park Memorial Institute Media 1640 (RPMI Media 1640) and the like. Typically, up to 20% fetal bovine serum (FBS) or 1-20% horse serum is added to the above medium in order to support the growth of cells. However, use of serum-free media, or media comprising cell extracts with no added serum is also envisaged. A defined medium can also be used if the growth factors, cytokines, and hormones necessary for culturing cells are provided at appropriate concentrations in the medium. Media useful in the methods of the disclosure may comprise one or more compounds of interest, including, but not limited to, antibiotics, mitogenic compounds, or differentiation compounds useful for the culturing of cells. The cells may be grown at temperatures between 27° C to 40° C, such as 31° C to 37° C, and may be in a humidified incubator. The carbon dioxide content may be maintained between 2% to 10% and the oxygen content may be maintained between 1% and 22%. In some aspects, cells can be25299833684.1cultured in hypoxic conditions. In some aspects, hypoxic conditions can comprise less than 7%, 6%, 5%, 4%, 3%, 2%, or 1% oxygen. The disclosure, however, should in no way be construed to be limited to any one method of isolating and culturing cells. Rather, any method of isolating and culturing cells should be construed to be included in the present disclosure. For use in the cell culture, media can be supplied with one or more further components. For example, additional supplements can be used to supply the cells with the necessary trace elements and substances for optimal growth and expansion. Such supplements include insulin, transferrin, selenium salts, and combinations thereof. These components can be included in a salt solution such as, but not limited to, Hanks' Balanced Salt Solution (HBSS), Earle's Salt Solution. Further antioxidant supplements may be added, e.g., P-mercaptoethanol. While many media already contain amino acids, some amino acids may be supplemented later, e.g., L-glutamine, which is known to be less stable when in solution. A medium may be further supplied with antibiotic and / or antimycotic compounds, such as, typically, mixtures of penicillin and streptomycin, and / or other compounds, exemplified but not limited to, amphotericin, ampicillin, gentamicin, bleomycin, hygromycin, kanamycin, mitomycin, mycophenolic acid, nalidixic acid, neomycin, nystatin, paromomycin, polymyxin, puromycin, rifampicin, spectinomycin, tetracycline, tylosin, and zeocin. Also contemplated is supplementation of cell culture medium with mammalian plasma or sera. Plasma or sera often contain cellular factors and components that are necessary for viability and expansion. The use of suitable serum replacements is also contemplated.

[0096] Reference to particular buffers, media, reagents, cells, culture conditions and the like, or to some subclass of same, is not intended to be limiting, but should be read to include all such related materials that one of ordinary skill in the art would recognize as being of interest or value in the particular context in which that discussion is presented. For example, it is often possible to substitute one buffer system or culture medium for another, such that a different but known way is used to achieve the same goals as those to which the use of a suggested method, material or composition is directed. In particular aspects, cells are cultured in a cell culture system comprising a cell culture medium, preferably in a culture vessel, in particular a cell culture medium supplemented with a substance suitable and determined for protecting the cells from in vitro aging and / or inducing in an unspecific or specific reprogramming.

[0097] In an aspect, the disclosed fibroblast cells and / or fibroblast-derived materials (such as organoids) may be cultured in any suitable media. The medium can be a serum-containing or26299833684.1serum-free medium, or xeno-free medium. From the aspect of preventing contamination with heterogeneous animal-derived components, serum can be derived from the same animal, and in an aspect, the same subject. The serum-free medium refers to medium with no unprocessed or unpurified serum and accordingly, can include medium with purified blood-derived components or animal tissue-derived components (such as growth factors). The medium may contain or may not contain any alternatives to serum. The alternatives to serum can include materials which appropriately contain albumin (such as lipid-rich albumin, bovine albumin, albumin substitutes such as recombinant albumin or a humanized albumin, plant starch, dextrans and protein hydrolysates), transferrin (or other iron transporters), fatty acids, insulin, collagen precursors, trace elements, 2-mercaptoethanol, 3 '-thioglycerol, or equivalents thereto. The alternatives to serum can be prepared by the method disclosed in International Publication No. 98 / 30679, for example (incorporated herein by reference in its entirety). Alternatively, any commercially available materials can be used for more convenience. The commercially available materials include knockout Serum Replacement (KSR), Chemically- defined Lipid concentrated (GIBCO™), and Glutamax (GIBCO™). In certain aspects, the medium may comprise one, two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more of the following: vitamins such as biotin; DL Alpha Tocopherol Acetate; DL Alpha-Tocopherol; vitamin A (acetate); proteins such as BSA (bovine serum albumin) or human albumin, fatty acid free Fraction V; catalase; human recombinant insulin; human transferrin; superoxide dismutase; other components such as corticosterone; D-galactose; ethanolamine HC1; glutathione (reduced); L-carnitine HC1; linoleic acid; linolenic acid; progesterone; putrescine 2HC1; sodium selenite; and / or t3 (Triiodo-L-thyronine). In specific aspects, one or more of these may be explicitly excluded.

[0098] In some aspects, the medium further comprises one or more vitamins. In some aspects, the medium comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13 of the following (and any range derivable therein): biotin, DL alpha tocopherol acetate, DL alpha-tocopherol, vitamin A, choline chloride, calcium pantothenate, pantothenic acid, folic acid nicotinamide, pyridoxine, riboflavin, thiamine, inositol, vitamin B 12, or the medium includes combinations thereof or salts thereof. In some aspects, the medium comprises or consists essentially of biotin, DL alpha tocopherol acetate, DL alpha-tocopherol, vitamin A, choline chloride, calcium pantothenate, pantothenic acid, folic acid nicotinamide, pyridoxine, riboflavin, thiamine, inositol, and vitamin27299833684.1B12. In some aspects, the vitamins include or consist essentially of biotin, DL alpha tocopherol acetate, DL alpha-tocopherol, vitamin A, or combinations or salts thereof. In some aspects, the medium further comprises proteins. In some aspects, the proteins comprise albumin or bovine serum albumin, a fraction of BSA, catalase, insulin, transferrin, superoxide dismutase, or combinations thereof. In some aspects, the medium further comprises one or more of the following: corticosterone, D-Galactose, ethanolamine, glutathione, L-carnitine, linoleic acid, linolenic acid, progesterone, putrescine, sodium selenite, or Triiodo-L-thyronine, or combinations thereof. In some aspects, the medium comprises one or more of the following: a B-27® supplement, xeno-free B-27® supplement, GS21TM supplement, or combinations thereof. In some aspects, the medium comprises or further comprises amino acids, monosaccharides, and / or inorganic ions. In some aspects, the amino acids comprise arginine, cystine, isoleucine, leucine, lysine, methionine, glutamine, phenylalanine, threonine, tryptophan, histidine, tyrosine, or valine, or combinations thereof. In some aspects, the inorganic ions comprise sodium, potassium, calcium, magnesium, nitrogen, or phosphorus, or combinations or salts thereof. In some aspects, the medium further comprises one or more of the following: molybdenum, vanadium, iron, zinc, selenium, copper, or manganese, or combinations thereof. In certain aspects, the medium comprises or consists essentially of one or more vitamins discussed herein and / or one or more proteins discussed herein, and / or one or more of the following: corticosterone, D-Galactose, ethanolamine, glutathione, L-camitine, linoleic acid, linolenic acid, progesterone, putrescine, sodium selenite, or Triiodo-L-thyronine, a B-27® supplement, xeno-free B-27® supplement, GS21TM supplement, an amino acid (such as arginine, cystine, isoleucine, leucine, lysine, methionine, glutamine, phenylalanine, threonine, tryptophan, histidine, tyrosine, or valine), monosaccharide, inorganic ion (such as sodium, potassium, calcium, magnesium, nitrogen, and / or phosphorus) or salts thereof, and / or molybdenum, vanadium, iron, zinc, selenium, copper, and / or manganese. In specific aspects, one or more of these may be explicitly excluded.

[0099] The medium may also comprise one or more externally added fatty acids or lipids, amino acids (such as non-essential amino acids), vitamin(s), antioxidant substances, 2- mercaptoethanol, pyruvic acid, buffering agents, and / or inorganic salts. In specific aspects, one or more of these may be explicitly excluded. In an aspect, the medium may also contain one or more nucleic acids, one or more cytokines, one or more chemokines, one or more growth factors,28299833684.1one or more transcription factors, one or more epigenetic factors, one or more hormones, or any combination thereof. In an aspect, the medium may further contain agents to activate immune cells, for example thymocytes.

[0100] One or more of the medium components may be added at a concentration of at least, at most, or about 0.1, 0.5, 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 180, 200, 250 ng / L, ng / ml, pg / ml, mg / ml, or any range derivable therein.

[0101] The culturing conditions can vary depending on the specific method and components of the culture. In some aspect, the fibroblast cells and / or fibroblast-derived materials may be cultured at a fixed or variable temperature ranging from about 20° to about 40 °C, or about 25 °C to about 38 °C, or about 37 °C. In an aspect, the organoid may be cultured at a fixed, or variable carbon dioxide concentration ranging from 1-10%, for example, about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, or about 10% carbon dioxide concentration. In an aspect, the oxygen tension can range from 1-20%, for example about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, or about 20% and any combination of ranges derivable therein.

[0102] In specific aspects, the fibroblast cells and / or fibroblast-derived materials of the disclosure are specifically formulated. They may or may not be formulated as a cell suspension. In specific cases they are formulated in a single dose form. They may be formulated for systemic or local administration. In some cases, the cells are formulated for storage prior to use, and the cell formulation may comprise one or more cryopreservation agents, such as DMSO (for example, in 5% DMSO), methylcellulose, ethylene glycol, or any combination thereof. In some aspects, the organoid may be cryopreserved for at least a day, at least a week, at least 2 weeks, at least 1 months, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 12 months, at least 1 year, at least 2 years or more before use.Cell Engineering

[0103] Aspects of the disclosure can include engineered cells and / or cell engineering. Engineering of a cell or population of cells can be achieved though means known in the art, including, for example, transduction and / or transfection.29299833684.1

[0104] As used herein, the term “transfection” can refer to the introduction of a heterologous nucleic acid into a cell by any means known in the art, including calcium phosphate coprecipitation, liposome fusion, microinjection, microparticle bombardment, electroporation, etc. The terms “uptake of nucleic acid by a cell”, “taking up of nucleic acid by a cell”, “uptake of particles comprising nucleic acid by a cell”, and “taking up of particles comprising nucleic acid by a cell” denote any process wherein a heterologous nucleic acid, with or without accompanying material, enters a cell.

[0105] A variety of methods are known in the art and suitable for transfection of nucleic acid into a cell. Polynucleotides of the present disclosure may be formulated, using the methods described herein. The formulations may contain polynucleotides which may be modified and / or unmodified. The formulations may further include, but are not limited to, cell penetration agents, a pharmaceutically acceptable carrier, a delivery agent, a bioerodible or biocompatible polymer, a solvent, and / or a sustained-release delivery depot.

[0106] The formulated polynucleotides may be delivered to the cell using routes of administration known in the art and described herein. Examples of typical methods include, but are not limited to, naked delivery, lipidoid mediate transfer, liposome-, lipoplexes, and / or lipid nanoparticle-mediated transfer, electroporation, calcium phosphate mediated transfer, nucleofection, sonoporation, heat shock, magnetofection, microinjection, microprojectile mediated transfer (nanoparticles), cationic polymer mediated transfer (DEAE-dextran, polyethylenimine, polyethylene glycol (PEG) and the like) or cell fusion.

[0107] As used herein the term “transduce” or “transduction” can refer to the process whereby a foreign nucleotide sequence is introduced into a cell by means of a virus or viral vector.

[0108] In certain aspects, the term “viral vector” can refer to a recombinant vector that retains the ability to infect and transduce dividing, quiescent, senescent, nondividing, and / or slowly- dividing cells and may integrate a heterologous polynucleotide into the target cell’s genome. In some aspects, the vector is derived from or based on a wild-type virus. In some aspects, the vector is derived from or based on a wild-type lentivirus. Examples of such include without limitation, human immunodeficiency virus (HIV), equine infectious anemia virus (EIAV), simian immunodeficiency virus (SIV) and feline immunodeficiency virus (Hy). Alternatively, it is contemplated that other retrovirus can be used as a basis for a vector backbone such murine30299833684.1leukemia virus (MLV). It will be evident that a viral vector according to the disclosure need not be confined to the components of a particular virus. The viral vector may comprise components derived from two or more different viruses, and may also comprise synthetic components. Viral vector components may be manipulated to obtain desired characteristics, such as target cell specificity.

[0109] Recombinant viral vectors may be derived from primates and non-primates. Examples of primate lentiviruses include the human immunodeficiency virus (HIV), the causative agent of human acquired immunodeficiency syndrome (AIDS), and the simian immunodeficiency virus (SIV). The non-primate lentiviral group includes the proto-type “slow virus” visna / maedi virus (VMV), as well as the related caprine arthritis-encephalitis virus (CAEV), equine infectious anemia virus (EIAV) and the more recently described feline immunodeficiency virus (FIV) and bovine immunodeficiency virus (BIV). Prior art recombinant lenti-viral vectors are known in the art, e.g., see U.S. Pat. Nos. 6,924,123; 7,056,699; 7,419,829 and 7,442,551, each incorporated herein by reference in its entirety.Nucleic Acids

[0110] Aspects of the disclosure can include nucleic acids for engineering. Nucleic acid sequences can exist in a variety of instances such as: isolated segments and recombinant vectors of incorporated sequences or recombinant polynucleotides encoding one or constructs of interest, such as CRISPR genes, guideRNAs, iRNAs, and / or receptors. The nucleic acids can be singlestranded or double-stranded and can comprise RNA and / or DNA nucleotides and artificial variants thereof (e.g., peptide nucleic acids). Nucleic acids of the disclosure can comprise a sequence coding for one or more genes of Marker List I. Nucleic acids of the disclosure can comprise a sequence complementary to a segment corresponding to one or more genes of Marker List I.

[0111] The term “polynucleotide” refers to a nucleic acid molecule that either is recombinant or has been isolated from total genomic nucleic acid. Included within the term “polynucleotide” are oligonucleotides (nucleic acids 100 residues or less in length), recombinant vectors, including, for example, plasmids, cosmids, phages, viruses, and the like. Polynucleotides include, in certain aspects, regulatory sequences, isolated substantially away from their naturally occurring genes or protein coding sequences. Polynucleotides may be single- stranded (coding31299833684.1or antisense) or double- stranded, and may be RNA, DNA (genomic, cDNA or synthetic), analogs thereof, or a combination thereof. Additional coding or non-coding sequences may, but need not, be present within a polynucleotide.

[0112] In certain embodiments, there are polynucleotide variants having substantial identity to the genomic or coding sequences of a gene or maker disclosed in Marker List I. The polynucleotide can be between about 1-5000 nucleotides. In some aspects, the polynucleotide if between about 10-30 nucleotides, including 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides. In some aspects, a polynucleotide can comprise a guide RNA comprising a spacer sequence of 17-20 nucleotides.

[0113] In some aspects, a polynucleotide can comprise at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% or higher sequence identity, including all values and ranges there between, to the genomic or coding sequence of a gene or maker disclosed in Marker List I (e.g., BLAST analysis using standard parameters). In certain aspects, a polynucleotide can comprise a nucleotide sequence encoding a polypeptide that has at least 90%, preferably 95% and above, identity to an amino acid sequence corresponding to one or more genes or makers of Marker List I. In some aspects, a polynucleotide may code for a CRISPR / CAS9, novel Cas Nucleases (NCN), CasMINI, Cas-CLOVER, Prokaryotic Argonautes (NgAgo), Zinc Finger Nucleases (ZFNs), and / or Transcription activator-Like Effector Nucleases (TALENs). In some aspects, a polynucleotide can encode one or more of Notch ligands, one or more nucleic acids, one or more cytokines, one or more chemokines, one or more transcription factors, one or more epigenetic factors, one or more growth factors, one or more hormones, one or more antigens, one or more antigen presenting molecules, one or more co-stimulatory receptors, one or more inhibitory receptors, any fragment, or any derivative thereof, and any combination thereof. In some aspects, a polynucleotide can encode G-CSF, GM-CSF, survivin, CXCR4, SCF, VEGF, BMP4, bFGF, TPO, EPO, IL-3, IL-6, IL-15, SDF-1, Hox genes, DLL4, DLL1, DLL3, X-delta 2, JAG1, JAG2, FOXN1, IL-7, FOXP3, FLT-3L, CCL25, CXCL12, CXCL19, Lymphotoxin-alpha / beta, insulingrowth factor-1 / 2, fibroblast growth factor-7 / 10, HoxAl, Eyal, Pax9, Sixl, Tbxl, Ripply3, E2F3, myc, miR-181a, Leptin receptor, ghrelin receptor, IL-22, fetal hemoglobin, hemoglobin, chimeric antigen receptor, or a fragment thereof, or a derivative thereof, or any combination thereof.32299833684.1

[0114] The nucleic acid segments, regardless of the length of the coding sequence itself, may be combined with other nucleic acid sequences, such as promoters, polyadenylation signals, additional restriction enzyme sites, multiple cloning sites, other coding segments, and the like, such that their overall length may vary considerably. The nucleic acids can be any length. They can be, for example, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 75, 100, 125, 175, 200, 250, 300, 350, 400, 450, 500, 750, 1000, 1500, 3000, 5000 or more nucleotides in length, and / or can comprise one or more additional sequences, for example, regulatory sequences, and / or be a part of a larger nucleic acid, for example, a vector. It is therefore contemplated that a nucleic acid fragment of almost any length may be employed, with the total length preferably being limited by the ease of preparation and use in the intended recombinant nucleic acid protocol. In some cases, a nucleic acid sequence may encode a polypeptide sequence with additional heterologous coding sequences, for example to allow for purification, selection, detection, transport, secretion, post- translational modification, or for therapeutic benefits such as targeting or efficacy. As discussed above, a tag or other heterologous polypeptide may be added to the modified polypeptide- encoding sequence.

[0115] Polycistronic expression constructs allow the expression of a plurality of gene products from a single nucleic acid and are useful in many basic research and therapeutic applications. One beneficial feature of polycistronic expression constructs is the possibility to express two or more gene products from the same nucleic acid construct, achieving simultaneous expression of the two or more gene products in a target cell. To co-express multiple gene in the same polycistronic transcription unit, the polycistronic transcription unit may comprise an internal ribosome entry site (IRES) or a sequence coding for at least one protease cleavage site and / or self-cleaving peptide for polycistronic transcription.

[0116] In certain aspects, internal ribosome entry sites (IRES) can be used to create multigene, or polycistronic, messages. IRES elements are able to bypass the ribosome scanning model of 5' methylated Cap dependent translation and begin translation at internal sites (Pelletier and Sonenberg, 1988). IRES elements from two members of the picomavirus family (polio and encephalomyocarditis) have been described (Pelletier and Sonenberg, 1988), as well an IRES from a mammalian message (Macejak and Sarnow, 1991). IRES elements can be linked to heterologous open reading frames. Multiple open reading frames can be transcribed together, each separated by an IRES, creating polycistronic messages. By virtue of the IRES element, each33299833684.1open reading frame is accessible to ribosomes for efficient translation. Multiple genes can be efficiently expressed using a single promoter / enhancer to transcribe a single message (see U.S. Pat. Nos. 5,925,565 and 5,935,819; each herein incorporated by reference in its entirety).

[0117] Self-cleaving peptides are 18-22 amino acids long 2A peptides that mediate “ribosomal skipping” between the proline and glycine residues and inhibit peptide bond formation without affecting downstream translation. These peptides allow multiple proteins to be encoded as polyproteins, which dissociate into component proteins upon translation. Use of the term “self-cleaving” is not intended to imply proteolytic cleavage reaction. Self-cleaving peptides are found in members of the Picomaviridae virus family, including aphthoviruses such as foot-and-mouth disease virus (FMDV), equine rhinitis A virus (ERAV), Thosea asigna virus (TaV) and porcine teschovirus-1 (PTV-1) (Donnelly, M L, et al., J. Gen. Virol., 82, 1027-101 (2001); Ryan, M D, et al., J. Gen. Virol., 72, 2727-2732 (2001) and cardioviruses such as Theilovirus (e.g., Theiler’s murine encephalomyelitis) and encephalomyocarditis viruses. The 2A peptides derived from FMDV, ERAV, PTV-1, and TaV are sometimes referred to herein as “F2A”, “E2A”, “P2A”, and “T2A”, respectively. Aphthovirus 2A polypeptides are typically about 18-22 amino acids long and contain a DxlEx2NPG, where xl is often valine or isoleucine. As noted above, the 2A sequence is believed to mediate ribosomal skipping between the proline and glycine, impairing normal peptide bond formation between the P and G without affecting downstream translation. The C terminus of cardiovirus 2A peptides is conserved, shows a high degree of similarity with FMDV 2A peptide, and has been shown to also mediate self-cleavage (Donnelly, M L, et al., J. Gen. Virol., 78, 13-21 (1997). FDMV 2A peptide has been shown to mediate cleavage of an artificial polyprotein (Ryan, M D and Drew, J., EMBO J., 13, 928-933 (1994). The ability to express four proteins efficiently and stoichiometrically from one polycistron in vivo was demonstrated using self-processing 2A peptides to express the four CD3 proteins (Szymczak et al., Nature Biotech. 5, 589-594, 2004). Polycistronic transgenes in which the individual cDNAs are separated by 2A peptides have been shown to promote polycistronic gene expression in transfected cells including human embryonic stem cells (Hasegawa, K., et al., Stem Cells. 2007 July; 25(7): 1707-12, 2007).34299833684.1Engineered Receptors

[0118] Engineered receptors can include Chimeric antigen receptors (CARs, also known as chimeric immunoreceptors), and chimeric T cell receptors (cTCRs; also known as artificial T cell receptors), which can provide targeting of a cell. Typically, these receptors graft the specificity of an antigen binding domain, e.g., an antibody, onto a cell. The receptors are called chimeric because they are often fused of parts from different sources.

[0119] Engineered receptors of the disclosure can provide targeting of a cell to markers found on other cells, such as cancer or immune cells. The engineering receptor may or may not be fused to an intracellular signaling domain. The engineering receptor may comprise one or more receptors from Marker List I that has been introduced or expressed into a cell. An engineered receptor may comprise an extracellular ligand recognition domain, which may be endogenous or natural to the receptor or may comprise a heterologous polypeptide such as a single-chain variable fragment (scFv).

[0120] An aspect of the disclosure, comprises CARs and or TCRs, which may target one or more genes or makers of Marker List I.Cell Enrichment

[0121] Aspects of the disclosure can comprise administration of select engineered cells or a select population of cells that have been enriched or selected for a specific gene expression profile or marker. As used herein “selection”, “select”, “sorted”, “sorting”, “enrich” or “enrichment” (and grammatical variants) can refer to obtaining a cell or population of cells with one or more desired characteristics. The cells or population of cells may be enriched for expression of a marker or gene. The cells or population of cells may be depleted for lack of expression of a marker or gene. A cell or population of cells, engineered or not engineering, may be enriched from a starting population of cells, engineered or not engineering.

[0122] Cells or populations of cells can be enriched by methods known in the art. Cell enrichment methods included, but are not limited to, fluorescent activated cell sorting (FACS), bead-based separation, density gradient-based separation, and / or positive or negative selection.

[0123] In some aspects, cells or a population of cells can be enriched by culturing a starting population of cells in conditions that select or enrich for the desired cells. For example, tissue35299833684.1sample can be dissociated and cultured in conditions that promote attachment and growth of fibroblasts.

[0124] In some aspects, a cell, such as a fibroblasts, can be enriched or selected for the expression of one or more makers. In some aspects, a fibroblast is selected for the increased, decreased, detectable, or non-detectable expression of Aminopeptidase N / CD13 CD90 / Thyl, DLK1, DPPIV / CD26, Fibroblast Activation Protein alpha / FAP*, Fibroblasts Marker (TE-7) Fibroblast Surface Protein (IB 10), FSP1 (S100A4), Integrin P1 / CD29, MAS516, PDGFRa, c-Kit (also known as CD 117), Hes related family bHLH transcription factor with YRPW motif 1 (Heyl), a-smooth muscle actin (SMA), Vimentin (including intracellular or extracellular vimentin), Cyclin D2, Snail, E-cadherin, NK2 homeobox 5 (Nkx2.5), GATA binding protein 4 (GATA4), cluster of differentiation (CD) 105, CD271, CD90, CD29, CD73, CD44, CD10, CD13, CD44, Wilms’ tumor 1 (Wtl), CXC motif chemokine receptor 4 (CXCR- 4), fibroblast growth factor 1 (FGF-1) receptor, stage specific embryonic antigen 3 (SSEA-3), tumor necrosis factor alpha (TNF-a) receptor- 1, toll like receptor 4 (TLR4), receptor for acetylated end products (RAGE), hepatocyte growth factor (HGF), express octamer-binding transcription factor 4 (Oct-4), CD-34, Kriippel-like factor 4 (KLF-4), Nanog, Sox-2, Rex-1 (also known as zinc finger protein 42), growth differentiation factor 3 (GDF-3), Stella (also known as developmental pluripotency-associated 3), or possess enhanced expression of GDF-11, or a combination thereof.

[0125] In some aspects, a population of cells can be enriched for fibroblasts. In some aspects, a population of cells can be depleted of mesenchymal stem cells. In some aspects, a population of cells comprises at least, at most, or about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% fibroblasts or engineered fibroblasts. In some aspects, at least, at most, or about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%,82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,98%, 99%, or 100% of a population of cells comprises detectable expression of one or more markers of the disclosure. In some aspects, at least, at most, or about 70%, 71%, 72%, 73%,74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%,90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% of a population of cells comprises non-detectable expression of one or more markers of the disclosure. In some aspects,36299833684.1at least, at most, or about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% of a population of cells comprises increased and / or decreased expression of one or more markers of the disclosure.

[0126] In some aspects, one or more fibroblasts, one or more population of fibroblasts, one or more organoids, one or more extracellular vesicles, one or more exosomes, one or more microvesicles, and / or one or more apoptotic bodies are engineering to target a normal tissue or cancer tissue. A tissue for targeting can include abdomen, abdominal adipose tissue, abdominal fat pad, acinus, adipose tissue, adrenal gland, adventitia, airway, airway epithelium, allocortex, alveolus, amniotic fluid, amniotic membrane, ampullary, anogenital tract, antecubital vein, anterior cruciate ligament, anterior presomitic mesoderm, aorta, aortic valve, artery, arthrosis, articular cartilage, ascites, ascitic fluid, atrium, auditory cortex, basal airway, basilar membrane, beige fat, bile duct, biliary tract, bladder, blood, blood vessel, bone, bone marrow, brain, breast, bronchial vessel, bronchiole, bronchoalveolar lavage, bronchoalveolar system, bronchus, brown adipose tissue, calvaria, capillary, cardiac atrium, cardiovascular system, carotid artery, carotid plaque, cartilage, caudal cortex, caudal forebrain, caudal ganglionic eminence, cavernosum, central amygdala, central nervous system, cerebellum, cerebral organoid, cerebrospinal fluid, cervix, choriocapillaris, chorionic villi, chorionic villus, choroid, choroid plexus, colon, colon epithelium, colorectum, cornea, corneal endothelium, corneal epithelium, coronary artery, corpus callosum, corpus luteum, cortex, cortical layer, cortical thymus, decidua, deciduous tooth, dental pulp, dermis, diencephalon, distal airway, dorsal forebrain, dorsal root ganglion, dorsolateral prefrontal cortex, ductal tissue, duodenum, ectocervix, ectoderm, embryo, embryoid body, embryonic kidney, embryonic brain, embryonic heart, embryonic prefrontal cortex, embryonic stem cell, endocardium, endocrine, endoderm, endometrium, endometrium stroma, entorhinal cortex, epidermis, epithelium, esophageal, esophagus, eye, fat pad, fetal leydig, fetal brain, fetal gonad, fetal heart, fetal ileums, fetal kidney, fetal liver, fetal lung, fetal pancreas, fetal thymus, fetal umbilical cord, fetus, foreskin, frontal cortex, fundic gland, gall bladder, gastric corpus, gastric epithelium, gastric gland, gastrointestinal tract, germ, germinal center, gingiva, gonad, gut, hair follicle, head, head and neck, heart, heart muscle, hippocampus, ileum, iliac crest, inferior colliculus, interfollicular epidermis, intervertebral disc, intestinal crypt, intestine, intrahepatic cholangio, jejunum, kidney, lacrimal gland, large intestine, laryngeal squamous37299833684.1epithelium, larynx, lateral ganglionic eminence, left lobe, ligament, limb bud, limbal epithelium, liver, lumbar vertebra, lung, lymph, lymph node, lymphatic vessel, lymphoid tissue, malignant pleural effusion, mammary epithelium, mammary gland, medial ganglionic eminence, medullary thymus, meniscus, mesenchyme, mesoblast, mesoderm, microvascular endothelium, microvessel, midbrain, middle temporal gyrus, milk, molar, muscle, myenteric plexus, myocardium, myometrium, nasal concha, nasal epithelium, nasal mucosa, nasal polyp, nasopharyngeal mucosa, nasopharynx, neck, neocortex, nerve, nose, nucleus pulposus, olfactory neuroepithelium, omentum, optic nerve, oral cavity, oral mucosa, osteoarthritic cartilage, ovarian cortex, ovarian follicle, ovary, oviduct, palatine tonsil, pancreas, pancreatic acinar tissue, pancreatic duct, pancreatic islet, parotid gland, periodontal ligament, periodontium, periosteum, peripheral blood, peritoneal fluid, peritoneum, pituitary, pituitary gland, placenta, plasma, pleura, pluripotent stem cell, polyp, posterior fossa, posterior presomitic mesoderm, prefrontal cortex, premolar, presomitic mesoderm, primitive streak, prostate, pulmonary arteriy, pyloric gland, rectum, renal glomerulus, respiratory tract, retina, retinal organoid, retinal pigment epithelium, right ventricle, saliva, salivary gland, scalp, sclerocorneal tissue, seminal plasma, septum transversum, serum, serum exosome, sinonasal mucosa, sinus tissue, skeletal muscle, skin, small intestinal crypt, small intestine, soft tissue, sperm, spinal cord, spleen, splenic red pulp, sputum, stomach, subcutaneous adipose tissue, submandibular gland, subpallium, subplate, subventricular zone, superior frontal gyrus, sympathetic ganglion, synovial fluid, synovium, taste bud, tendon, testis, thalamus, thymus, thyroid, tongue, tonsil, tooth, trachea, tracheal airway epithelium, transformed artery, trophoblast, umbilical cord, umbilical cord blood, umbilical vein, undefined, ureter, urine, urothelium, uterine cervix, uterus, vein, venous blood, ventral thalamus, ventricle, ventricular and atrial, ventricular zone, vessel, visceral adipose tissue, vocal cord, vocal fold, white adipose tissue, white matter, Wharton’s jelly, yolk sac, or a combination thereof.

[0127] In some aspects, one or more fibroblasts, one or more population of fibroblasts, one or more organoids, one or more extracellular vesicles, one or more exosomes, one or more microvesicles, and / or one or more apoptotic bodies are engineering to target a normal cell or cancer cell. A cell for targeting (or “target cell”) can include 1-cell stage cell (Blastomere), 1 lb+ dendritic cell, 1 lb- dendritic cell, 4-cell stage cell (Blastomere), 8-cell stage cell (Blastomere), Al astrocyte, A2 astrocyte, AIRE-enriched cell, AXL+ SIGLEC6+ dendritic cell,38299833684.1AXL+SIGLEC6+ dendritic cell, Abnormal myeloid cell, Abnormal plasma cell, Acinar cell, Activated B cell, Activated CD25+ regulatory T cell, Activated CD4+ T cell, Activated CD8+ T cell, Activated T cell, Activated dendritic cell, Activated double-positive T cell, Activated effector memory CD4+ T cell, Activated effector memory CD8+ T cell, Activated endothelial cell, Activated hepatic stellate cell, Activated Langerhans’ cell, Activated macrophage, Activated memory B cell, Activated memory CD8+ T cell, Activated memory T cell, Activated microglial cell, Activated myofibroblast, Activated naive CD8+ T cell, Activated naive T cell, Activated natural killer cell, Activated peripheral helper T cell, Activated regulatory T cell, Activated tissue resident memory CD4+ T cell, Activated tissue resident memory CD8+ T cell, Active intestinal stem cell, Adenocarcinoma stem-like cell, Adipocyte, Adipocyte progenitor cell, Adipose multilineage-differentiating stress-enduring cell, Adipose progenitor cell, Adipose- derived stem cell, Adipose-derived stromal cell, Adrenal gland cell, Adrenal medulla cell, Adult neural stem cell, Adult neuronal stem cell, Adult podocyte, Adult spermatogonia, Adult stem cell, Adventitial cell, Aerocyte, Aerocyte endothelial cell, Age-associated B cell, Aged memory B cell, Airway basal cell, Airway secretory cell, Airway smooth muscle cell, Alpha cell (a cell), Alveolar cell, Alveolar cell Type 1, Alveolar cell Type 2, Alveolar epithelial cell Type 1, Alveolar epithelial cell Type 2, Alveolar epithelial progenitor cell, Alveolar macrophage, Alveolar pneumocyte Type I, Alveolar pneumocyte Type II, Alveolar type 2-like cell, Alveolar type II (ATII) cell, Amacrine cell, Amnion epithelial cell, Amnion-like cell, Amniotic fluid stem cell, Angiogenic T cell, Anterior cell, Anterior foregut endoderm cell, Anterior hindbrain cell, Anterior midbrain cell, Anterior placode cell, Anterior presomitic mesoderm (aPSM) cell, Antibody Secreting B cell, Antibody-secreting cell, Antigen presentation cancer-associated fibroblast, Antigen-presenting cell, Antrum gastric epithelial cell, Apical cell, Apical ectodermal ridge cell, Arterial endothelial cell, Arteriole endothelial cell, Artery cell, Artery endothelial cell, Ascending vasa recta cell, Astrocyte, Astrocyte progenitor cell, Astroglial progenitor cell, Atrial cell, Atrioventricular canal cell, Atypical B cell (ABC), Atypical memory B cell, Axl+ CD1 lc+ Plasmacytoid dendritic cell (CDl lc+ Axl+ DC), Axl+ CD123+ Plasmacytoid dendritic cell (CD123+ Axl+DC), B cell, B cell lineage, B progenitor cell, B-2 cell, Bl cell, BIO Regulatory B cell, Basal cell, Basal epithelial cell, Basal epithelial progenitor cell, Basal forebrain cholinergic neuron (BFCN), Basal gland mucous cell, Basal keratinocyte, Basal progenitor cell, Basal-like cell, Basophil, Beige adipocyte, Beige adipogenic precursor cell, Beta cell (P cell),39299833684.1Beta-like cell, Bile duct cell, Biliary cell, Biliary epithelial cell, Bipolar cell, Bladder epithelial cell, Blast cell, Blood cell, Blood vessel cell, Bone marrow stem cell, Bone marrow stromal cell, Bone-specific cell, Border-associated macrophage, Bowman’s gland cell, Brain cell, Breast cancer stem-like cell, excitatory neuron, Bronchial vessel cell, Brown adipocyte, Brown adipogenic precursor cell, Brush cell (Tuft cell), Buccal epithelial stem cell, Bud tip progenitor cell, Bulge stem cell, CAR-T cell, CCR7+ dendritic cell, CD 106+ mesenchymal stem cell, CD 14 monocyte, CD 14+ CDlc+ dendritic cell, CD 14+ endothelial progenitor cell, CD 14+ macrophage, CD 14+ monocyte, CD 14+ monocyte-derived macrophage, CD 14+CD 16- monocyte, CD 14+CD 16+ monocyte, CD 141+ myeloid dendritic cell, CD141+CLEC9A+ dendritic cell, CD 16 monocyte, CD 16+ dendritic cell, CD 16+ dendritic cell (CD 16+ DC), CD 16+ monocyte, CD1C+ dendritic cell, CDlc+ myeloid dendritic cell, CD1C+ A dendritic cell, CD1C+ B dendritic cell, CD1C-CD141- dendritic cell, CD20+ B cell, CD25 LAG3+ T cell, CD25+LAG3+ T cell, CD27+ memory B cell, CD3 / CD28-stimulated NK cell, CD3 / CD28- stimulated T cell, CD34+ common lymphoid progenitor cell, CD34+ erythroid progenitor cell, CD34+ granulocytic progenitor cell, CD34+ hematopoietic stem cell, CD34+ lympho-myeloid progenitor cell, CD34+ megakaryocyte-erythroid progenitor cell, CD34+ pre-B cell, CD34+ pre- T cell, CD34+ progenitor cell, CD34+ thymocyte, CD4 peripherally derived regulatory T cell, CD4 T cell, CD4+ central memory like T (Tcm-like) cell, CD4+ cytotoxic T lymphocyte, CD4+ cytotoxic T1 cell, CD4+ cytotoxic T2 cell, CD4+ recently activated effector memory or effector T cell (CTL), CD4+ T cell, CD4+ T helper cell, CD4+ Terminally Differentiated Effector Memory Cell, CD4+ tumor antigen-specific T (Tas) cell, CD4+ T helper 1 cell, CD4+ T helper 17 cell, CD4+CD25+ regulatory T cell, CD40LG+ T helper cell, CD45+ immune cell, CD4- CD28- T cell, CD4-CD28+ T cell, CD5+ dendritic cell, CD56+ natural killer cell, CD56bright Natural killer cell, CD56dim Natural killer cell, CD8 T cell, CD8 tumour-infiltrating lymphocyte, CD8+ mucosal-associated invariant T cell(CD8+ MAIT), CD8+ recently activated effector memory or effector T cell (CTL), CD8+ T cell, CD8+ T helper 1 cell, CD8+ T helper 17 cell, CD8+ terminally differentiated effector memory re-expressing CD45RA T cell(CD8+ TEMRA), CD8+ tissue-resident memory T cell, CD8+ tumor antigen-specific T (Tas) cell, CD8+ intraepithelial cell, Central memory CD4+ T cell, Central memory CD8+ T cell, Central memory T cell, Central memory T cell precursor, Central memory T helper 1 cell, Central nervous system cell, Central nervous system stem cell, cervical squamous cell, Chandelier cell,40299833684.1Chemo-resistant cancer cell, Chief cell, Cholangiocyte, Cholinergic neuron, Chondrocyte, Choriocapillaris cell, Choroid plexus cell, Chromaffin cell, Chronically activated CD4+ T cell, Chronically activated CD8+ T cell, Ciliary body cell, Ciliated airway epithelial cell, Ciliated cell, Ciliated epithelial cell, Circulating activated B cell, Circulating angiogenic cell, Circulating fetal cell, Circulating memory T cell, Circulating natural killer cell, Circulating plasma cell, Circulating precursor cell, Circulating progenitor cell, Circulating stem like cell, Circulating T follicular helper cell, Circulating tumor cell, Circulating tumour cell (CTC), Clara cell, Class switched memory B IgGK cell, Class switched plasmablast, Classical B cell, Classical Barrett’s esophagus cell, Classical cancer associated fibroblast, Classical dendritic cell a (cDCa), Classical dendritic cell b (cDCb), Classical glioblastoma cell, Classical monocyte, Classical plasma cell, Class-switched memory B cell, Claudin-low cell, CLEC10A+ dendritic cell, CLEC9A+ dendritic cell, Club cell (Clara cell), CMP cell, Collecting duct & Ureteric Bud cell, Collecting Duct Principal Cell, Collecting ductal cell, Collecting duct-intercalated cell (type A), Collecting duct-intercalated cell (type B), Collecting duct-principal cell, Collecting duct-transitional cell, Colonic stem cell, Colonocyte, Colorectal stem cell, Columnar epithelial cell, Common lymphoid progenitor cell, Common myeloid progenitor cell, Complement-secreting cancer associated fibroblast, Cone cell, Cone photoreceptor cell, Connecting tubular cell, Conventional CD4 T cell, Conventional CD4+ T cell, Conventional CD8+ T cell, Conventional dendritic cell, Conventional dendritic cell l(cDCl), Conventional dendritic cell 2(cDC2), Conventional dendritic cell 2-A (cDC2-A), Conventional dendritic cell 2a(cDC2a), Conventional dendritic cell 2-B (cDC2-B), Conventional dendritic cell 2b(cDC2b), Conventional dendritic cell(cDC), Conventional T(Tconv) cell, Corneal cell, Corneal endothelial cell, Corneal epithelial cell, Corneal epithelial progenitor cell, Corneal epithelial stem cell, Corneal limbal stem cell, Comeocyte-like cell, Cortical cell, Cortical neuron, Cortical somatostatin (SST) interneuron, Cortical stromal cell, Cortical thymus epithelial cell, Corticotroph cell, Corticotroph tumor cell, Cranial neural crest cell, Cranial neural crest-derived mesenchymal cell, Cross-presenting dendritic cell, Crypt cell, Crypt stem cell, Cutaneous squamous cell carcinoma (cSCC)cell, Cycling B cell, Cycling cell, Cycling epithelial cell, Cycling transient-amplifying cell, Cytokine induced killer cell, Cytotoxic lymphocyte, Cytotoxic CD4+ T cell, Cytotoxic CD4+ T2 cell, Cytotoxic CD8 T cell, Cytotoxic CD8+ T cell, Cytotoxic cell, Cytotoxic double-positive T cell, Cytotoxic effector memory T cell, Cytotoxic effector T cell, Cytotoxic Lymphocyte, Cytotoxic41299833684.1natural killer cell, Cytotoxic NK cell, Cytotoxic T cell, Cytotoxic T cell 2, Cytotoxic T helper 1 cell, Cytotrophoblast, DI -MSN (medium spiny neuron), D2-MSN (medium spiny neuron), DCLK1+ progenitor cell, Damage-associated transient progenitor cell, Dark zone cell, Decidual cell, Dedifferentiation adipocyte, Deep layer cell, Deep layer excitatory neuron, Deep layer neuron, Definitive endoderm cell, Definitive zone cell, Delta cell, Demyelinating macrophage, Demyelinating microglial cell, Dendritic cell, Dendritic cell 2A, Dendritic cell lineage, Dendritic cell progenitor, Dental follicle (DF) cell, Dental pulp cell, Dental pulp stem cell, Dentate granule cell, Dentate gyrus granule cell, Dermal cell, Dermal dendritic cell, Dermal fibroblast, Dermal papilla cell, Dermal progenitor cell, Descending thin limb cell, Descending thin limb of LOH cell, Descending vasa recta cell, Deuterosomal cell, Developing corpus callosum cell, Developing nephron, Differentiated effector T cell, Differentiated keratinocyte, Differentiated muscle cell, Differentiating progenitor cell, Diffuse gastric cancer cell, Disease-associated microglial cell, Distal cell, Distal convoluted tubular cell, Distal convoluted tubule Type 1 (DCT1) cell, Distal convoluted tubule Type 2 (DCT2) cell, Distal epithelial cell, Distal stem cell, Distal tubular cell, Distal tubule & loop of Henle cell, Dividing T cell, Dividing cardiomyocyte, Dividing cell, Dividing plasma B cell, Dopamine neuron, Dopaminergic neuron, Dorsal anterior hindbrain cell, Dorsal cell, Dorsal forebrain progenitor cell, Dorsal lateral ganglionic eminence precursor cell, Dorsal medial ganglionic eminence precursor cell, Double-negative B cell, Double-negative T cell, Double-negative memory B cell, Double-positive T cell, Doublepositive Treg cell, Ductal cell, Ductal epithelial cell, Ductal progenitor cell, Duodenal epithelial cell, Dysfunctional T cell, EBV+ B lymphoma cell, EMRA CD4+ T cell, EMRA CD8+ T cell, EMT cancer stem cell, EMT non-cancer stem cell (EMT non-CSC), EMT-like cell, Early B cell, Early CD34+ megakaryocyte-erythroid progenitor cell, Early T cell progenitor (ETP), Early activated CD4+ T cell, Early activated CD8+ T cell, Early effector T cell, Early embryonic cell, Early endothelial cell, Early erythrocyte, Early erythroid progenitor cell, Early hemangioblast, Early hematopoietic cell, Early megakaryocyte progenitor cell, Early myeloid cell, Early myoblast, Early neutrophil, Early progenitor cell, Early proximal tubule cell, Early response secretory cell, Early secretory cell, Early transit-amplifying prostate epithelial cell, Early vascular cell, Early-born neuron, Early-erythroblast, Ectoderm cell, Ectodermal cell, Effector (EMRA) CD8+ T cell, Effector CD4+ T cell, Effector CD4+ memory T (Tern) cell, Effector CD8 T cell, Effector CD8+ T cell, Effector CD8+ memory T (Tern) cell, Effector Memory RA42299833684.1Cell (Temra), Effector T cell, Effector T helper 1 cell, Effector T (Teff) cell, Effector Th2 cell, Effector Th2-like cell, Effector chondrocyte, Effector memory CD4 T cell, Effector memory CD4+ T cell, Effector memory CD8 T cell, Effector memory CD8+ T cell, Effector memory T cell, Effector natural killer cell, Effector regulatory T (eTreg) cell, Elongating cell, Hematopoietic progenitor-like cell, Embryonic cell, Embryonic stem cell, Endocardial cell, Endocrine cell, Endocrine progenitor cell, Endoderm progenitor cell, Endodermal cell, Endodermal progenitor cell, Endometrial progenitor cell, Endometrial stem cell, Endometrial stromal cell, Endometrial stromal stem cell, Endothelial cell, Endothelial precursor cell, Endothelial progenitor cell, Endothelial stem cell, Ensheathing glial cell, Enteric neuron, Enterochromaffin cell, Enterocyte, Enterocyte progenitor cell, Enteroendocrine cell, Eomesodermin homolog (EOMES)+ regulatory T cell type 1, Eosinophil, Ependymal cell, Ependymal-like cell, Epiblast cell, Epiblast-like cell, Epicardial cell, Epicardial progenitor cell, Epicardium-derived cell, Epidermal cell, Epidermal posterior cell, Epidermal progenitor cell, Epidermal stem cell, Epidermal transit amplifying cell, Epidermis cell, Epithelial cell, Epithelial cell Type 1, Epithelial cell Type 2, Epithelial ductal cell, Epithelial hair follicle stem cell, Epithelial progenitor cell, Epithelial stem cell, Epithelial-mesenchymal cell, Epithelial- mesenchymal transition cancer stem cell, Epithelioid macrophage, Epsilon cell, Erythroblast, Erythrocyte, Erythroid lineage cell, Erythroid precursor, Erythroid progenitor cell, Esophageal cell, Esophageal epithelial cell, Esophageal mucosal cell, Esophageal progenitor cell, Esophageal squamous cell, Esophageal stem cell, Excitatory neuron, Exhausted CD8+ T cell, Exhausted CD4+ T cell, Exhausted CD8 + T cell, Exhausted CD8+ T cell, Exhausted CD8+ T progenitor cell, Exhausted double-positive T cell, Exhausted T cell progenitor, Exhausted T (Tex) cell, Exocrine cell, Extratelencephalic (ET) cell, Extravillous trophoblast cell, Fat cell (adipocyte), Fetal hepatocyte, Fetal ley dig progenitor cell, Fetal myoblast, FGFRlHigh NME5- epithelial cell, FGFRlLow NME5- epithelial cell, Fibro-adipogenic progenitor cell, Fibroblast, Fibroblastic reticular cell, Fibroblast-like cell, Fibrocartilage chondrocyte, Fibrochondrocyte, Fibrochondrocyte progenitor cell, Fibrocyte, Fibrous astrocyte, Terminally differentiated Effector Memory (TEMRA) memory T cell, Flkl+ mesodermal cell, Foam cell, Foetal endothelial cell, Follicular B cell, Follicular cell, Follicular cytotoxic CD8+ T cell, Follicular dendritic cell, Follicular helper (Tfh) T cell, Follicular regulatory T(Tfir) cell, Follicular T cell, Follicular T helper-like memory cell, Forebrain cell, Foregut cell, F0XN4+ cell, FOXP3+43299833684.1natural regulatory T (Treg) cell, Foxp3+ regulatory T cell, Foxp3+IL-17+ T cell, F-Pericyte, Frontal cortex cell, Full mesenchymal cell, Fully activated dendritic cell, Fundic gland cell, Fusiform cerebral cell, GABAergic neuron, Gallbladder cell, Gamma cell, Gamma delta (76) T cell, Ganglion cell, Gastric foveolar epithelial cell, Gastric mucous neck cell, Gastric neuroendocrine cell, Gastric parietal cell, Gastric progenitor cell, Gastric stem cell, General capillary cell, Germ cell, Germinal center B cell, Germinal center cell, Germinal Centre (GC)- like cell, Germinal stem cell, Germline stem cell, Gland cell, Gland ductal cell, Gland mucous cell, Glandular Barrett' s esophagus cell, Glial cell, Glial neural progenitor cell, Glioma stem cell, Globose basal cell, Glomerular cell, Glomerular endothelial cell, glomerular Endothelial cell (ECg), Glomerular epithelial cell, Glomerular mesangial cell, Glomerular parietal epithelial cell, Glutamatergic neuron, Goblet cell, Goblet progenitor cell, Goblet secretory cell, Gonadal endothelial cell, Gonadal mitotic phase fetal germ cell, Gonadotrope, Gonadotroph cell, Gonocyte, GP2-preferred medullary thymic epithelial cell, Granule cell, Granulocyte, Granulocyte-monocyte progenitor, Granulocyte-monocyte progenitor cell (GMP), Granulocytic myeloid-derived suppressor cell (G-MDSC), Granulocytic-UNK, Granulosa cell, GrB+ Regulatory B cell, GZMB+ T cell, GZMK CD8 cell, GZMK+ T cell, Hl embryonic stem cell, Haematopoietic cell, Haematopoietic progenitor cell, Haematopoietic stem cell, Hair follicle cell, Head And Neck Squamous Cell, Healing Enriched-Fibroblast, Heart cell, Helper innate lymphoid cell, Hemangioblast, Hematopoietic cell, Hematopoietic origin cell, Hematopoietic precursor cell, Hematopoietic progenitor cell, Hematopoietic stem cell, Hematopoietic-related cell, Hepatic cell, Hepatic progenitor cell, Hepatic progenitor-like cell, Hepatic stellate cell, Hepatoblast, Hepatocyte, HES1 High progenitor cell, Highly differentiated effector CD8 + T cell, Hillock cell, Hindgut cell, Histiocyte, hMSC-treated B cell, Hodgkin and Reed-Sternberg cell, Hofbauer cell, Homeostatic chondrocyte, Homeostatic microglial cell, Horizontal basal cell, Horizontal cell, Human pluripotent stem cell (hPSC), Human rheumatoid synovial cell (HRSC), Human-induced pluripotent stem cell (iPSC), Hypertrophic chondrocyte, Hypoblast cell, Hypoblast-like cell, Idiopathic pulmonary fibrosis cell, Idiopathic pulmonary fibrosis myofibroblast, IgA memory B cell, IgA+ Regulatory B cell, IgG memory B cell, IgM memory B cell, IgM only B cell, IL-17R alpha T cell, IL7R T helper cell, Immature B cell, Immature cortical thymic epithelial cell, Immature dendritic cell, Immature endocrine cell, Immature endothelial cell, Immature erythroid cell, Immature glial cell, Immature medullary thymic44299833684.1epithelial cell, Immature myeloid cell, Immature neuron, Immature neutrophil, Immature olfactory neuron, Immature osteoblast, Immature transitional B cell, Immune cell, Immune cells, Immune oligodendroglial cell (imOLG), Immune suppressive macrophage, Immuneendothelial cell, Immunoregulatory natural killer cell, Immunosuppressive neutrophil, Indistinct epithelial cell, Induced pluripotent stem cell, Induced pluripotent stem cell (iPSC), Induced regulatory T (Treg) cell, Infiltrated mononuclear cell, Infiltrating macrophage, Infiltrating monocyte, Inflammatory cancer-associated fibroblast, Inflammatory cancer-associated fibroblast (iCAF), Inflammatory cell, Inflammatory dendritic cell, Inflammatory Dendritic Epidermal Cell (IDEC), Inflammatory fibroblast, Inflammatory monocyte, Infundibulum basal layer cell, Inhibitory neuron, Injured Proximal tubular cell, Innate B cell, Innate lymphoid cell, Innate lymphoid cell (ILCs), Innate lymphoid cell 1, Innate lymphoid cell Type 2, Inner Cell, Inner cell mass cell, Inner radial glial cell, Intercalated cell, Interferon responsive secretory cell, Intermediate exhausted T cell, Intermediate keratinocyte, Intermediate mesoderm cell, Intermediate monocyte, Intermediate monocyte cell, Intermediate progenitor cell, Inter-mediate progenitor cell, Intermediate transition memory B cell, Interneuron, Interneuron precursor cell, Interstitial cell, Interstitial macrophage, Interstitial progenitor cell, Intestinal cell, Intestinal epithelial cell, Intestinal epithelial stem cell, Intestinal gastric cancer cell, Intestinal metaplasia cell, Intestinal stem cell, Intraepithelial lymphocyte cell, Intrathymic fibroblast (Fbl), Intrinsic neuron, Intrinsic primary afferent neuron, lonocyte, lonocyte cell, Iris puttative stem cell, Isthmus cell, Ito cell (hepatic stellate cell), Juxtaglomerular cell, Keratinocyte, Keratinocyte progenitor cell, Ki-67+ epithelial cell, KIR + RA + T cell, KLRF+ natural killer cell, Kupffer cell, Kupffer-like cell, Lactotrope, Lactotroph cell, LAMP3+ dentritic cell, Langerhans cell, Langerin-positive dendritic cell, Large granular lymphocyte, Late effector T cell, Late endothelial cell, Late neuronal progenitor cell, Late transit-amplifying prostate epithelial cell, Later-stage progenitor cell, Lateral ganglionic eminence cell, Layer 4 cell, Leptomeningeal cell, Leukemia stem cell, Leukemic progenitor cell, Leukemic stem cell, Leukocyte, Leydig and myoid-like cell, Leydig cell, Leydig precursor cell, LGE-lineage cell (lateral ganglionic eminence), LGR5+ stem cell, Light zone cell, Limbal epithelial stem cell, Limbal mesenchymal cell, Limbal stem cell, Lining fibroblast, Lipid-associated macrophage (LAM), Lipofibroblast, Live CD 19+ cell, Liver bud hepatic cell, Liver progenitor cell, Liver stem cell, Leydig cell, LNCaP cell, Lobe cell, Lonocyte, Loop of Henle cell, Loop of Henle thick ascending limb cell (TAL), Loop progenitor cell, Low-45299833684.1density neutrophil, Lower layer neuron, Lower motor neuron, LTF granulocyte, Luminal cell, Luminal epithelial cell, Luminal progenitor cell, Lung cell, Lung epithelial cell, Lung progenitor cell, Luteinizing granulosa cell, Lymph node cell, Lymph vessel cell, Lymphangioleiomyomatosis cell (LAMcore), Lymphatic cell, Lymphatic endothelial cell, Lymphoblast, Lymphoblastoid cell, Lymphocyte, Lymphoid cell, Lymphoid progenitor cell, Lymphoid stem cell, Lymphoid structure cell, Lymphoid-primed multipotent progenitor cell (LMPP), NECK cell, natural killer (NK) cell, Naive 1 progenitor cell, Naive B Cell, Naive CD4 T cell, Naive CD4+ T cell, Naive CD8 T cell, Naive CD8+ T cell, Naive IL7R+ T cell, Naive T cell, Naive T(ThO) cell, Naive cell, Naive cytotoxic T cell, Naive double-positive T cell, Naive human pluripotent stem cell, Naive memory B cell, Naive progenitor cell, Naive regulatory T (Treg) cell, Naive-like T cell, Nascent mesodermal cell, Nascent nephron cell, Native T (ThO) cell, Natural Killer CD56+ dim cell, Natural Treg (nTreg), Natural killer CD4+ T cell, Natural killer CD56 bright cell, Natural killer CD56 dim cell, Natural killer CD8+ T cell, Natural killer T (NKT) cell, Natural killer T (NKT) cell, Natural killer T (NKT)-like cell, Natural memory B cell, Natural regulatory T (Treg) cell, Natural regulatory T cell, Naive cell, Naive or central memory T cell, Negative mesenchymal stem cell, Neovascular endothelial cell, Nephron epithelial cell, Nephron progenitor cell, Nerve cell, Neural Crest (NC) cell, Neural cell, Neural crest stem cell, Neural crest stemlike cell, Neural crest-derived cell, Neural crest-like cell, Neural ectodermal cell, Neural plate cell, Neural precursor cell, Neural progenitor cell, Neural retina cell, Neural stem cell, Neural stem-like cell, Neural tube cell, Neuroectoderm cell, Neuroendocrine cell, Neuroepithelial cell, Neurogenic retinal progenitor cell, Neuron, Neuronal intermediate progenitor cell, Neuronal precursor cell, Neuronal progenitor cell, Neuronal-like cell, Neutrophil, Neutrophil lineage, Neutrophil progenitor cell, Non PT tubular cell, Non class- switched memory B cell, Non-classical monocyte, Non-malignant epithelial cell, Non-neural ectoderm cell, Non-neuron, Non-recirculating tissue-resident memory T cell, Non-switched B cell, Non-switched memory B cell, Non-P endocrine cell, Nonhematopoietic heteroploid cell, Nonmyelinating Schwann cell, Nonpathogenic T helper 17 (Thl7) cell, follicular cell, Notochord cell, Noval lymphangioleiomyomatosis cell, Nucleus pulposus cell, Nucleus pulposus progenitor cell, Null cell, Oligodendrocyte, Oligodendrocyte precursor cell, Oligodendrocyte progenitor cell, Oligodendrocyte-like cell, Oligodendroglial cell, Oocyte, Oogenesis phase fetal germ cell, Oral keratinocyte stem cell, Osteoblast, Osteoclast, Osteocyte, Osteogenic precursor-like cell,46299833684.1Osteoprogenitor cell, Outer radial glia, Oval cell, Ovalbumin-specific regulatory T cell, Ovarian cell, Ovarian germ stem cell, Ovarian somatic cell, Ovarian stromal cell, Oviduct-derived stem cell, OxPhos monocyte, Oxyntic progenitor cell, Oxyntic stem cell, P53-like cell, PD-1 high Regulatory B cell, PD-L1+ Regulatory B cell, PDX1+ pancreatic progenitor cell, pancreatic polypeptide (PP) cell, PROCR+ progenitor cell, PR0M1 high progenitor cell, PR0M1 low progenitor cell, Pacemaker cell, Paget cell, Pan Proximal tubular cell, Pan fibroblast, Pan leukocyte, Pan monocyte, Pan-B cell, Pan-Collecting duct-intercalated cell, Pan-T cell, Pancancer associated fibroblast, Pan-endothelial cell, Pan-fibroblast, Pan-leukocyte, Panmacrophage, Pan-microglial cell, Pan-neuronal cell, Pan-reactive astrocyte, Pan-trophectoderm cell, Pancreatic cell, Pancreatic ductal stem cell, Pancreatic endoderm cell, Pancreatic polypeptide cell, Pancreatic progenitor cell, Pancreatic stellate cell, Pancreatic stem cell, Paneth cell, Pan-neuron, Pan-vascular cell, Pan-T cell, Papillary fibroblast, Parafollicular cell, Paraxial mesoderm cell, Parietal cell, Parietal progenitor cell, Parvalbumin interneuron, Platelet, Pathogenic T peripheral helper cell, Patrolling monocyte, Pelvic epithelial cell, Perichondrial embryonic skeletal stem cell, Pericyte, Peridermal keratinocyte, Parietal cell, Periodontal ligament stem cell, Periodontal stem cell, Periosteum-derived progenitor cell, Peripheral blood mononuclear cell (PBMC), Peripheral immune cell, Peritoneal macrophage, Peritubular capillary cell, Peritubular myoid cell, Perivascular cell, Perivascular macrophage, Perivascular-like cell, Phagocyte, Pharyngeal arch cell, Pharyngeal arch 1 mesenchyme cell, Pharyngeal arch mesenchyme cell, Photoreceptor cell, Pigment epithelial cell, Pit cell, Pit mucous cell, pit mucous cell (PMC), Pit progenitor cell, Pituicyte, Pituitary stem cell, Pituitary stem cell (PSC), Placenta cell, Placental tissue cell, Placode cell, Plasma cell, Plasmablast, Plasmablast B cell, Plasmablast like cell, Plasmacytoid dendritic cell, Plasmacytoid dendritic cell (pDC), Pluripotency cell, Pluripotent cell, Pluripotent stem cell, Pluripotent very small embryonic-like cell, Podocyte, Podocyte precursor cell, Podocyte progenitor, Polymorphonuclear leukocyte, Polymorphonuclear myeloid-derived suppressor cell, Polymorphonuclear myeloid-derived suppressor (PMN-MDSC) cell, Polymorphonuclear neutrophil, Polymorphonuclear neutrophil (PMN), Polyploid giant cancer cell, Portal fibroblast, Portal vein cell, Portal vein epithelial cell, Positive mesenchymal stem cell, Posterior cell, Posterior foregut cell, Posterior placode cell, Posterior presomitic mesoderm (pPSM) cell, Post-meiotic spermatid cell, Postmitotic neuron, Preadipocyte, Preadipocyte progenitor cell, Pre-B cell, Pre-conventional dendritic cell, Precursor47299833684.1cell, Precursor memory cell, Precursors CD8+ cell, Pre-dendritic cell, Pre-dendritic cell (preDC), Pre-exhausted CD8+ T cell, Prehypertrophic chondrocyte, Premeiotic germ cell, pre-MSN (medium spiny neuron), Pre-neutrophil, Presomite cell, Presomitic mesoderm cell, Presomitic mesoderm (PSM) cell, Pre-T cell, Pretubular aggregate cell, Pre-tubular aggregate cell, Primed human pluripotent stem cell, Primitive endoderm cell, Primitive erythrocyte, Primitive hematopoiesis cell, Primitive hematopoietic progenitor, Primitive streak cell, Primitive stromal cell, Primitive vesicle cell, Primordial germ cell, Primordial germ cell (PGC), Principal cell, Proangiogenic B cell, Pro-B cell, Proerythroblast, Profibrotic macrophage, Progenitor-like angiogenesis-promoting cell, Progenitor-like CD8+ T cell, Pro-inflammatory Ml macrophage, Pro-inflammatory macrophage, Proliferating cell, Proliferating medullary thymic epithelial cell, Proliferating myeloid cell, Proliferating progenitor cell, Proliferating stem cell, Proliferating T cell, Proliferative CD4+ T cell, Proliferative CD8+ T cell, Proliferative chondrocyte, Proliferative ductal cell, Proliferative flbrochondrocyte, Proliferative lymphocyte, Proliferative macrophage, Proliferative neural progenitor cell, Proliferative T cell, PR0M1 high progenitor cell, PR0M1 low progenitor cell, Proneural cell, Proneural glioblastoma cell, Pro-neutrophil, Prospermatogonia, Prostate cell, Prostate stem cell, Protoplasmic astrocyte, Pro-tumor M2 microglial cell, Pro-tumor type-2 pericyte, Proximal convoluted tubular cell, Proximal segment cell, Proximal stem cell, Proximal straight tubular cell, Proximal tubular cell, Proximal tubule (PT) cell, Proximal tubule cell, Proximal tubule progenitor cell, Proximal tubule-Sl cell, Pulmonary alveolar cell Type 2, Pulmonary neuroendocrine cell, Purkinje cell, Putative hepatic stem cell, Putative myogenic progenitor cell, Putative myogenic stem cell, Pyloric cell, Pyramidal cell, Quiescent T stem cell, Radial glial cell, Reactive astrocyte, Recent bone marrow B-cell emigrant (RBE), Recent thymic T-cell emigrant, Red blood cell (erythrocyte), Regulatory B cell, Regulatory B (Breg) cell, Regulatory CD25+ T cell, Regulatory CD4 T cell, Regulatory CD4+ T cell, Regulatory CD8+ T cell, Regulatory T (Treg) cell, Regulatory T cell 1, Regulatory T(Treg) cell, Regulatory chondrocyte, Regulatory innate lymphoid cell, Regulatory natural killer cell, Renal pelvic epithelial cell, Renal progenitor cell, Renal tubular cell, Renal vesicle & comma-shaped body cell, Resident basal cell, Resident memory CD8+ T cell, Resident memory T cell, Residual embryonic cell, Respiratory ciliated cell, Respiratory gland progenitor cell, Respiratory horizontal basal cell, Respiratory secretory cell, Responder T cell, Responding conventional T cell, Resting T cell, Resting memory B cell, Resting microglial cell, Resting48299833684.1naive B cell, Resting regulatory T cell, Reticular fibroblast, Retina cell, Retina ganglion cell, Retinal Muller glia cell, Retinal astrocyte, Retinal cell, Retinal ganglion cell, Retinal pigment epithelial cell, Retinal progenitor cell, Retinoid acid signaling-responsive fetal germ cell, Reverse-migrated neutrophil, Revertant memory CD8+ T cell, Rhabdomyoblastic cell, Rod cell, Rosetting T cell, SLC16A7+ cell, Satellite cell, Scar-forming astrocyte, Scar-associated macrophage (SAM), Schwann cell, Schwann cell precursor cell, Secretory (glandular) cell, Secretory club cell, Secretory epithelial Cell, Secretory progenitor cell, Secretory transientamplifying cell, Semilunar valve cell, Senescent CD8+ T Cell, Sensory neuron, Septum transversum mesenchyme cell, Septum transversumal cell (STC), Serotonergic neuron, Serous acinar cell, Serous cell, Sertoli cell, Short-lived effector cell (SLEC), Side-population cell, Sinusoidal cell, Sinusoidal endothelial cell, Skeletal muscle cell, Skeletal muscle stem cell, Skin resident T cell, Small intestinal stem cell, Smooth muscle cell, Smooth muscle-like cell, Somatic cell, Somatic hypermutation B cell, Somatic stem cell, Somatostatin interneuron, Somatotrope, Somatotroph cell, Specialist antigen presenting cell, Spermatogenic cell, Spermatogonial cell, Spermatogonial stem cell, Spermatogonium, Spinal-progenitor-like cell, Spindle cell, Spinous cell, Squamous cell, Squamous epithelial cell, Squamous-differentiation cell, Stellate cell, Stem cell, Stem memory T cell, Stem-cell-derived-alpha cell, Stem-cell-derived-beta cell, Stem-cell- derived-endothelial cell, Stem-like CD8 T cell, Stem-like CD8+ T cell, Stem-like cell, Stem / progenitor cell, Stratified esophageal cell, Stratified keratinocyte, Stromal cell, Stromal progenitor cell, Stromal stem cell, Stromal vascular fraction cell, Sublining fibroblast, Submandibular gland stem cell, Subpallium cell, Subplate cell, Subplate neuron, Superficial layer excitatory neuron, Superpotent cancer stem cell, Suppressive monocyte, Suppressive regulatory T cell, Suppressor T cell, Suprabasal cell, Suprabasal epithelial cell, Supratentorial- radial-glia-like cell, Surface ectoderm cell, Sustentacular cell, Sweat and sebaceous gland cell, Sweat gland cell, Switched memory B cell, Switched memory B cell (Sw MB), Sympathoadrenal cell, Sympathoblast cell, Syncytiotrophoblast, Syncytiotrophoblast cell, Synthetic smooth muscle cell, Systemic-venous endothelial cell, Sezary cell, T cell, T cell large granular lymphocytic leukemia cell, T cell progenitor, T cytotoxic cell, T follicular helper cell, T follicular helper (Tfh) cell, T helper (Th) cell, T helper l(Thl) cell, T helper 17 (Th 17) cell, T helper 2 (Th2) cell, T helper 9 (Th9) cell, T memory stem cell, T peripheral helper (Tph) cell, T-cell lineage, T1 (Transitional) B cell, T2 (Transitional) B cell, T2-MZP Regulatory B cell, TER cell,49299833684.1TIM-1+ Regulatory B cell, Tc 17 cell, Tendon cell, Tenogenic cell, Terminal differentiated B cell, Terminal effector CD8+ T cell, Terminal effector memory T cell, Terminal effector T cell, Terminally differentiated CD8+ cell, Terminally differentiated effector memory CD4+ T cell, Terminally differentiated effector memory CD8+ T cell, Terminally differentiated effector memory T cell, Testis somatic cell, Thalamic cell, Theca cell, Theca interna cell, Thecal cell, Thick Ascending Limb cell, Thin Ascending Limb cell, Thymic emigrant cell, Thymic epithelial cell, Thymic epithelial cell (TEC), Thymocyte, Thymus seeding progenitor (TSP), Thyroid cell, Thyrotrope, Thyrotroph cell, Tip cell, Tissue migratory CD4+ T cell (TMC), Tissue resident cell, Tissue resident effector memory T cell, Tissue resident macrophage, Tissue resident memory CD4+ T cell, Tissue resident memory CD8+ T cell, Tissue resident memory T (TRM) cell, Tissue resident memory-like T cell, Tissue-like memory B cell, Tissue-resident cell, Tissueresident macrophage, Tissue-resident memory T (TRM) cell, T-killer cell, Tol DC-induced regulatory T cell, Tonsil cell, Trabecular meshwork cell, Transient-amplifying (TA) cell, Transit-amplifying cell, Transitional B cell, Transitional basal progenitor cell, Transitional CD8+ T cell, Transitional dendritic cell, Transitional exhausted CD8+ T cell, Transitional memory cell, Transitional memory T cell, Trophectoderm cell, Trophoblast cell, Trophoblast stem cell, Truncated radial glial cell, Tubular cell, Tuft progenitor cell, Tuft-like cell, Tuft-like medullary thymic epithelial cell, Tumor cell, Tumor endothelial cell, Tumor epithelial cell, Tumor regulatory T cell, Tumor-associated macrophage (TAM), Tumor-associated microglia cell, Tumor-infiltrating B cell, Tumor-infiltrating CD8+ T cell, Tumor-infiltrating lymphocyte (TIL), Tumor-infiltrating regulatory T cell, Tumor-infiltrating T cell, Tumor-initiating cell, Tumor-initiating stem cell (tSC), Tumor-propagating cell, Tumor-reactive CD8+ infiltrating T cell, Tumor-reactive T cell, Tumor-specific T cell, Type 17 T cell, Type 3 dendritic cell (DC3), Type A intercalated cell, Type I pneumocyte, Type II pneumocyte, Umbilical cord blood (CB) cell, Umbrella cell, Undifferentiated pancreatic progenitor cell, Unrestricted somatic stem cell, Unswitched and switched memory B cell, Unswitched memory B cell (UnSw MB), Unswitched plasmablast, Upper airway basal stem cell, Upper layer cell, Upper layer cortical neuron, Ureteric bud cell, Urethelial cell, Urine-derived stem cell, Urothelial cell, Urothelium cell, Vaginal cell, Vaginal Epidermal Dendritic Cell (VEDC), Valvular cell, Vas afferens cell, Vascular cell, Vascular endothelial cell, Vascular progenitor cell, Vascular smooth muscle cell (VSMC), Vascular stem cell, Vasculature cell, Vein endothelial cell, Vellus hair follicle cell, Venous cell,50299833684.1Venous endothelial cell, Ventral lateral ganglionic eminence precursor cell, Ventral medial ganglionic eminence precursor cell, Ventricular cardiomyocyte, Ventricular cell, Ventricular radial glial cell, Venular endothelial cell, Venule endothelial cell, Vessel cell, Villous cytotrophoblast, Villous stromal cell, Visceral endodermal cell, von Economo neuron (VEN), White adipocyte cell, White blood cell, White preadipocyte, Yolk sac-derived myeloid-biased progenitor cell (YSMP), Zona fasciculata cell, Zona glomerulosa cell, Zona reticularis cell, Zygote cell, Zymogenic chief cell, or a combination thereof.

[0128] In some aspects, the cells or populations of cells of the disclosure can have increased targeting for a specific tissue or cell type. Targeting efficiency can be determined using methods known in the art. For example, engineered cells expressing a reporter (e.g., luciferase) can be monitored for migration and / or accumulation near or in tissues of interest or near cells of interest. Targeting efficiency can be assessed in vitro, ex vivo, and / or in vivo.

[0129] In some aspects, one or more fibroblasts, one or more population of fibroblasts, one or more organoids, one or more extracellular vesicles, one or more exosomes, one or more microvesicles, and / or one or more apoptotic bodies have one or more surface markers, one or more genes, or one or more tissue-specific antigens bound thereto added, removed, and / or modified. In some aspects, one or more fibroblasts, one or more population of fibroblasts, one or more organoids, one or more extracellular vesicles, one or more exosomes, one or more microvesicles, and / or one or more apoptotic bodies are engineered to migrate to or target one or more surface markers, one or more genes, or one or more tissue-specific antigens. In some aspects, the one or more surface markers, one or more genes, or one or more tissue-specific antigens comprise (CCL)-22, 160 kDa neurofilament medium, 1HLA, 200kDa neurofilament heavy, 25F9, 2810422 J05RIK, 2b4, 2DL3, 2DS2, 33D1, 3A7, 3C4, 3CB2, 3G5, 41BB, 4-1BB, 4930556M19RIK, 5430435G22RIK, 5D4-KSPG, 5-LO, 5T4, 610L, A100A9, A12, A1BG, A1F1, A2B5, A2M, A2ML1, A4GALT, A549, A9, AADAC, AADACL2, AADAT, AAGAB, AAK1, AAMDC, AAMP, AARD, AARS, AARS2, AARSD1, AASDH, AASDHPPT, AASS, AAT, AATF, ab213215, ab22510, ab31947, ab9221, AB ALON, AB AT, ABCA1, ABCA10, ABCA13, ABCA17P, ABCA2, ABCA3, ABCA4, ABCA5, ABCA7, ABCA9, Abeam, ABCB1, ABCB10, ABCB4, ABCB5, ABCB7, ABCB8, ABCB9, ABCC1, ABCC13, ABCC2, ABCC3, ABCC4, ABCC5, ABCC6, ABCC9, ABCD3, ABCE1, ABCF1, ABCF2, ABCF3, ABCG1, ABCG2, ABCG5, ABHD10, ABHD12, ABHD12B, ABHD13, ABHD14A, ABHD14B,51299833684.1ABHD15, ABHD17A, ABHD17B, ABHD2, ABHD3, ABHD5, ABHD6, ABHD8, ABH, ABI2, ABI3, ABI3BP, ABL2, ABLIM I, ABLIM2, ABLIM3, ABO, ABPARTS, ABRACL, ABT1, ABTB1, AC002467.7, AC004069.2, AC004791.2, AC006369.2, AC009041.1, AC009403.2, AC009501.4, AC018865.8, AC020656.1, AC026202.3, AC069363.1, AC079922.3,AC090498.1, AC092159.2, AC092580.4, AC104699.1, AC104820.2, AC113189.5,AC113404.1, AC116366.6, AC119211.1, AC131056.3, AC133, AC134452.1, AC137932.4, AC140481.1, AC151602.1, AC154650.1, AC241585.2, AC245100.1, Aca-1, ACAA1, ACAA2, ACACA, ACACB, ACAD10, ACAD11, ACAD8, ACADM, ACADS, ACADSB, ACADVL, AC AN, ACAP1, ACAP2, ACAT1, ACAT2, ACBD3, ACBD4, ACBD6, ACBD7, ACCSL, ACD, ACE, ACE2, ACER3, Acetylcholinesterase, AChE, ACINI, ACKR1, ACKR3, ACKR4, ACLY, ACN9, ACO1, ACO2, ACOT11, ACOT2, ACOT4, ACOT9, ACOX1, Acox3, ACPI, ACP2, ACP5, ACPA, ACPA-S100, ACPP, ACRC, ACRP30, ACRV1, ACSBG1, ACSF2, ACSF3, Acsll, ACSL3, ACSL4, ACSL6, ACSM1, Acsm2, ACSM2A, ACSM2B, ACSM3, ACSS1, ACSS2, ACSS3, ACTA1, ACTA2, ACTA2 , ACTA3, ACTA4, ACTB, ACTC1, ACTG, ACTG1, ACTG2, ACTH, Actin, Activin RUB, ACTL6A, ACTL7B, ACTL8, ACTN1, ACTN2, ACTN4, ACTR10, ACTR1A, ACTR1B, ACTR2, ACTR3, ACTR3B, ACTR3C, ACTRT3, AcTUB, AcTUB , ACVR1, ACVR1B, ACVR1C, ACVR2A, ACVRL1, ACY3, ACYP1, ACYP2, ADA, ADAD1, ADAD2, ADAL, ADAM I 0, ADAM12, ADAM I 5, ADAM I 7, ADAM I 9, ADAM22, ADAM28, ADAM33, ADAM8, ADAM9, ADAMDEC1, ADAMTS I, ADAMTS13, ADAMTS14, ADAMTS16, ADAMTS17, ADAMTS2, ADAMTS4, ADAMTS5, ADAMTS6, ADAMTS7, ADAMTS9, ADAMTSL1, Adamtsl2, ADAMTSL3, AD API, ADAP2, ADAR, AD ARBI, ADARB2, ADAT1, ADAT2, ADCK1, ADCK3, ADCY1, ADCY3, ADCY5, ADCY7, ADCY8, ADCY9, ADCYAP1, ADCYAP1R1, ADD1, ADD2, Add3, Additional GABA Compounds, ADGB, ADGRB1, ADGRB2, ADGRD1, ADGRD2, ADGRE1, ADGRE2, ADGRE3, ADGRE5, ADGRF5, ADGRG1, ADGRG3, ADGRG5, ADGRG6, ADGRL1, ADGRL2, ADGRL3, ADGRL4, ADH1B, ADH1C, ADH5, ADH7, Adhesion molecules, Adhesion molecules LFA2, ADHFE1, ADI1, ADIPOQ, ADIPOR1, ADIPOR2, ADIRF, ADK, ADM, ADNP, ADNP2, ADORA2A, ADORA2A-AS1, ADORA2B, ADORA3, ADPGK, ADPRH, ADPRHL2, ADRA1A, ADRA1D, ADRA2A, ADRB2, ADRBK1, ADRBK2, ADRM1, ADSCs, ADSS, ADSSL1, ADT, ADTRP, Aebpl, AEN, AES, AF107846, AF131217.1, AFAP1, AFAP1-AS1, AFAP1L2, AFDN, a-fetoprotein, AFF1, AFF3,52299833684.1AFF4, AFF6, AFG1L, AFG3L2, AFP, AFTPH, AGAP2, AGAP3, AGAP6, AGBL2, AGBL4, AGBL4-IT1, AGBL5, AGC1, AGER, AGFG1, AGFG2, AGGF1, Aggrecan, AGK, AGL, AGMAT, AGMO, AGO2, AGO3, AGO4, AGP ATI, AGPAT2, AGPAT4, AGPAT5, AGPAT6, AGPAT9, AGPS, AGR2, AGR3, AGT, AGTPBP1, AGTR1, AGTRAP, AGXT2L1, AHA1, AHCY, AHCYL1, AHU , AHNAK, AHNAK2, A HR, AHRR, AHSA1, AHSA2, AHSP, AICDA, AID, AIDA, AIF1, AIF1L, AIFM1, AIM1, AIM2, AIMP1, AIMP2, AIP, AIPL1, Aire, AJUBA, AK057596, AK093551, AK095700, AK1, AK123771, AK124399, AK125727, AK128525, AK2, AK3, AK307192, AK4, AK5, AK7, AK8, AK9, AKAP I , AKAPI 1, AKAP I 2, AKAP13, AKAPI 4, A K API 7 A, AKAP2, AKAP5, AKAP7, AKAP8, AKAP8L, AKAP9, AKD1, AKIP1, AKIRIN1, AKIRIN2, AKNA, AKR1A1, AKR1A4, AKR1B1, AKR1B10, Akrlb7, AKR1C1, AKR1C2, AKR1C3, AKR1D1, AKR7A2, AKR7A3, AKT, AKT2, AKT3, AKTIP, AL080130, AL117190.2, AL137655, AL157895.1, AL356585.2, AL592183.1, AL663027.1, AL713998.1, AL833181, AL928768.3, AL928935.1, ALAS1, Alas2, ALB, Albumin, ALCAM, ALDEFLUOR, Aldehyde dehydrogenase 1, Aldehyde Dehydrogenase 1- Al, ALDH, ALDH1, ALDH-1, ALDH-1, ALDH16A1, ALDH1A1, ALDH1A2, ALDH1A3, ALDH1B1, ALDH1L1, ALDH2, ALDH3A1, ALDH3A2, ALDH3B1, ALDH4A1, ALDH5A1, ALDH6A1, ALDH7A1, ALDH9A1, ALDHA1, ALDHIA1, ALDN1, ALDOA, ALDOB, ALDOC, ALF1, ALG1, ALG12, ALG13, ALG14, ALG2, ALG5, ALG6, ALG8, ALK, ALK3, ALK4, ALK6, ALKAL2, Alkaline phosphatase, ALKBH2, ALKBH3, ALKBH4, ALKBH5, ALKBH6, ALKBH7, ALMS1, ALOX12P2, ALOX15B, ALOX5, ALOX5AP, ALP, Alphaactinin, alpha-naphthyl-acetate-esterase, alpha-Sarcoglycan, alpha-SMA, alpha-smooth muscle actin, ALPI, ALPK1, ALPL, ALPP, ALPPL2, ALS2, ALX3, ALX4, ALYREF, AMACR, AMBN, AMBP, AMD1, AMER3, AMH, aMHC, AMHR2, AMIG01, AMIG02, Aminopeptidase-N, AMN1, AMOT, AM0TL1, AM0TL2, AMPD2, AMPD3, AMPH, AMT, AMTN, AMY1, AMY2A, AMY2B, AMYP1, AMZ2, AMZ2P1, ANAPC1, ANAPC11, ANAPC15, ANAPC16, ANAPC4, ANAPC5, Anastellin, Androgen receptor, Androgen-binding protein, ANG, ANGEL 1, ANGEL2, ANGPT1, ANGPT2, ANGPTL1, ANGPTL2, ANGPTL3, ANGPTL4, ANHX, Anion exchanger 2, ANK, ANK1, Ank2, ANK3, ANKH, ANKHD1, ANKHD1-EIF4EBP3, ANKIB1, ANKK1, ANKLE1, ANKLE2, ANKMY1, ANKRA2, ANKRD1, ANKRD10, ANKRD11, ANKRD12, ANKRD13A, ANKRD13D, ANKRD16, ANKRD17, ANKRD18A, ANKRD18DP, ANKRD2, ANKRD20A12P, ANKRD20A4,53299833684.1ANKRD20A8P, ANKRD20A9P, ANKRD26P1, ANKRD26P3, ANKRD27, ANKRD28, ANKRD30A, ANKRD30BP2, ANKRD31, ANKRD32, ANKRD34B, ANKRD36, ANKRD36B, ANKRD36BP1, ANKRD36BP2, ANKRD37, ANKRD39, ANKRD42, ANKRD44, ANKRD45, ANKRD46, ANKRD49, ANKRD50, ANKRD54, ANKRD6, ANKRD62, ANKRD65, ANKRD66, ANKRD7, ANKRD9, ANKS3, ANKS4B, ANKS6, ANKUB1, ANKZF1, ANLN, Annexin V, ANO 10, ANO7, ANOS1, ANP, ANP32A, ANP32A- IT1, ANP32B, ANP32E, ANPEP, anti-Ibal, anti-MPO, anti -Mullerian hormone, ANTXR1, ANXA1, ANXA11, ANXA2, ANXA2P2, ANXA2R, ANXA3, ANXA4, ANXA5, ANXA6, ANXA7, ANXA8, ANXA8L1, AOAH, AOC1, AOC2, AOC4P, AOP4, AOX1, AP000476.1, AP003774.1, AP1AR, AP1B1, AP1G1, AP1G2, AP1M1, AP1S2, AP1S3, AP2A, AP2A1, AP2A2, AP2B1, AP2-gamma, AP2M1, AP2S1, AP3B1, AP3D1, AP3M1, AP3M2, AP3S1, AP4B1, AP4B1-AS1, AP4S1, AP5B1, AP5Z1, APBA1, APBA2, APBA3, APBB1, APBB1IP, APBB2, APC, APCDD1, APCDD1L, APCDD1L-AS1, APEH, Apela, Apelin, APEX1, APG- 1252-M1, APH1A, APH1B, API5, APIP, Apj, APLN, APLNR, APLP2, APMAP, APOA1, APOA1BP, APOA2, APOA4, APOB, APOBEC3A, APOBEC3B, APOBEC3C, APOBEC3D, APOBEC3F, APOBEC3G, APOBEC3H, APOBEC4, APOBR, APOCI, APOC1P1, APOC2, APOC3, APOC4, APOD, APOE, APOH, APOL1, APOL2, APOL3, APOL6, APOLD1, apolipoproteins, APOM, APOO, APOPT 1, APP, APPBP2, APPL1, APPL2, APRIL, APRT, AQP1, AQP2, AQP3, AQP4, AQP5, AQP6, AQP7, AQP8, AQP9, AQR, Aquaporin-0, aquaporin-1, AR, ARAF, ARAP1, ARAP2, ARAP3, ARC, ARCN1, AREG, AREL1, ARF1, ARF3, ARF4, ARF4-AS1, ARF5, ARF6, ARFGAP1, ARFGAP2, ARFGAP3, ARFGEF1, ARFIP2, ARFRP1, Arg, ARG1, ARG2, ARGFX, Arginase, arginase 1, ARGLU1, ARHGAP1, ARHGAP10, ARHGAP12, ARHGAP15, ARHGAP17, ARHGAP18, ARHGAP20,ARHGAP21, ARHGAP23, ARHGAP24, ARHGAP25, ARHGAP26, ARHGAP28,ARHGAP29, ARHGAP3, ARHGAP30, ARHGAP32, ARHGAP35, ARHGAP39, ARHGAP4, ARHGAP45, ARHGAP5, Arhgap6, ARHGAP8, ARHGAP9, ARHGDIA, ARHGDIB, ARHGEF1, ARHGEF10, ARHGEF11, ARHGEF12, ARHGEF16, Arhgefl7, ARHGEF18, ARHGEF19, ARHGEF2, ARHGEF26, ARHGEF26-AS1, ARHGEF3, ARHGEF33, ARHGEF38, ARHGEF39, ARHGEF4, ARHGEF6, ARHGEF7, ARID 1 A, ARID2, ARID3B, ARID4A, ARID4B, ARID5A, ARID5B, ARIH I , ARIH2, ARIH2OS, ARL1, ARL11, ARL13B, ARL14, ARL14EP, ARL15, ARL16, ARL17A, ARL2BP, ARL3, ARL4A, ARL4C, ARL4D,54299833684.1ARL5A, ARL5B, ARL6, ARL6IP1, ARL6IP4, ARL6IP5, ARL6IP6, ARL8B, ARMCI, ARMC2, ARMC3, ARMC4, ARMC5, ARMC8, ARMC9, ARMCX2, ARMCX3, ARNT, ARNT2, ARNTL, ARNTL2, ARPC1A, ARPC1B, ARPC2, ARPC3, ARPC4, ARPC4-TTLL3, ARPC5, ARPC5L, ARPP19, ARPP21, ARR3, ARRB1, ARRB2, ARRDC1, ARRDC1-AS1, ARRDC2, ARRDC3, ARRDC3-AS1, ARRDC4, ARSA, ARSE, ARSI, ARSJ, ART3, ARV1, ARX, ASAHI, ASAP1, ASAP2, ASB1, ASB11, ASB13, ASB15, ASB16-AS1, ASB2, ASB7, ASB8, ASB9, ASCC1, ASCC2, ASCC3, ASCL1, ASCL2, ASCL3, ASFIA, ASF1B, ASGPR, ASGPR1, ASGR1, ASGR2, ASH1L, ASH2L, ASIC1, ASIC4, ASL, ASMA, a-SMA, ASMTL, ASNA1, ASNS, ASNSD1, ASPA, Aspg, ASPH, ASPM, ASPN, ASPRV1, ASRGL1, ASS1, AST, ASTN1, ASTN2, ASUN, ASXL1, ASXL2, ASXL3, ASZ1, ATI, AT2, ATAC2, ATAD1, ATAD2, ATAD2B, ATAD3A, ATAD3B, ATAD3C, ATAD5, ATAT1, ATCA2, ATCAY, ATF1, ATF2, ATF3, ATF4, ATF5, ATF6B, ATF7IP, ATF7IP2, ATG10, ATG1O1, ATG12, ATG13, ATG14, ATG16L2, ATG2A, ATG3, ATG4B, ATG4D, ATG5, ATG7, ATG9A, ATGL, ATHL1, ATIC, ATL1, ATL2, ATM, ATN1, ATOH1, ATOH7, ATOH8, ATOX1, ATP10A, ATP10B, ATP10D, ATP11A, ATP11A-AS1, ATP11B, ATP11C, ATP13A2, ATP13A3, ATP13A4, ATP1A, Atplal, ATP1A1-AS1, ATP1A2, ATP1A3, Atpla4, ATP1B1, ATP1B2, ATP1B3, ATP1B4, ATP2A1, ATP2A3, ATP2B, ATP2B1, ATP2B4, ATP2C2, ATP4A, ATP4B, ATP5A1, ATP5B, ATP5C1, ATP5D, ATP5E, ATP5EP2, ATP5F1, ATP5G1, ATP5G2, ATP5G3, ATP5H, ATP5I, ATP5J, ATP5J2, ATP5L, ATP5L2, ATP5O, ATP5S, ATP5SL, ATP6AP1, ATP6AP1L, Atp6ap2, ATP6V0A1, ATP6V0A4, ATP6V0B, ATP6V0C, ATP6V0CP3, ATP6V0D1, ATP6V0D2, Atp6v0e, ATP6V0E1, ATP6V0E2, ATP6V1A, ATP6V1B1, ATP6V1B2, ATP6V1C1, ATP6V1C2, ATP6V1D, ATP6V1E1, ATP6V1F, ATP6V1G1, ATP6V1G3, ATP6V1H, ATP7A, ATP8A1, ATP8B1, ATP8B2, ATP8B4, ATP9A, ATP9B, ATPAF2, ATPIF1, ATR, Atraid, ATRN, ATRNL1, ATRX, ATXN1, ATXN10, ATXN1L, ATXN2, ATXN2L, ATXN3, ATXN7, ATXN7L3, ATXN7L3B, ATXN8OS, AUP1, AURKA, AURKAIP1, AURKB, AURKC, AUTS2, AVEN, AVIL, AVP, Avprla, AVPR2, Axl, AX747832, AX747844, AXIN1, Axin2, AXL, AZGP1, AZI2, AZINI, AZIN2, AZU1, B cell, B1B2, B220, B2M, B3GALNT1, B3GALNT2, B3GALT2, B3GALT6, B3GALTL, B3GAT1, B3GAT2, B3GAT3, B3GLCT, B3GNT2, B3GNT4, B3GNT5, B3GNT6, B3GNT7, B4GALNT1, B4GALT1, B4GALT2, B4GALT3, B4GALT4, B4GALT5, B4GALT6, B7H1, B7-H1, B7-H3, B9D1, B9D2, BAI, BAALC, BAB AMI, BACE1, BACE2, BACH1, BACH2,55299833684.1BAD, BAFF-R, BAG1, BAG2, BAG6, BAHD1, BAIAP2, BAIAP2-AS1, BAIAP2L1, BAIAP2L2, BAIAP3, BAK1, BAMBI, BANF1, BANK1, BANP, BAP1, BARHL1, BARX1, BASP1, BAT, BATF, BATF3, BAX, BAZ1A, BAZ1B, BAZ2A, BAZ2B, BBIP1, BB0X1, BBOX1-AS1, BBS1, BBS10, BBS2, BBS4, BBS5, BBS7, BBS9, BBX, BC034268, BC051760, BCAM, BCAN, BCAP29, Bcap31, BCAR1, BCAR4, BCAS1, BCAS2, BCAS3, BCAS4, BCAT1, BCAT2, b-catenin, B-cell-specific activator protein (BSAP), BCHE, BCL11A, BCL11B, BCL2, Bcl-2, BCL2A1, BCL2A1D, BCL2L10, BCL2L11, BCL2L12, BCL2L13, BCL2L15, BCL3, BCL6, BCL-6, BCL6# (exonl-2, BCL6#1 (exon3-4, BCL6B, BCL7A, BCL7B, BCL9, BCLAF1, BCLL1 IB, Bcl-xL, BCMA, BCO1, BCOR, BCR, BCRP1, BCYRN1, BDCA1, BDCA-1, BDCA2, BDCA-2, BDCA3, BDCA-3, BDCA4, BDCA-4, BDH2, BDNF, BDP1, BEND2, BEND3, BEND4, BEND5, BEND7, BEST1, BEST-1, BEST4, BET1L, beta III tubulin, beta-2-microglobulin, Beta2Microglobulin(B2M), Beta-catenin, Beta-Sarcoglycan, BEX1, BEX2, BEX3, BEX4, BEX5, BFAR, Bfl-1, BFSP1, BG255923, BGLAP, BGN, BHLHB26, BHLHB27, BHLHB9, BHLHE40, BHLHE40-AS1, BHLHE41, BHMT2, BICC1, BICD1, BID, Biglycan, BIK, BINI, BIN2, BIN3, BIN3-IT1, BioNeu, BIRC2, BIRC3, BIRC5, Birc6, BISPR, BIVM, BL A36, BLBP, BLCAP, BLIMP 1, Blimp- 1, BLK, BLM, BLNK, BLOC 1 S 1, BLOC 1 S2, BLOC 1 S3, BLOC 1 S4, BLOC 1 S5, BLOC 1 S6, BLR1, BLVRA, BLVRB, BLZF1, BMF, BMI1, BMP, BMP1, BMP15, BMP2, BMP2K, BMP3, Bmp4, BMP5, BMP-5, BMP6, BMP-6, BMP7, BMP7 Heterodimer, BMP8B, BMPER, BMPR1 A, BMPR1B, BMPR2, BMPRIB, BMPR-II, BMS1, BMS1P5, BMX, BNC1, BNC2, BNIP1, BNIP2, BNIP3, BNIP3L, BNIP3P11, BNIPL, BOB1, BOB-1, BOC, BOD1L1, BOK, BOLA2B, BOLA3, BOLL, Bone sialoprotein, BOP1, BORCS7, BP1, Bpgm, BPHL, BPIFA1, BPIFA2, BPIFB1, BPTF, BRACHYURY, BRAF, Brain isoform glycogen phosphorylase, BRAP, BRAT1, BRCA1, BRCA2, BRD1, BRD2, BRD3, BRD4, BRD7, BRD8, BRD9, BRDT, BrdU, BRE, BRE-AS1, BRF1, BRG1, BRI3, BRICD5, BRINP3, BRIP1, BRK1, BRMS1, BRN2, BRN3a, Brn-3B, BROX, BRPF1, BRPF3, BRSK1, BRWD1, BSAP, BSCL2, BSG, BSN-AS2, BSND, BSP1, BSPRY, BST1, BST2, BTAF1, BTBD1, BTBD10, BTBD11, BTBD17, BTBD18, BTBD3, BTBD6, BTBD7, BTBD9, BTC, BTD, BTF3, BTF3L4, BTG1, BTG2, BTG3, BTG4, BTK, BTLA, BTN2A1, BTN2A3P, BTN3A1, BTN3A2, BTN3A3, BTNL8, BTNL9, BUB1, BUB1B, BUB3, BUD13, BUD31, Burl, BX647938, BYSL, BZRAP1, BZRAP1-AS1, BZW1, BZW2, C receptor, C10orfl07, ClOorfl l, C10ORF118, C10orfl26, C10ORF128, C10orfi2, C10ORF46,56299833684.1C10ORF54, C10ORF58, C10orf76, C10orf88, C10orf99, Cllorfl, Cllorfl6, C110RF21, Cllorf24, Cllorf31, Cllorf48, Cllorf49, Cllorf52, Cllorf58, Cllorf63, Cllorf65, Cllorf68, Cl lorf70, Cl lorf72, Cl lorf73, Cl lorfBO, Cl lorf85, Cl lorf86, Cl lorf88, Cl lorf96, Cl lorf97, Cl lorf98, C12orfl0, C12orf29, C12orf40, C12orf42, C12orf43, C12ORF44, C12ORF45, C12orf47, C12orf49, C12orf5, C12orf57, C12orf71, C12ORF75, C12orf76, C13orf34, C14orfl, C14orfl05, C14orfll9, C14orfl32, C14orfl42, C14orfl47, C14orfl59, C14orfl66, C14orfl82, C14orf2, C14orf23, C14orf37, C14orf39, C15orf26, C15ORF39, C15orf40, C15orf43, C15orf48, C15orf52, C15orf53, C15orf57, C15orf65, C16orfl3, C16orf46, C16orf52, C16orf54, C16orf57, C16orf71, C16orf74, C16orf87, C16orf89, C16orf91, C16orf95, C17orfl00, C17orfl04, C17ORF109, C17orf49, C17orf58, C17orf62, C17orf64, C17orf67, C17orf75, C17orf76-ASl, C17orf78, C17orf85, C17orf89, C17orf97, C18orfl, C18orf21, C18orf25, C18orf42, C18orf61, C18orf63, C18ORF8, C19orfl0, C19orfl2, C19orf33, C19ORF38, C19orf40, C19orf43, C19orf48, C19orf53, C19orf54, C19orf57, C19orf6, C19orf60, C19orf66, C19orf68, C19orf70, C19orf77, C19orf84, CID, C1GALT1, C1GALT1C1, Clgb, Clorfl05, Clorfl06, Clorfl09, Clorfl l2, Clorfll5, Clorfl22, Clorfl23, Clorfl27, Clorfl31, Clorfl32, Clorfl41, Clorfl46, Clorfl62, Clorfl68, Clorfl74, Cl ORF 186, Clorfl89, Clorfl92, Clorfl94, C1ORF21, Clorf210, Clorf220, Clorf226, Clorf228, Clorf43, Clorf50, Clorf52, Clorf53, Clorf54, C1ORF55, Clorf56, Clorf61, Clorf87, C1Q, C1Q , C1QA, Clqb, C1QBP, C1QC, C1QL2, CIQs, C1QTNF2, C1QTNF3, C1QTNF3-AMACR, C1QTNF6, C1QTNF7, C1R, CIS, C2, C20ORF112, C20orfl44, C20orfl94, C20orfl96, C20orfl97, C20orf24, C20orf26, C20orf27, C20orf78, C20orf85, C20orf96, C21orfl 19, C21orf2, C21orf33, C21orf58, C21orf59, C21orf62, C21orf91, C22orfl3, C22orf23, C22orf29, C22orfi9, C2CD2, C2CD2L, C2orfl5, C2orf27A, C2orf29, C2orf40, C2orf47, C2orf49, C2orf61, C2orf70, C2orf72, C2orf74, C2orf80, C2orf81, C2orf82, C2orf88, C2orf91, C3, C3AR, C3AR1, C3orfl7, C3orf33, C3orfi8, C3orf52, C3orf56, C3orf58, C3orf62, C3orf67, C3orf70, C4b, C4BPB, C4orfl5, C4orfl9, C4orf22, C4orf27, C4orf29, C4orfi, C4orfi3, C4orf47, C4orf48, C5, C5AR1, C5orfl5, C5orfl7, C5orf22, C5ORF25, C5orf28, C5orfi4, C5orfi6, C5orf42, C5ORF45, C5orf47,C5orf49, C5orf55, C5orf56, C5orf58, C5ORF62, C5orf63, C5ORF64, C6orfl, C6orfl l8,C6orfl36, C6orfl65, C6ORF170, C6orf203, C6orf211, C6orf226, C6ORF25, C6orf47, C6orf48, C6orf52, C6orf62, C6orf89, C6orf99, C7, C7orfl0, C7orf25, C7orf26, C7orf50,C7orf54, C7orf55, C7orf57, C7orf63, C7orf65, C7orf66, C7orf73, C8G, C8orf31, C8orfi4,57299833684.1C8orf37-ASl, C8orf4, C8orf44, C8orf44-SGK3, C8orf46, C8orf59, C8orf76, C9orfll4, C9orfll6, C9orfll7, C9orfl35, C9orfl39, C9ORF142, C9orfl52, C9orfl56, C9orfl6, C9orfl71, C9orf24, C9orB, C9orf43, C9orf69, C9ORF72, C9orf78, C9orf84, C9orf85, C9ORF89, C9orf9, C9ORF91, CAI, CA10, CA12, CA125, CA-125, CAB, CA153, CA-153, CA199, CA-199, CA2, CA3, CA4, CA5B, CA6, CA7, CA8, CA9, CAAP1, CABIN1, CABLES1, CABLES2, CABP4, CABYR, CACA4, CACFD1, CACHD1, CACNA1A, CACNA1C, CACNA1D, CACNA1F, CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, CACNB1, Cacnb2, CACNB4, CACNG6, CACNG8, CACYBP, CADH1, CADH2, CADM1, CADM2, CADM4, Cadps, CADPS2, CALB1, CALB2, calbindin, CALC A, Calcitonin and Related Receptor Agonists, Calcitonin and Related Receptor Antagonists, Calcitonin R, CALCOCO1, CALCOCO2, CALCR, CALCRL, Calcyclin, CALD1, CALHM2, CALLA, CALM1, CALM2, CALM3, CALML3, CALML4, Calmodulin-dependent phosphodiesterase, CALN1, calpastatin, Calponin, Calponin 1, Calprotectin, CALR, CALR3, Calretinin, CALU, CALY, CAM 5.2, CAMK1, CAMKID, CaMK2 alpha, CAMK2A, CAMK2B, CAMK2D, CAMK2G, CAMK4, CAMKII-alpha, CAMKK2, CAMKMT, CAMKV, CAMLG, CAMP, CAMSAP1, CAMSAP3, CAMTAI, CAND1, CAND2, CANX, CAP1, CAPG, CAPN1, CAPN10-AS1, CAPN12, CAPN13, CAPN15, CAPN2, CAPN3, CAPN5, CAPN8, CAPNS1, CAPRIN2, CAPS, CAPS2, CAPSL, CAPZA1, CAPZA2, CAPZB, CAR, Carl, CAR8, CARBONIC-ANYDRASE, Carboxypeptidase M, CARD11, CARD16, CARD17, CARD19, CARD8, CARF, CARHSP1, CARKD, CARNMT1, CARS, CARS2, CARTPT, CASC1, CASC2, CASC3, CASC4, CASC5, CASD1, CASK, CASP1, CASP10, CASP2, CASP3, CASP4, CASP5, CASP7, CASP8, CASP8AP2, CASQ1, CASR, CAST, CASZ1, CAT, CATSPER2P1, CATSPERD, CATSPERG, CAV1, Cav-1, Cav2, Caveolin-1, CAVIN1, CAVIN2, CBF1, CBFA2T2, CBFA2T3, CBFB, CBLB, CBLL1, CBLN1, CBLN4, CBR1, CBR2, CBR3, CBS, CBWD1, CBWD5, CBX1, CBX2, CBX3, CBX4, CBX5, CBX6, CBX7, CBX8, CBY1, CC Chemokine Receptor D6, CC receptor, CC10, CC19, CC2512, CC27, CC2D2A, CCAR1, CCAT1, CCBE1, CCDC101, CCDC102A, CCDC102B, CCDC103, CCDC104, CCDC106, CCDC107, CCDC109B, CCDC11, CCDC110, CCDC112, CCDC113, CCDC114, CCDC115, CCDC12, CCDC121, CCDC122, CCDC124, CCDC125, CCDC127, CCDC13, CCDC130, CCDC132, CCDC134, CCDC136, CCDC137, CCDC141, CCDC142, CCDC144A, CCDC144B, CCDC144CP, CCDC144NL-AS1, CCDC146, CCDC148, CCDC15,58299833684.1CCDC150, CCDC152, CCDC153, CCDC155, CCDC157, CCDC158, CCDC160, CCDC162P, CCDC167, CCDC168, CCDC170, CCDC172, CCDC173, CCDC174, CCDC176, CCDC178, CCDC18, CCDC181, CCDC186, CCDC191, CCDC22, CCDC23, CCDC24, CCDC25, CCDC28A, CCDC28B, CCDC30, CCDC33, CCDC36, CCDC37, CCDC39, CCDC40, CCDC42, CCDC42B, CCDC43, CCDC47, CCDC50, CCDC57, CCDC59, CCDC6, CCDC60, CCDC64, CCDC65, CCDC66, CCDC67, CCDC69, CCDC7, CCDC72, CCDC73, CCDC74A, CCDC74B, CCDC78, CCDC79, CCDC80, CCDC81, CCDC82, CCDC83, CCDC84, CCDC85A, CCDC85B, CCDC85C, CCDC86, CCDC88A, CCDC88B, CCDC88C, CCDC90B, CCDC91, CCDC92, CCDC93, CCDC94, CCDC97, CCHCR1, CCK, CCKAR, CCKBR, CCL1, CCL11, CCL12, CCL13, CCL14, CCL15, CCL163, CCL17, CCL18, CCL19, CCL2, CCL-2, CCL20, CCL21, Ccl21a, CCL22, CCL23, CCL24, CCL25, CCL3, CCL3L3, CCL4, CCL4 / 5, CCL4L1, CCL4L2, CCL5, CCL6, CCL7, CCL8, Ccl9, CCM2, CCM2L, CCNA2, CCNB1, CCNB1IP1, CCNB2, CCNB3, CCNC, CCND1, CCND2, CCND3, CCNDBP1, CCNE2, CCNF, CCNG1, CCNG2, CCNH, CCNI, CCNI2, CCNJ, CCNJL, CCNK, CCNL1, CCNL2, CCNO, CCNT1, CCNT2, CCPG1, CCR1, CCR10, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, Ccr9, CCRL2, CCS, CCSER1, CCSER2, CCT2, CCT3, CCT4, CCT5, CCT6A, CCT6B, CCT7, CCT8, CCZ1, CCZ1B, CD1, CD1 A, CD1 C, CD10, CD100, CD101, CD102, CD103, CD104, CD105, CD106, CD107, CD107A, CD107b, CD109, CD10-CD45RA-Flt3, CD10-CD45RA- Flt3-CD71, CD11, CD110, CD111, CD112, CD113, CD114, CD115, CD116, CD117, CD119, CDl la, CDl la-d, CDl lb, CDl lc, CD120, CD120a, CD120b, CD121a, CD121b, CD122, CD123, CD124, CD125, CD126, CD127, CD128, CD129, CD13, CD130, CD131, CD132, CD133, CD133A, CD134, CD135, CD137, CD138, CD14, CD140, CD140a, CD140b, CD141, CD142, CD143, CD144, CD146, CD147, CD148, CD15, CD150, CD151, CD152, CD154, CD156b, CD157, CD158, CD158a, CD158b, CD158blb2j, CD158e, CD158ele2, CD159a, CD16, CD160, CD161, CD162, CD162E, CD162P, CD163, CD163L1, CD164, CD164L2, CD 165, CD 166, CD 167, CD 167a, CD 169, CD16B, CD 17, CD 170, CD 171, CD 172a, CD172ab, CD172b, CD172g, CD173, CD177, CD178, CD18, CD180, CD181, CD182, CD183, CD184, CD185, CD186, CD19, CD19+, CD191, CD192, CD193, CD194, CD195, CD196, CD197, CD198, CDla, CDlb, CD1C, CD1D, CD1E, CDllb, CD2, CD20, CD20+, CD200, CD200R, CD200R1, Cd200r3, CD201, CD202b, CD203c, CD204, CD205, CD206, CD207, CD207 , CD209, CD209 , Cd209a, Cd209d, CD21, CD212, CD217, CD218, CD218a, CD22, CD220,59299833684.1CD223, CD224, CD226, CD227, CD229, CD23, CD230, CD231, CD233, CD235, CD235a, CD235ab, CD24, CD242, CD243, CD244, CD247, CD248, CD25, CD250, CD252, CD253, CD254, CD257, CD258, CD26, CD267, CD268, CD269, CD27, CD27+, CD270, CD271, CD272, CD273, CD274, CD275, CD276, CD277, CD278, CD279, CD27-AS1, CD28, CD281, CD282, CD283, CD284, CD286, CD287, CD288, CD289, CD28H, CD29, CD292, CD294, CD298, CD299, CD2AP, CD2BP2, CD3, CD30, CD300A, CD300C, CD300E, CD300g, CD300LB, CD300LF, CD300LG, CD301, CD302, CD303, CD304, CD305, CD307d, CD309, CD30L, CD31, CD314, CD317, CD318, CD319, CD32, CD320, CD323, CD324, CD325, CD326, CD328, CD32b, CD33, CD332, CD335, CD336, CD337, CD338, CD34, CD340, CD344, CD344, CD349, CD35, CD352, CD354, CD355, CD357, CD36, CD360, CD365, CD366, CD369, CD37, CD370, CD371, CD38, CD39, CD3D, CD3D25, CD3E, CD3EAP, CD3G, CD3Z, CD3y, CD38, CD3s, CD3 CD4, CD4+, CD40, CD40L, CD40LG, CD41, CD41a, CD41b, CD42, CD42a, CD42b, CD42c, CD42d, CD43, CD43+, CD431, CD44, CD44 variant6, CD44R, CD44v, CD44v3, CD44v6, CD44v8-10, CD44v9, CD45, CD45.1, CD45.2, CD45b, CD45d, CD45R, CD45RA, CD45RB, CD45RO, CD45RO, CD46, CD46RO, CD47, CD48, CD49, CD49a, CD49b, CD49c, CD49d, CD49e, CD49f, CD4D, CD5, CD50, CD51, CD52, CD53, CD54, CD55, CD56, CD57, CD58, CD59, CD5A, CD5E, CD5L, CD6, CD60a, CD60b, CD61, CD62, CD62E, CD62L, CD62P, CD63, CD63-PS, CD64, CD65, CD66, CD66a, CD66b, CD66c, CD66D, CD66e, CD68, Cd-68, CD68, CD6824, CD69, CD69, CD69a, CD7, CD70, CD71, CD72, CD73, CD74, CD75, CD77, CD78, CD79, CD798, CD79A, CD79B, CD8, CD8+, CD80, CD81, CD82, CD83, CD84, CD85, CD85a, CD85d, CD85g, CD85h, CD85j, CD85k, CD86, CD87, CD88, CD89, CD8A, CD8aa, CD8B, Cd8bl, CD8EM1, CD8a, CD8P, CD9, CD90, CD91, CD92, CD93, CD94, CD95, CD96, CD97, CD98, CD99, CD9g, CDA, CDADC1, CDC123, CDC14A, CDC14B, CDC16, cDC2, CDC20, CDC20B, CDC23, CDC25B, CDC25C, CDC26, CDC34, CDC37, CDC37L1, CDC40, CDC42, CDC42 1, CDC42EP1, CDC42EP2, CDC42EP3, CDC42EP4, CDC42SE1, CDC42SE2, CDC45, CDC5L, CDC7, CDC73, Cdca3, CDCA4, CDCA5, CDCA7, CDCA7L, CDCA8, CDCP1, CDF15, CDH1, CDHl / E-cadherin, CDH11, CDH12, CDH13, CDH17, CDH1718, CDH18, CDH19, CDH2, CDH23, CDH3, CDH4, CDH5, CDH6, CDH9, CDHR1, CDHR3, CDHR4, CDHR5, CDIC, CDIP1, CDIPT, CDIPT-AS1, CDK1, CDK11A, CDK11B, Cdkl2, CDK13, CDK14, CDK15, CDK17, CDK18, CDK2AP1, CDK2AP2, CDK4, CDK5, CDK5R1, CDK5RAP1, Cdk5rap3,60299833684.1CDK6, Cdk7, CDK9, CDKL1, CDKL2, CDKL3, CDKN1A, CDKN1B, CDKN1C, CDKN2A, CDKN2AIP, CDKN2B, CDKN2B-AS1, CDKN2C, CDKN2D, CDKN3, CD01, CDON, CDR1, CDR2, CDR3, CDS1, CDS2, CDSN, CDT1, CDV3, CDW198, CDw32, CDw338, CDX1, CDX2, CDYL, CEA, CEACAM, CEACAM1, CeacamlO, CEACAM21, CEACAM22P, CEACAM3, CEACAM5, CEACAM6, CEACAM7, CEACAM8, CEACM6, CEBPA, CEBPB, CEBPD, CEBPE, CEBPG, CEBPZ, CEBPZOS, CEBPa, CECAM4, CECR1, CECR2, CECR4, CECR5, CEL, CELA2A, CELA3A, CELA3B, CELF1, CELF2, CELF4, CELP, CELSR1, CENP1, CENPA, CENPC, CENPE, CENPF, CENPJ, CENPK, CENPM, CENPN, CENPP, CENPQ, CENPT, CENPU, CENPW, CEP104, CEP120, CEP131, CEP135, CEP152, CEP162, CEP164, CEP19, CEP250, CEP290, CEP295, CEP350, CEP44, CEP57, CEP63, CEP68, CEP76, CEP78, CEP83, CEP85L, CEP95, CEP97, Cepbe, CEPT1, CER1, CERCAM, Cerebellin, CERK, CERS3, CERS4, CERS5, CERS6, CES1, CES1P1, CES2, CES4A, CETN2, CETN3, CF, CFAP126, CFAP20, CFAP221, CFAP299, CFAP36, CFAP43, CFAP44, CFAP46, CFAP47, CFAP52, CFAP53, CFAP54, CFAP57, CFAP58, CFAP61, CFAP69, CFAP70, CFAP97, CFB, CFD, CFDP1, CFH, CFHR1, CFHR4, CFI, CFL1, CFL1P1, CFL2, CFLAR, c- Fos, CFP, CFTR, CG030, CGA, CGB, CGGBP1, cGMP-dependent protein kinase, CGNL1, CGRP, CGRRF1, CH17-189H20.1, CH17-340M24.3, CH17-353B19.1, CH25H, CHAC2, CHAF1A, CHAT, CHC22, CHCHD10, CHCHD2, CHCHD3, CHCHD4, CHCHD5, CHCHD6, CHCHD7, CHD1, CHD1L, CHD2, CHD3, CHD4, CHD5, CHD6, CHD7, CHD9, CHDH, CHE1, CHEK1, CHEK2, CHEK2P2, CHERP, CHFR, CHG1, CHGA, CHGB, CHI3L1, CHI3L2, CHICI, CHIC2, Chill, CHIT1, CHKB, Chll, CHM, CHMP1A, CHMP1B, CHMP1B2P, CHMP2A, CHMP2B, CHMP4A, CHMP4B, CHMP4C, CHMP6, CHMP7, CHN1, CHN2, Choline acetyltransferase, CHORDCI, CHP1, CHP2, CHPF, CHPF2, CHPT1, CHRAC1, CHRDL1, CHRDL2, CHRM3, CHRM3-AS2, CHRNA1, CHRNA3, CHRNA7, CHRNB1, CHRNB4, CHRNE, Chromogranin, Chromogranin A, CHST1, Chstl l, CHST12, CHST13, CHST15, CHST2, CHST3, CHST5, CHST8, CHST9, CHSY1, CHTF8, CHTOP, CHUK, CHURC1, CIAO1, CIAPIN1, CIART, CIB1, CIB2, CIC, CIDEA, CIDEB, CIITA, CILP, CINP, CIPC, CIR1, CIRBP, CIRH1A, CISDI, CISD2, CISD3, CISPLATIN, CITED, CITED1, CITED2, CITED4, CIZ1, CK, CK13, CK14, CK15, CK17, CK-17, CK18, CK19, CK- 19, CK20, CK3, CK44, CK5, CK6, CK7, CK8, CK9, CKAP2, CKAP2L, CKAP4, CKAP5, CKB, cKIT, c-Kit, CKLF, Ckm, CKMT2, CKMT2-AS1, CKS1B, CKS2, CLACSF13, CLASP1,61299833684.1CLASP2, CLASRP, class III beta-tubulin, Claudin, Claudin-1, Claudin-4, claudin-5, CLC, CLCA1, CLCA2, CLCA4, CLCC1, CLCN2, CLCN3, CLCN5, CLCNKA, CLCNKB, CLDN1, CLDN10, CLDN11, CLDN12, CLDN15, CLDN16, CLDN18, CLDN19, CLDN2, CLDN23, CLDN3, CLDN4, CLDN5, CLDN6, CLDN7, CLDN8, CLDND1, CLE4C, CLEC1OA, CLEC11A, CLEC12A, CLEC14A, CLEC16A, CLEC17A, CLEC18A, CLEC18B, CLEC1A, CLEC1B, CLEC2B, CLEC2D, CLEC3B, CLEC4A, CLEC4C, CLEC4D, CLEC4E, CLEC4F, CLEC4G, CLEC4GP1, CLEC4M, CLEC5A, CLEC7A, CLEC9A, CLEC9Q, CLECL1, CLGN, CLHC1, Clicl, CLIC2, CLIC3, CLIC5, CLIC6, CLIM1, CLINT1, CLIP1, CLIP-170, CLIP3, CLIP4, CLK1, CLK3, CLK4, CLKT1, CLL1, CLL-1, CLMN, CLMP, CLN3, CLN8, CLND5, CLNK, CLNS1A, CLOCK, clone C8 / 144B, clone KPI, CLP1, CLPP, CLPS, CLPTM1, CLPTM1L, CLPX, CLSPN, CLSTN2, CLSTN3, CLTB, CLTC, CLTCL1, CLU, CLUAP1, CLUH, Clusterin, CMA1, c-Maf, CMAH, CMAHP, CMAS, CMBL, CMC1, CMC2, CMC4, c- Met, CMIP, CMKLR1, CMo, CMPK1, CMPK2, CMSS1, CMTM2, CMTM3, CMTM6, CMTM7, CMTR1, CMTR2, CMYA5, c-Myc, CNAs, CNBG3, CNBP, CNDP1, CNDP2, CNEP1R1, CNGA1, CNIH1, CNIH3, CNIH4, CNKSR1, CNKSR2, CN-LOH, CNN1, CNN2, Cnn3, CNNM2, CNNM3, CNOT1, CNOT11, CNOT2, CNOT3, CNOT4, CNOT6L, CNOT7, CNP, CNPPD1, CNPY2, CNPY3, CNR1, CNR2, CNRIP1, CNTD1, CNTD2, CNTLN, CNTN1, CNTN2, CNTN3, CNTN4, CNTNAP1, CNTNAP2, CNTNAP3, CNTRL, CNTROB, CNV, CO3D, COA1, COA3, COA4, COA5, COA7, Coagulation Factor III, COASY, COBL, COBLL1, COCH, COG1, COG2, COG3, COG4, COG5, COG6, COG7, COL I, COL1, COL10A1, COL11A1, COL11A2, COL12A1, COL13A1, COL14A1, COL15A1, Coll6al, COL17A1, COL18A1, COL19A1, COL1A, COL1A1, COL1A1, COL1A2, COL1A4, Collal, COL2, COL20A1, COL21A1, COL22A1, COL23A1, COL23A13, COL24A1, COL25A1, COL27A1, COL28A1, COL2A1, COL2A2, COL3A1, COL4A1, COL4A2, COL4A3, COL4A4, COL4A5, COL5A1, COL5A2, COL5A3, COL6A1, COL6A2, COL6A3, COL6A5, COL6A6, COL7A1, COL8A1, COL8A2, COL9A1, COL9A2, COL9A3, COLCA2, ColeclO, COLECI 1, COLEC12, COLGALT1, collagen I, Collagen-1, collagenla2, collagen3al, collagens, COLQ, C0MMD1, COMMDIO, C0MMD2, C0MMD3, C0MMD5, C0MMD6, C0MMD7, C0MMD8, COMP, COMT, Connexin 43, COPB1, COPB2, COPE, COPG1, COPS3, COPS4, COPS5, COPS6, COPS7B, COPS8, COPZ1, COQIOA, COQIOB, COQ4, COQ5, COQ7, COQ8A, COQ9, CORIN, CORO1A, CORO1B, COROIC, CORO2A, CORO7, CORO7-62299833684.1PAM16, CORT, COSMIC v89, COTL1, COUP-TF, COX11, COX14, COX15, COX16, COX17, COX18, COX19, COX2, COX4I1, COX4I2, COX5A, COX5B, COX6A1, COX6A2, COX6B1, COX6B2, COX6C, COX7A1, COX7A2, COX7A2L, COX7B, COX7B2, COX7C, COX8A, COX8C, Coxsackievirus and adenovirus receptor, CP, CPA1, CPA2, CP A3, CPA33, CPA6, CPB1, CPB2, CPD, CPE, CPEB1, CPED1, C-peptide, CPLX2, CPM, CPN1, CPNE1, CPNE2, CPNE3, CPNE4, CPNE5, Cpne8, CPODXL, CPOX, CPPED1, CPS1, CPSF3, CPSF3L, CPSF4, CPSF6, CPSF7, CPS-II, CPT1A, CPT1C, CPT2, CPVL, CPXM1, CPZ, CR1, CR1P1, CR2, CR3, CRABP1, CRABP2, CRABPI, CRACR2A, CRALBP, CRAMP1L, CRAT, CRB1, CRBN, CRBP1, CRCP, CREB1, CREB3, CREB3L1, CREB3L2, CREB3L4, CREB5, CREBBP, CREBL2, CREBRF, CREBZF, CREG1, CREG2, c-Rel, CRELD1, CRELD2, CREM, CRH, CRHBP, CRIg, CRIM1, CRIP1, CRIP2, CRIPAK, CRIPT, Cripto, CRISPED 1, CRISPLD2, CRKL, CRLF1, CRLF2, CRLF3, CRMP1, CRNDE, CRNKL1, CROCC, CROCCP2, CRP, CRTAC1, CRT AM, CRTAP, CRTC1, CRTC2, CRTC3, CRTH2, CRTR1, CRX, CRY1, CRY2, CRYAB, CRYBA2, CRYBB1, CRYBB2, CRYBG3, CRYGD, CRYL1, CRYM, CRYM-AS1, CRYZ, CRYZL1, CSAD, CSC, CSDC2, CSDE1, CSF1, CSF1R, CSF2, CSF2RA, CSF2RB, CSF3, CSF3R, Csgalnactl, CSGALNACT2, CSK, CSMD1, CSMD3, CSN1S1, CSN2, CSNK1A1, CSNK1D, CSNK1E, CSNK1G1, CSNK1G2, CSNK1G3, CSNK2A1, CSNK2A2, CSNK2B, CSPG2, CSPG4, CSPG4 / NG2, CSPG5, CSPP1, c-Src, CSRNP1, CSRNP3, CSRP1, CSRP2, CSRP2BP, Csrp3, CST1, CST2, CST3, CST4, CST6, CST7, CSTA, Cstal, CSTB, CSTF2T, CSTF3, CSTV, CT, CT47B1, CTA-246H3.8, CTA- 293F17.1, CTAGE5, CTB-178M22.2, CTB-31O20.2, CTB-43P18.1, CTB-61M7.2, CTBP1, CTBP1-AS, CTBP1-AS2, CTBP2, CTBS, CTC1, CTC-479C5.12, CTC-487M23.8, CTC- 523E23. i l, CTCF, CTCFL, CTD-2020K17.1, CTD-2035E11.3, CTD-2090I13.1, CTD- 2162K18.3, CTD-2201I18.1, CTD-2325P2.4, CTD-2341M24.1, CTD-2384A14.1, CTD- 2538C1.2, CTD-2540F13.2, CTD-2544N14.3, CTD-3184A7.4, CTDNEP1, CTDP1, CTDSP1, CTDSP2, CTDSPL, CTDSPL2, CTF1, CTGF, CTH, CTHRC1, CTIP2, Ctkl, CTL, CTLA, CTLA4, CTLA-4, cTnl, CTNNA1, CTNNA3, Ctnnall, CTNNB1, CTNNB1 S37C, Ctnnbipl, CTNNBL1, CTNS, cTnT, CTPS1, CTR, CTR2, CTR9, CTRB1, CTRB2, CTRC, CTRL, CTSA, CTSB, CTSC, CTSD, CTSE, CTSF, CTSG, CTSH, CTSK, Ctsl, CTSL1, CTSO, CTSS, CTSV, CTSW, CTSZ, CTTNBP2, CTTNBP2NL, CTXN1, CTXN3, C-type lectin-like receptor dectin- 1, CUBN, CUEDC2, CUL1, CUL2, CUL3, CUL4A, CUL4B, CUL5, CUL9, CUTA, CUTC,63299833684.1CUX1, CUX2, CUZD1, CWC15, CWC22, CWC25, CWF19L1, CWF19L2, CWH43, CX26, CX37, CX3CL1, CX3CR1, Cx3crl-GFP, CX3XR1, CX43, CXADR, CXC chemokine receptor, CXCL1, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, CXCL16, CXCL17, CXCL2, CXCL3, CXCL5, CXCL6, CXCL8, CXCL9, CXCR, CXCR1, CXCR2, CXCR3, CXCR4, CXCR5, CXCR6, CXCR7, CXORF21, CXorf23, CXorfiO, CXorfi6, CXorfi8, CXorf40A, CXorf58, CXorf65, CXorf67, CXXC1, CXXC4, CXXC5, CYB561, CYB561A3, CYB561D2, CYB5A, CYB5B, CYB5D1, CYB5D2, CYB5R2, CYB5R3, CYB5R4, CYB5RL, CYBA, CYBASC3, CYBB, CYBRD1, CYC1, Cyclic potein-2, CyclinA2, CYCS, CYFIP1, CYFIP2, CYGB, CYLD, CYorfl5B, CYP11A1, CYP11B1, CYP11B2, CYP17, CYP17A1, CYP19A1, CYP1B1, CYP20A1, CYP26A1, CYP26B1, CYP27A1, CYP2A13, CYP2B7P, CYP2C9, CYP2E1, CYP2F1, CYP2F2, CYP2J2, CYP2R1, CYP2S1, CYP2U1, CYP2W1, CYP3A1, CYP3A4, CYP3A5, CYP3A7, CYP46A1, CYP4B1, CYP4F12, CYP4F3, CYP4V2, CYP4X1, CYP51A1, CYP51A1-AS1, Cyp7bl, CYPD2, Cyr61, CYSLTR1, CYSLTR2, Cystatin C, Cystic fibrosis transmembrane conductance regulator, CYSTM1, CYTH1, CYTH3, CYTH4, CYTIP, CYTL1, Cytokeratin, Cytokeratin 19, cytokeratin 20, cytokeratin 5, Cytokeratin AE1, Cytokeratin AE3, Cytokeratin- 14, Cytokeratin- 15, Cytokeratin- 17, Cytokeratin- 18, Cytokeratin- 19, Cytokeratin-20, Cytokeratin- 5, Cytokeratin-7, Cytokeratin-8, cytokeratins, CYTOR, CYYR1, DI 05, D2R, D7-FIB, DAAM1, DAAM2, DAB1, DAB2, DAB2IP, DACH1, DACH2, DACT1, DADI, DAG1, DAGLA, DAK, Dako, DALRD3, DANCR, DAND5, DANNF1, DAP, DAP3, DAPI, Dapkl, DAPK2, DAPL1, DAPP1, DARC, DARS, DARS-AS1, DAW1, DAXX, DAZAP1, DAZAP2, DAZL, DAZL1, DBF4, DBH, Dbi, DBIL5P2, DBN1, DBNL, DBT, DBX1, DBX2, DCAF10, DCAF11, DCAF12, DCAF12L1, DCAF13, DCAF16, DCAF4, DCAF4L1, DCAF4L2, DCAF5, DCAF6, DCAF7, DCAKD, DCAMKL-1, DCBLD2, DCD, DCDC1, DCDC2, Dcdc2a, DCDC5, DCHS1, DCHS2, DCIR, DCK, DCL, DCLAMP, DC-LAMP, DCLK1, DCLK2, DCLRE1A, DCLRE1C, DCN, DCP1A, DCP1B, DCP2, DCPS, DC-SIGN, DCSTAMP, DC-STAMP, DCT, DCT2, DCTD, DCTN1, DCTN2, DCTN3, DCTN4, DCTN5, DCTN6, DCUN1D1, DCUN1D2, DCUN1D3, DCUN1D5, DCX, DCXR, DDA1, DDAH1, DDAH2, DDB1, DDB2, DDC, ddhCTP, DDHD1, DDHD2, DDIT3, DDIT4, DDIT4L, DDOST, Ddrl, DDR2, DDRGK1, DDT, DDX1, DDX10, DDX11, DDX11L5, DDX17, DDX18, DDX19B, DDX21, DDX23, DDX24, DDX26B, DDX27, DDX28, DDX31, DDX39A, DDX39B, DDX3X, DDX3Y, DDX4, DDX41, DDX46, DDX47,64299833684.1DDX49, DDX5, DDX50, DDX51, DDX52, DDX55, DDX58, DDX59, DDX6, DDX60, DDX60L, DECI, DECR1, DECR2, Dectin-1, DEDD, DEDD2, DEF6, DEFA4, DEFA5, DEFA6, DEFBI, Degsl, DEGS2, DEK, deltaNp63, DENND1B, DENND1C, DENND2C, DENND2D, DENND3, DENND4A, DENND4C, DENND5A, DENND5B, DENND6A, DENR, DEPDC1, DEPDC1B, DEPDC7, DEPTOR, DERA, DERL1, DERL2, DERL3, DES, Desert hedgehog, DESI1, DESI2, DESMIN, desmoplakins, DEUP1, DFFA, DFNA5, DFNB31, DGAT1, DGAT2, DGCR6, DGCR6L, DGKA, DGKB, DGKD, DGKE, DGKG, DGKH, Dgki, DGKQ, DGKZ, DGUOK, DGU0K-AS1, DHCR24, DHCR7, DHFR, DHFRL1, DHPS, Dhrsl, DHRS13, DHRS2, DHRS3, DHRS4-AS1, DHRS7, DHRS9, DHTKD1, DHX29, DHX30, DHX32, DHX33, DHX35, DHX36, DHX38, DHX40, DHX58, DHX8, DHX9, DIABLO, DIAPH1, DIAPH2, DIAPH3, DID01, DIEXF, DIMT1, DIO2, DIP2A, DIP2B, DIP2C, Dipeptidyl peptidase 4, DIPK1C, DIRAS3, DIS3, DIS3L, DISCI, DISP1, DISP2, DIXDC1, DKC1, DKFZP451J181, DKFZP58611420, DKFZP667P0924, DKK1, DKK2, DKK3, DLA- CTC, DLAT, DLC1, DLD, DLEC1, DLEU1, DLG1, DLG3, DLG5, DLG5-AS1, Dlgapl, DLGAP1-AS1, DLGAP1-AS2, DLGAP4, DLGAP4-AS1, DLGAP5, DLK, DLK1, DLK2, DLL1, DLL3, DLL4, DLX1, DLX2, DLX4, DLX5, DLX6, DLX6-AS1, DMBT1, DMBT1P1, DMBX1, DMC1, DMD, DMGDH, DMKN, DMP1, DMPK, DMRT, DMRT1, DMRT2, DMRTB1, DMRTC2, DMTF1, DMTN, DMXL1, DMXL2, DNA1, DNA2, DNAAF1, DNAAF2, DNAAF3, DNAH1, DNAH10, DNAH11, DNAH12, DNAH14, DNAH17, DNAH2, DNAH3, DNAH5, DNAH6, DNAH7, DNAH9, DNAI1, DNAI2, DNAJA1, DNAJA2, DNAJA4, DNAJB1, DNAJB11, DNAJB12, DNAJB13, DNAJB14, DNAJB2, DNAJB4, DNAJB6, DNAJB9, DNAJC1, DNAJC10, DNAJC11, DNAJC12, DNAJC14, DNAJC15, DNAJC17, DNAJC19, DNAJC2, DNAJC21, DNAJC22, DNAJC25, DNAJC27, DNAJC3, DNAJC30, DNAJC3-AS1, DNAJC4, DNAJC5B, DNAJC6, DNAJC7, DNAJC8, DNAJC9, DNAL1, DNAL4, DNALI1, DNAM-1, DNASE1, DNASE1L3, DNASE2, DNASE2B, DND1, DNER, DNHD1, DNLZ, DNM1, DNM1L, DNM1P46, DNM2, DNMBP, DNMBP-AS1, DNMT1, DNMT3A, DNMT3B, Dnmt31, DNPEP, DNPH1, DNTT, DNTTIP1, DNTTIP2, DOC2A, DOC2GP, DOCK1, DOCKIO, DOCK11, DOCK2, DOCK4, DOCK5, DOCK6, DOCK7, DOCK8, DOCK9, DOG1, DOK2, DOK3, DOK4, DOK5, DOK7, DOLPP1, Dopamine transporter, DOPEY1, Doublecortin, Doublecortin-like kinase 1, DPAGT1, DPCD, DPEP1, DPEP2, DPEP3, DPF1, DPF2, DPF3, DPH3, DPH5, DPH7, DPIV, DPMI, DPM3, DPP3, DPP4,65299833684.1DPP6, DPP7, DPP9, DPPA2, Dppa3, DPPA4, DPPA5, DPT, DPY19L1, DPY19L1P1, DPY19L2, DPY19L2P2, DPY30, DPYD, DPYS, DPYSL2, DPYSL3, DPYSL5, DQ572107, DQ575504, DQ576756, DR, DR1, DR6, DRAM2, DRAP1, DRAXIN, DRCI, DRD1, DRD2, DRG2, Drp6, DSAP, DSC1, DSC2, DSC3, DSCAM, DSCR3, DSE, DSEL, DSG1, DSG3, DSN1, DSP, DST, DSTN, DSTNP2, DSTYK, DTD1, DTHD1, DTL, DTNA, DTNB, DTNBP1, DTX3, DTX3L, DTX4, DTYMK, DU0X2, DU0XA2, DUS1L, DUS3L, DUS4L, DUSP1, DUSP10, DUSP11, DUSP13, DUSP16, DUSP18, DUSP19, DUSP2, DUSP22, DUSP23, DUSP4, DUSP5, DUSP6, DUSP7, DUSP8, DUSP9, DUT, DUXA, DVL1, DVL2, DVL3, DYDC1, DYDC2, DYM, DYNC1H1, DYNC1I2, DYNC1LI1, DYNC1LI2, DYNC2H1, DYNC2LI1, DYNLL1, DYNLL2, DYNLRB1, DYNLRB2, DYNLT1, DYNLT3, DYRK1A, DYRK2, DYRK4, DYSF, DYX1C1, DZANK1, DZIP1, DZIP1L, DZIP3, El l, E2-2, E2F2, E2F3, E2F4, E2F5, E2F7, E2F8, E4BP4, EAAT1, EAAT2, EAF1, EAF2, EAPP, EARS2, EBAG9, EBER, EBER1, EBF1, EBF2, Ebf3, EBB, EBLN2, EBLN3, EBNA1BP2, EBP, EBPL, EC, ECAD, E-CADH, Ecadherin, E-cadherin, E-cadherin, ECD, ECE1, ECE2, ECHI, ECHDC1, ECHDC2, ECHS1, ECI2, ECM, ECM1, ECM2, ECP, ECSCR, ECSIT, ECT2, ECT2L, EDARADD, EDC4, EDEMI, EDEM2, EDF1, EDG1, EDG3, EDG5, EDG6, EDG8, EDIL3, EDN1, EDNRA, EDNRB, EEF1A1, EEF1A2, EEF1B2, EEF1D, EEF1G, eEFlal, EEF2, EEF2K, EEF2KMT, EEFSEC, EEPD1, EFCAB1, EFCAB1O, EFCAB11, EFCAB13, Efcabl4, EFCAB2, EFCAB5, EFCAB7, EFEMP1, EFEMP2, EFGF, EFHB, EFHC1, EFHC2, EFHD1, EFHD2, EFNA1, EFNA2, EFNA3, EFNA5, EFNB1, EFNB2, EFR3A, EFR3B, EFTUD2, EGF, EGFEM1P, EGFL6, EGFL7, EGFLAM, EGFR, EGFR2, EGFR-TKI, EGFRvIII, EGLN1, EGLN2, EGLN3, EGR1, Egr2, EGR3, EGR4, EHBP1L1, EHD1, EHD2, Ehd3, EHD4, EHF, EHHADH, EHMT1, EHMT2, EI24, EID1, EID3, EIF1, EIF1AD, EIF1AX, EIF1AX-AS1, EIF1AY, EIF1B, eIF2, EIF2A, EIF2AK1, EIF2AK2, EIF2AK3, EIF2B1, EIF2B2, EIF2B4, EIF2B5, EIF2D, EIF2S1, EIF2S2, EIF2S2P3, EIF2S3, EIF3A, EIF3B, EIF3D, EIF3E, EIF3EP1, EIF3F, EIF3G, EIF3H, EIF3I, EIF3J, EIF3K, EIF3L, EIF3M, EIF4A1, EIF4A2, EIF4A3, EIF4B, EIF4E, EIF4E2, EIF4EBP1, EIF4EBP2, EIF4ENIF1, eIF4G, EIF4G1, EIF4G2, EIF4H, EIF5, eIF5A, EIF5A2, EIF5AL1, EIF5B, eIF6, ELA2, ELAC1, ELAC2, ELANE, ELAVL1, ELAVL2, ELAVL3, ELAVL4, ELF1, ELF2, ELF3, ELF5, ELK1, ELK3, ELK4, ELL2, ELMO1, ELMOD1, ELMOD3, ELMSAN1, ELN, ELN, ELOF1, ELOVL1, ELOVL2, ELOVL2-AS1, ELOVL3, ELOVL4, ELOVL5, ELOVL6, ELP2, ELP4, ELP5, ELP6,66299833684.1ELTD1, EMA, EMB, EMBP, EMC 10, EMC2, EMC3, EMC3-AS1, EMC4, EMC6, EMC7, EMC8, EMC9, EMCN, EMD, EMG1, EMIDI, EMILIN2, EML2, EML3, EML4, EML6, EMMPRIN, EMP1, EMP2, EMP3, EMR1, EMR2, EMR4P, EMT, EMX1, EMX2, EN1, EN2, ENAH, ENAM, ENCI, Endocan, ENDOD1, ENDOG, Endoglin, Endomucin, ENG, ENGASE, ENHO, ENKD1, ENKUR, ENO1, ENO2, ENOPH1, ENOS, ENOSF1, Enoxl, ENPEP, ENPP1, ENPP2, ENPP3, ENPP4, Enpp5, ENPP6, ENPP7, ENPP7P13, ENSA, ENTHD2, ENTPD1, ENTPD1-AS1, ENTPD2, ENTPD3, ENTPD4, ENTPD6, ENTPD7, ENTPD8, ENY2, EOMES, EOS, EP300-AS1, EP400, EPAS1, EPB41, EPB41L1, EPB41L2, EPB41L3, EPB41L4A-AS1, EPB41L4B, EPB41L5, EPB42, EPCI, EPC2, EPCAM, EpCAM, EPCR, Epdrl, EPG5, EPHA10, EPHA1-AS1, EPHA2, EPHA4, EPHA7, EPHB1, EPHB2, EPHB4, EPHX1, EPHX2, Epithelial cellular adhesion molecule, Epithelial Sodium Channels alpha, Epithelial Sodium Channels beta, Epithelial Sodium Channels delta, Epithelial Sodium Channels gamma, EPM2AIP1, EPN1, EPN2, EPO, Epor, EPRS, EPS15, EPS15L1, EPS8, EPS8L1, EPS8L2, EPS8L3, epsilon-Sarcoglycan, EPSTI1, EPX, EPYC, ER, ERAP1, ERAP2, ERBB2, Erbb2ip, ERBB3, ERBB4, ERC1, ERCC1, ERCC3, ERCC4, ERCC5, ERCC6L2, EREG, ERF, ERG, ERGIC1, ERGIC2, ERGIC3, ERH, ERI1, ERB, ERICH1, ERICH2, ERICH5, ERICH6-AS1, ERK, ERLEC1, ERMARD, ERMN, ERMP1, ERN1, ERN2, ERO1B, ERO1LB, ERP27, ERP29, ERP44, ERRFI1, ERSP1, ERVK13-1, ERVK3-1, ERVV-1, Eryth, Erythropoietin R, Erythropoietin receptor, ESA, ESAM, ESCO1, ESCO2, ESD, ESE3B, ESF1, ESGP, ESMI, ESRI, ESR2, ESRG, ESRP1, ESRP2, ESRRB, ESX1, ESYT1, ESYT2, ESYT3, ETF1, ETFA, ETFB, ETFDH, ETHE1, ETL4, ETNK1, ETNK2, ETNNPL, ETS1, ETS2, ETV1, ETV2, ETV3, ETV4, ETV5, ETV6, ETV7, EVA1A, EVA1B, EVC2, EVI1, EVI2A, EVI2B, EVI5, EVI5L, EVL, EVPL, EVT, EWSR1, EXD2, EXD3, EXO5, EXOCI, EXOC2, EXOC3, EXOC3L1, EXOC3L2, EXOC4, EXOC7, EXOG, EXOSC1, EXOSCIO, EXOSC2, EXOSC3, EXOSC5, EXOSC6, EXOSC7, EXOSC8, EXPH5, EXT1, EXTL2, EYA1, EYA2, EYA3, EYS, EZH1, EZH2, EZR, Ezrin, F10, FUR, F13A1, F2, F2R, F2RL1, F3, F4, F4 / 80, F5, F8, F80, FA2H, FAAH2, FAAP20, Fab7, FABP1, FABP2, FABP3, FABP4, FABP5, FABP5P3, FABP6, FABP7, FABP8, FABP9, F-ACTIN, FADS2, FADS6, FAH, FAHD1, FAHD2A, FAHD2B, FAIM, FAIM2, FAK, FAM101B, FAM102A, FAM102B, FAM103A1, FAM104A, FAM104B, FAM105A, FAM106A, FAM107A, FAM107B, FAM108C1, FAM109A, FAM110A, FAM110B, F AMI 10C, FAM111A, FAM111B, FAM114A1, FAM114A2, FAM117A,67299833684.1FAM117B, FAM118A, FAM119A, FAM120AOS, FAM122B, FAM122C, FAM124A, FAM124B, FAM126A, FAM126B, FAM127B, FAM129A, FAM129B, FAM129C, FAM132B, FAM133A, FAM133B, FAM134B, FAM134C, FAM135A, FAM136A, FAM13A, FAM149A, FAM150B, FAM151B, FAM153C, FAM154B, FAM157C, FAM159A, FAM159B, FAM160A1, FAM160A2, FAM160B1, FAM161A, FAM162A, FAM162B, FAM166B, FAM167A, FAM167A-AS1, FAM168A, FAM168B, FAM169A, FAM171A1, FAM172A, FAM173A, FAM174A, FAM174B, FAM175B, FAM177A1, FAM177B, FAM178A, FAM178B, FAM179A, FAM181B, FAM183A, FAM184A, FAM184B, FAM188A, FAM189A1, FAM189A2, FAM190A, FAM192A, FAM193B, FAM195A, FAM195B, FAM198B, FAM19A1, FAM19A4, FAM200B, FAM204A, FAM207A, FAM208A, FAM208B, FAM20B, FAM20C, FAM210B, FAM212A, FAM212B, FAM213A, FAM214A, FAM214B, FAM216A, FAM216B, FAM217B, FAM219A, FAM219B, FAM220A, FAM221 A, FAM222A, FAM222B, FAM227A, FAM227B, FAM228A, FAM228B, FAM229A, FAM229B, FAM230B, FAM23 ID, FAM26F, FAM26F, FAM27C, FAM301, FAM30A, FAM32A, FAM35A, FAM3B, FAM3C, FAM41C, FAM43A, FAM45A, FAM45B, FAM46A, FAM46B, FAM46C, FAM49A, FAM49B, FAM50A, FAM50B, FAM53B, FAM53C, FAM58A, FAM60A, FAM63B, FAM64A, FAM65A, FAM65B, FAM65C, FAM69A, FAM69B, FAM71E1, FAM71F2, FAM73A, FAM74A3, FAM76A, FAM76B, FAM78A, FAM81B, FAM83A, FAM83C, FAM83D, FAM83E, FAM83G, FAM84A, FAM84B, FAM89B, FAM8A1, FAM92A1, FAM92B, FAM95C, FAM96A, FAM96B, FAM98A, FAM98C, FAM9B, FAM9C, FAN1, FANCD2, FANCI, FANCL, FANK1, FAP, FAP-1, FAR1, FAR2, FAR2P1, FARP1, FARP2, Fars2, FARSB, FAS, FASL, FASLG, FASLG (soluble), FASN, FASTK, FASTKD2, FAT1, FAT10, FAT2, FATE1, FATP1, FATP2, FATP4, FATP5, FATP6, fatty acid binding protein 4, FAU, FB, FBL, FBLIM1, FBLN1, FBLN2, FBLN5, FBLN7, FBN1, FBN2, FBP1, FBRS, FBRSL1, FBXL13, FBXL18, FBXL19-AS1, FBXL2, FBXL20, FBXL3, FBXL5, FBXL7, FBXO11, FBXO15, FBXO16, FBXO17, Fbxo2, FBXO21, FBXO22, FBXO25, FBXO3, FBXO31, FBXO32, FBXO33, FBXO34, FBXO36, FBXO38, FBXO4, FBXO43, FBXO44, FBXO47, FBXO48, FBXO5, FBXO6, FBXO7, FBXO9, FBXW12, FBXW2, FBXW4, FBXW5, FBXW7, FBXW9, Fc, Fc part of the IgG, FCAR, Fc-epsilon Rl-alpha, FceRl, FCER1A, FCER1G, FCER2, FceRIa, FCF1, FCG3RA, FCGBP, Fcgrl, FCGR1A, FCGR1B, FCGR1C, FCGR2A, FCGR2B, FCGR2C, FCGR3, FCGR3A, FCGR3A26, FCGR3B, FcgRII, FCGRN3A,68299833684.1FCGRT, FCH01, FCHO2, FCHSD2, FCMR, FCN1, FCN2, FCN3, FCR, FCRla, Fc-receptor- like proteins, FcRI, FcRIV, FCRL1, FCRL2, FCRL3, FCRL4, FCRL5, FCRL6, FCRLA, Feris, FcRy, FcyRI, FcsRI, FcsRIa, FDC, FDFT1, FDGFRA, FDPS, FDPSP2, FDX1, FDXR, FE65, FECH, Feline sarcoma-related tyrosine kinase, FEN1, FER1L4, FER1L6, FERMT1, FERMT2, FERMT3, FES, FEV, FEZ1, FEZF2, FFAR1, FFAR2, FFAR4, FGB, FGD2, FGD3, FGD4, Fgd5, FGD5P1, FGD6, FGF1, FGF10, FGF12, FGF14, FGF18, FGF2, FGF23, FGF3, FGF4, FGF7, FGF8, FGF9, FGFBP1, FGFBP2, FGFBP3, Fgfrl, FGFR1OP, FGFR1OP2, FGFR2, FGFR3, FGFR4, FGG, FGL1, FGL2, FGR, FH, FHAD1, FHIT, FHL1, FHL2, FHL3, FH0D1, FH0D3, FIBIN, FIBP, Fibroblast activation protein alpha, Fibromodulin, Fibronectin, fibronectins, FICOLIN3, FIGD, FIGF, FIGLA, FILIP1, FILIP1L, FIP1L1, FIS1, FIZZ1, FJX1, FKBP10, FKBP11, FKBP14, FKBP1A, FKBP1AP1, FKBP1A-SDCBP2, FKBP1C, FKBP2, FKBP3, FKBP4, FKBP5, FKBP51, FKBP6, FKBP7, FKBP8, FKRP, FLCN, FLG, FLG2, FLU, FLJ11151, FLJ20699, FLJ30403, FLJ31104, FLJ32255, FLJ35934, FLJ42102, FLJ42627, FLJ43663, FLJ45079, FLJ46066, FLJ46906, FLK1, FLK-1, FLK2, FLNA, FLNB, FLNC, FLOT2, FLRT2, FLRT3, FLT1, FLT3, FLT-3, FLT3LG, FLT4, FLVCR1, FLVCR2, FLYWCH1, FLYWCH2, FMC7, FMLP, FMN1, FMNL1, FMNL2, FMNL3, FMRI, FN1, FNBP1, FNBP4, FNDC1, FNDC3A, FNDC3B, FNDC5, FNIP1, FNIP2, FNTA, FOCAD, focal H+ / K+-ATPase, FOLH1, Follicle regulatory protein, Follicle-stimulating hormone receptor, FOLR1, FOLR2, FOPNL, FOPX3, FORSE1, FOS, FOSB, FOSL1, FOSL2, FOX, F0XA1, F0XA2, F0XA3, FOXCI, FOXC2, F0XD1, F0XD2, FOXD2-AS1, F0XD3, F0XD3, FOXF1, FOXF2, F0XG1, F0XG1+, Foxi, FOXI1, FOXJ, FOXJ1, FOXJ2, F0XK1, F0XK2, Foxll, FOXL2, F0XM1, F0XN1, F0XN3, F0XN4, FOXO1, FOXO3, FOXO4, FOXP1, FOXP2, FOXP3, FOXP3, FOXP31, FOXP4, FOXQ1, FOXR1, F0XRED1, FOXRED2, FOXS1, FPGFR3, FPGS, FPGT-TNNI3K, FPR1, FPR2, FPR3, FPRL1, FR4, FRA10AC1, FRAS1, FRAT2, FREM1, FREM2, FRG1, Frizzled-2, Frizzled-3, Frizzled-5, Frizzled-7, Frizzled-9, FRMD3, FRMD4A, FRMD4B, FRMD6, FRMD6-AS1, FRMD8, FRMPD1, FRMPD2, FRRS1, FRY-AS1, FRYL, FRZB, FSCN1, FSD1, FSD1L, FSD2, FSHB, FSHR, FSIP2, FSP1, FSP-1, FSP-1, FST, Fstll, FSTL3, FSTL4, FSTL5, FTCD, FTH1, FTL, Ftll, FTSJ3, FUBP1, FUCA1, FUCA2, FUK, FUNDC2, FUOM, FURIN, FUS, FUSIP1, FUT, FUT11, FUT2, FUT4, FUT5, FUT6, FUT7, FUT8, FUZ, FVIII, FXIIIA, FXN, FXR1, FXR2, Fxydl, FXYD2, FXYD2- gamma, FXYD3, FXYD4, FXYD5, FXYD6, FXYD6-FXYD2, FXYD7, FYB, FYCO1, FYN,69299833684.1FYTTD1, FZ4, FZD, FZD1, FZD10-AS1, FZD2, FZD3, FZD4, FZD8, FZD9, FZR1, G0S2, G3BP1, G3BP2, G6PC2, G6PC3, G6PD, GAA, GABI, Gab2, GAB3, GABA, GABA B Receptor Compounds, GABA transporter 1, GABA Transporter Inhibitors, GABA-B Rl, GAB AB receptor 1, GAB AB receptor 2, GABA-B Receptor Agonists, GABA-B Receptor Antagonists, GABA-B Receptor Modulators, GABARAP, GABARAPLl, GABARAPL2, GABAT, GABBR1, GABBR2, GABPB1, GABPB1-AS1, GABPB2, GABRA1, GABRA3, GABRB1, GABRB2, GABRB3, GABRG1, GABRG2, GABRP, GABRQ, GABRR1, gACRP30, GAD1, Gad2, GAD65, GAD67, GADD45A, GADD45B, Gadd45g, GADD45GIP1, GAGE2A, GAK, GAL, Gal-3, GAL3ST4, GALC, GALE, Galectin-1, Galectin-12, Galectin-3, Galectin-7, Galectin-9, GALK1, GALM, GALNS, GALNT1, GALNT10, GALNT11, GALNT13, GALNT14, GALNT15, GALNT16, GALNT18, GALNT2, GALNT3, GALNT5, GALNT6, GALNT7, GALNTL6, GALT, Gamma glutamyl transferase, GAMT, GAN, GAP43, GAPDH, GAPDH2, GAPDHP42, GAPT, GAREM, GARNL3, GARP, GARS, GART, GAS1, GAS2L1, GAS2L2, GAS2L3, GAS5, GAS6, GAS7, GAS8, GAST, Gatal, gatala, GATA2, GATA3, GATA-3, GATA4, GATA5, GATA6, GATA6-AS1, GATAD2A, GATC, GATM, GATSL2, GATSL3, GBA, GBAS, GBN3, GBP1, GBP1P1, GBP2, GBP4, GBP5, GBX2, GC, GCA, GCAT, GCC1, GCC2, GCDFP15, GCDFP-15, GCDH, GCET2, GCG, GCH1, GCHFR, GCKR, GCM3, GCNT1, GCNT3, GCSAM, GCSAML, G-CSF, GCSH, GCT, GCTM-2, GCTS, GD2, GDA, GDAP1, GDAP1L1, GDE1, GDF10, GDF15, GDF3, GDF9, GDI1, GDI2, GDNF, GDPD1, Gdpd2, GDPD3, GDPD5, GEM, GEMIN5, GEMIN7, GEMIN8, GEN1, GET4, GFAP, GFAP157, GFAP41, GFAP43, GFAPD, GFAPdelta, GFER, GFI1, GFI1B, Gfi3, GFM1, GF0D1, GF0D2, GFPT2, GFRA1, GFRA2, GFRA3, GFRB, GGA1, GGA2, GGCT, GGH, GGNBP2, GGPS1, GGT, GGT1, GGT5, GGT6, GGT8P, Ggtal, GGTA1P, GH1, GH2, GHITM, GHR, GHRHR, GHRL, GID4, GID8, GIF, GIGYF2, Gill, GIMAP1, GIMAP2, Gimap3, GIMAP4, GIMAP5, GIMAP6, GIMAP7, GIMAP8, GINS2, GINS4, GIP, GIPC2, GIPR, GIRK2, GIT1, GIT2, GITR, GITRL, GJA1, GJA4, GJA5, GJA9-MYCBP, GJB1, GJB2, GJB3, GJB6, GJC1, GJC2, GJD4, GK, GK5, GKAP1, GKN1, GKN2, GLA, GLAST, GLB1, GLB1L, GLB1L2, GLCCI1, GLCE, GLDC, GLDN, GLE1, GLG1, GLI1, GLI-1, GLI2, GLI3, GLI4, Glial fibrillary acidic protein, GLIDR, GLIPR1, GLIPR1L2, GLIPR2, GLIS3, GLIS3- AS1, GLMN, GL01, GL0D4, GLRA2, GLRA3, GLRX, GLRX2, GLRX3, GLS, GLT1, GLT- 1, GLT1D1, GLT8D1, GLT8D2, GLTP, GLTSCR1L, GLTSCR2, Glucagon, Glucose70299833684.1transporter type 2, GLUD1, GLUL, GLUT1, GLUT-1, GLUT2, GLUT3, GLUT4, Glutaminase, Glutamine synthetase, GlyA, GLYAT, Glycophorin, GlycophorinA, Glypican-3, GM10012, GM10059, GM10073, GM10076, GM10086, GM10116, GM10136, GM10154, GM10186, GM10269, GM10275, GM10288, GM10443, GM10925, GM11263, GM11361, GM11410, GM11428, GM11478, GM11741, GM11953, GM12005, GM12334, GM12630, GM13047, GM13048, GM13192, GM13196, GM13226, GM13340, GM13341, GM13408, GM13436, GM13456, GM13532, GM13570, GM13826, GM13841, GM13864, GM14303, GM14328, GM14456, Gml4964, GM15427, GM15430, GM15500, GM15590, GM15710, GM15772, GM15796, GM16238, GM16247, GM1673, GM17682, GM2000, GM2574, GM2A, Gm3448, GM3511, GM4149, GM4604, Gm4876, GM5054, GM5239, GM5244, GM5559, GM5805, GM5963, GM6030, GM6136, GM6166, GM6202, GM6286, GM6316, GM6863, GM7331, GM7363, GM8129, GM8730, GM8759, GM9000, GM9294, GM9493, GM9843, GMCL1, GM- CSF, GMDS, GMDS-AS1, GMEB1, GMFG, GMIP, GMNN, GMPPA, GMPPB, GMPR, GMPS, GNA11, GNA12, Gnal3, GNA15, GNAI, GNAI1, GNAI2, GNAI3, GNAL, GNA01, GNAQ, GNAS, GNAT1, GNAT2, GNAT3, GNB2, GNB2L1, GNB4, GNB5, GNE, GNG11, GNG12, GNG13, GNG2, GNG3, GNG4, GNG5, GNG7, GNG8, GNGT1, GNGT2, GNL1, GNL2, GNL3, GNLY, GNPDA1, GNPDA2, GNPNAT1, GNPTAB, GNPTG, GNRHR, GNRHR2, GNS, Go-alpha, G0LGA1, G0LGA2, GOLGA2P5, G0LGA3, G0LGA4, GOLGA6L10, GOLGA6L4, GOLGA6L9, G0LGA7, G0LGA7B, G0LGA8A, G0LGA8B, G0LGA8M, G0LGA8R, Golgbl, G0LIM4, G0LM1, GOLPH3, GOLPH3L, GOLT1A, GOLT1B, G0N4L, GOPC, GORASP2, GOS2, GOSR1, GOT1, GOT2, GP110, gpl30, GP1BA, GP2, GP6, GP9, GP90-MC301, GPA, GPA33, GPAA1, GPAM, GPANK1, GPAT2, GPAT3, GPATCH11, GPATCH2, GPATCH2L, GPATCH4, GPATCH8, GPBAR1, GPBP1, GPBP1L1, GPC1, GPC3, GPC4, GPC5, GPC5-AS1, GPC6, GPCPD1, GPD1, GPD1L, GPD2, GPHA2, GPHN, GPI, GPIb, GPIHBP1, GPKOW, GPLD1, GPM6A, GPM6B, gpmb, GPN1, GPN3, GPNMB, GPR108, GPR114, GPR116, GPR119, GPR125, GPR132, GPR137, GPR137B, GPR137C, GPR146, GPR149, GPR15, GPR153, GPR155, GPR160, GPR161, GPR162, GPR17, GPR171, GPR18, GPR182, GPR183, GPR25, GPR34, GPR35, GPR37, GPR37L1, GPR38, GPR44, GPR49, GPR55, GPR56, GPR62, GPR64, GPR65, GPR68, GPR75, GPR77, GPR82, GPR83, GPR84, GPR89A, GPR89B, GPRASP1, GPRC5A, GPRC5B, GPRC5C, GPRC5D, GPRIN2, GPRIN3, GPS1, GPS2, GPSM1, GPSM3, GPT2, GPX1, GPX2, GPX3,71299833684.1Gpx4, GPX6, GPX7, Grl, GRAMD1A, GRAMD1B, GRAMD2, GRAMD3, Granzyme, Granzyme A, Granzyme B, Granzyme(GZM)-B, granzymes, GRAP, GRAP2, GRASP, GRB, GRB10, GRB14, GRB2, GRB7, GREB1, GREB1L, GREM1, GREM2, GRHL2, GRHL3, GRIA1, GRIA2, GRIA3, GRIA4, Grid2, GRIK1, GRIK2, GRIK3, GRIK4, GRIN1, GRIN2B, Grin2c, GRINA, GRIPAP1, GRK5, GRK6, GRK7, GRM2, GRM3, GRM4, Grm5, GRM6, GRM8, GRN, GRP, GRP78, GRPEL1, GRPEL2, GRSF1, GRTP1, GRWD1, GS, GS1- 259H13.2, GS1-279B7.2, GSAP, GSC, GSDMB, GSDMD, GSE1, GSG1, GSK3B, GSKIP, GSN, GSPT1, Gsr, GSS, GSTA1, GSTA2, GSTA3, GSTA4, GSTCD, GSTK1, Gstml, GSTM2, GSTM3, GSTM4, GSTM5, GSTO1, GSTP, GST-P, GSTP1, GSTT1, GSTTP2, GSX2, GTAT3, GTF2A2, GTF2B, GTF2E2, GTF2F1, GTF2H1, GTF2H2, GTF2H2B, GTF2H3, GTF2H5, GTF2I, GTF2IRD2, GTF2IRD2B, GTF3A, GTF3C1, GTF3C2, GTF3C3, GTF3C6, GTGF, GTPase, GTPBP1, GTPBP10, GTPBP2, GTPBP4, GTPBP6, GTPBP8, GTSE1, GTSF1, GUCA1A, GUCA1B, GUCA1C, GUCA2A, GUCA2B, GUCD1, GUCY1A2, GUCY1B3, GUF1, GUK1, GULP1, GUSB, GUSBP1, GUSBP2, GUSBP3, GVHD, GVINP1, GWAS, GXYLT1, GXYLT2, GYG1, GYG2P1, GYLTL1B, Gypa, GYPA2, GYPB, GYPC, GYS2, GZMA, GZMB, GZMH, GZMK, GZMM, H+K+-ATPase, Hl 781, Hl 9, H1F0, H1FNT, H1FOO, H1FX, H1FX-AS1, H25, H2-Aa, H2-Abl, H2AFJ, H2AFV, H2AFX, H2AFY, H2AFY2, H2AFZ, H2-D1, H2-K1, H2-M2, H3cit, H3F3A, H3F3B, H3F3C, H3K18ac, H3K27me3, H3K9me3, H6PD, HABP2, HACD1, HACL1, HADH, HADHA, HADHB, HAGH, HAGLR, HAL, HAMP, HANOI, Hand2, HAP1, HAPLN1, HAPLN3, HARE, HARS, HAS2, HAT1, HAUS1, HAUS2, HAUS3, HAUS7, HAVCR1, HAVCR2, HAVCR2, HAVR2C, HAX1, HB9, HBA, HBA1, HBA2, Hba-al, Hba-a2, HBB, HBD, HBE1, HBEGF, HB-EGF, HBG1, HBG2, HBM, HBME-1, HBP1, HBQ1, HBS1L, HBZ, HCAR1, HCAR2, HCAR3, HCCS, hCD14, hCD19, hCD4, hCD45, hCD56, hCD8, HCFC1R1, HCFC2, HCG11, HCG18, HCK, HCLS1, HCN1, HCN4, HCRTR2, HCST, HCT116, HD-5, HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, HOC, HDDC2, HDDC3, HDGF, HDGFRP3, HDHD1, HDHD2, HE4, HEATR1, HEATR2, HEATR3, HEBP1, HEBP2, HECA, HECTD1, HECTD2, HECTD4, HECW2, HEG1, HEIH, HELB, HELIOS, HELLS, HELZ, HELZ2, HEMGN, HEMK1, HENMT1, HEPACAM, HEPACAM2, HEPN1, HER2, Her-2, HER4, HERC1, HERC2, HERC2P2, HERC2P9, HERC4, HERC5, HERC6, HERPUD1, HERPUD2, HERV-H, HERV-K, HERV-W, HES1, HES3, HES4, Hes5, HES6,72299833684.1HES7, HESX1, HEV, HEXA, HEXB, Hexim 1, HEXIM1, HEY1, HEY2, Heyl, hfb_G_000352, HFB-16, HFE, HFM1, HGAL, HGF, HGFR, HGH1, HHAT, HHEX, HHIP, HHIP-AS1, HHLA1, HHLA2, HHLA3, HIAT1, HIATL2, HIC1, HID1, HIF1 A, HIF3A, HIGD18, HIGD1 A, HIGD2A, High affinity IgE receptor, HILPDA, HILS1, HINFP, HINT1, HINT2, HINT3, HIP1, HIP1R, HIPK1, HIPK1-AS1, HIPK2, HIPK4, HIRIP3, HIST1H1C, HIST1H1D, HIST1H1E, HIST1H2AA, HIST1H2AE, HIST1H2BA, Histlh2bc, HIST1H2BD, HIST1H2BG, HIST1H2BH, HIST1H2BK, HIST1H3J, HIST1H4C, HIST1H4I, HIST1H4J, HIST1H4K, HIST2H2AA3, HIST2H2AA4, HIST2H2AC, HIST2H2BA, HIST3H2A, Histamine H2 R, HIVEP1, Hivep2, HIVEP3, HJURP, HK1, HK2, HK3, HKR1, HLA, HLA class I, HLA class II, HLA-A, HLA- ABC, HLA-B, HLA-B 705, HLA-B2709, HLA-B27, HLA-B2705, HLA-C, HLA-DMA, HLA-DMB, HLA-D0A1, HLA-DOB, HLA-DP, HLA-DPA1, HLA-DPA1, HLA- DPB1, HLA-DPB1, HLA-DPB2, HLA-DQ, HLA-DQA1, HLA-DQA2, HLA-DQB, HLA- DQB1, HLA-DQB2, HLA DR, HLA-DR, HLA-DR, HLADR / DQ / DP, HLA-DRA, HLA-DRA, HLA-DRB1, HLA-DRB1.1, HLA-DRB5, HLA-DRB6, HLA-DRs, HLA-E, HLA-F, HLA-G, HLA-I, HLA-II, HLA-J, HLD-DR, HLF, HLTF, HLX, HM13, HMB45, HMB-45, HMB0X1, HMCES, HMCN1, HMCN2, HMG20B, HMGA1, HMGA2, HMGB1, HMGB2, HMGB3, Hmgclll, HMGCR, HMGCS1, HMGCS2, HMGN1, HMGN2, HMGN3, HMGN4, HMGN5, HMGXB4, HMHA1, HMMR, HMNA, HM0X1, HM0X2, HMWCK, Hmx2, HN1, HN1L, HNF1 A, HNF1A-AS1, HNF1B, Hnfip, HNF4A, HNK1, HNL, HNMT, HNRNDP, HNRNPAO, HNRNPA1, HNRNPA1L2, HNRNPA2B1, HNRNPA3, HNRNPAB, HNRNPC, HNRNPCL2, HNRNPD, HNRNPDL, HNRNPF, HNRNPH1, HNRNPH2, HNRNPH3, Hnrnpk, HNRNPL, HNRNPLL, HNRNPM, HNRNPR, HNRNPU, HNRNPU-AS1, HNRNPUL1, HNRNPUL2- BSCL2, HNRPH1, Hoechst, Hoechst 33342, H0MER2, H0MER3, H00K1, H00K2, H00K3, HOPX, H0RMAD1, H0RMAD2, HOTAIRM1, HOXA1, HOXAIO, HOXA2, HOXA3, HOXA5, HOXA6, HOXA9, HOXA-AS2, HOXA-AS3, HOXB1, HOXB13, HOXB2, HOXB4, HOXB5, HOXB6, HOXB7, HOXB-AS1, HOXB-AS3, HOXCIO, HOXC11, HOXC6, Hoxc8, Hoxc9, HOXD1, HOXD11, HOXD3, HOXD8, HOXD9, HOXP1, HP, HP1BP3, HPC, HPCAL1, HPD, HPGD, HPGDS, HPN, HPRT1, HPS1, HPS3, HPS4, HPSE, HPSE2, HR, HRASLS2, HRASLS5, HRAT5, HRAT56, HRH4, HRK, HRNR, Hrspl2, HS3ST1, HS3ST2, HS3ST3AT, HS3ST3B1, HS3ST4, HS3ST6, HS6ST1, HSBP1, HSCB, HSD11B1, HSD11B1L, Hsdl lb2, HSD17B1, HSD17B10, HSD17B11, Hsdl7bl2, HSD17B14, HSD17B2, HSD17B3,73299833684.1Hsdl7b4, HSD17B8, HSD3B, HSD3B1, HSD3B2, HSF1, HSF2, HSF2BP, HSF5, HSH2D, HSL, HSP90AA1, HSP90AB1, HSP90B1, HSPA12A, HSPA12B, HSPA13, HSPA14, HSPA1A, HSPA1B, HSPA1L, Hspa2, HSPA4, HSPA4L, HSPA5, HSPA6, HSPA7, HSPA8, HSPA9, HSPB1, HSPB11, HSPB2-C1 lorf52, HSPB6, HSPB8, HSPBAP1, HSPBP1, HSPD1, HSPE1, HSPG2, HSPH1, HSSD17B6, HTATIP2, HTATSF1, HTATSF1P2, HTL, HTN1, HTR1D, HTR1F, HTR2B, HTR2C, HTRA1, HTRA2, HTRA3, Hu-1, HuC / D, human myeloid inhibitory C-lectin, HUNK, HUS1, HUWE1, HVCN1, Hxyd2, HYAL2, HYDIN, HYI, HYLS1, HYPK, I-A / E, IAH1, IAPP, IARS, IB4, IBA1, Iba-1, IBA57, IBSP, IBTK, IC, ICA1, ICA1L, ICAM, ICAM1, ICAM-1, ICAM2, ICAM3, ICAM4, ICE1, ICE2, ICFBP5, ICFBP7, ICOC, ICOS, ICT1, ID1, ID1-4, ID2, ID2, ID2-AS1, ID3, ID4, IDH1, Idh2, IDH3A, IDH3B, IDH3G, IDI1, ID01, IDO2, IDS, IdU, IER2, IER3, IER3IP1, IER5, IFAP, IFFO1, IFFO2, IFH6, IFI27, IFI27L1, IFI27L2, Ifi2712a, IFI27L2B, IFI30, IFI35, IFI44, IFI44L, IFI6, IFIH1, IFIT1, IFIT2, IFIT3, IFIT5, IFITM, IFITM1, IFITM10, IFITM2, IFITM3, IFNAR2, IFNG, IFN-G, IFN- gamma, IFNG-AS1, IFNGR1, IFNGR2, IFN-y, IFNa, IFNy, IFN-y, IFRD1, IFRD2, IFT122, IFT172, IFT20, IFT22, IFT27, IFT43, IFT46, IFT52, IFT57, IFT80, IFT81, IFT88, IgA, IGBP1, IgD, IgE, IGF1, IGF1R, IGF2, IGF2BP1, IGF2BP2, IGF2BP2-AS1, IGF2BP3, IGF2R, IGFBP1, IGFBP2, IGFBP3, IGFBP4, IGFBP5, IGFBP6, IGFBP7, IGFBPL1, IGFIR (soluble), IGFLR1, IgG, IgGK, IgGA, IGH1, IGHA, IGHA1, IGHA2, IGHD, IGHE, IGHG, IGHG1, IGHG2, IGHG3, IGHG4, IGHGP, IGHM, IGHMBP2, IGHV3-15, IGHV3-23, IGHV3-33, IGHV3-7, IGHV4-34, IGHV6-1, IGJ, IGKC, IGKV1-12, IGKV1-39, IGKV1-5, IGKV3-15, IGKV3-20, IGKV3D-11, IGKV3D-20, IGKV4-1, IGKV-IGKJ, IGL, IGL@, IGLC2, IGLC3, IGLC4, IGLC5, IGLC6, IgLC7, IGLL1, IGLL5, IGLV3-1, IGLV3-10, IGLV3-19, IGLV4-69, IGLV6- 57, IGLV7-43, IgM, IGSF1, IGSF10, IGSF11, IGSF2, IGSF6, IGSF9, IGTA4, IgK / Ig , IHH, III beta-tubulin, IK, IKAROS, IKBIP, IKBKB, IKBKE, IKBKG, IKZF1, IKZF2, IKZF3, IKZF4, IKZF5, IL-1, IL-1 alpha, IL-1 RI, IL10, IL-10, IL-10, IL10R, IL10RA, IL10RB, IL10RB-AS1, IL-11, IL11R, IL11RA, IL-12, IL12A, IL12B, IL12R, IL12RB1, IL12RB2, IL13, IL-13, IL-13 R alpha 1, IL-13alphal, IL13R, IL13RA1, IL13RA2, IL14R, IL15, IL-15, IL-15R, IL-15Rb, IL 16, IL 17, IL- 17, IL 17 A, IL- 17a, IL-17A-GFP, IL17B, IL17F, IL-17F, IL17R, IL-17R, IL17Ra, IL-17RB, IL17RD, IL17RE, IL18, IL-18, IL18BP, IL-18R, IL18R1, IL18RAP, ILIA, IL1B, IL-1R, IL1R1, IL-1R-1, IL1R2, IL-lra, IL1RAP, IL1-RAP, IL-1RAP, IL1RAPL2, IL1RL1, IL1RN, IL-1RN, IL-la, IL-1 , IL2, IL-2, IL-20, IL20RA, IL20RB, IL21, IL-21, IL21R,74299833684.1IL-21R, IL21R-AS1, IL22, IL-22, IL22RA1, IL22RA2, IL-23, IL23A, IL23R, IL-23R, IL24, IL25, IL-25, IL-25R, IL26, IL-26, IL-27, IL27RA, IL28RA, IL2R, IL-2R, IL2RA, IL-2RA, IL2RB, IL2RG, IL-2RP, IL-3 receptor alpha subunit, IL32, IL33, IL-33, IL-33R, IL-3R, IL3RA, IL3R-alpha, IL-3R-alpha, IL3RC, IL-3Ra, 114, IL-4, IL4I1, IL4R, I14ra, IL-5, IL5RA, IL-5R- alpha, IL-5Ra, IL6, IL-6, IL6R, IL-6R-alpha, IL6ST, IL-6ST, IL7, IL7A, IL7R, IL-7R, IL7Rhi, IL7Ra, IL8, IL-8, IL8R, IL8RA, IL8RB, IL-9, IL9R, IL-9R, ILDR2, ILF2, ILF3, ILF3-AS1, ILK, ILKAP, IL-RAP, ILRN, ILRUN, ILT1, ILT2, ILT3, ILT7, ILTMP, IMMP1L, IMMT, IMo, IMP3, IMP4, IMPA1, IMPA2, IMPACT, IMP ADI, IMPDH1, IMPDH2, IMR32, INA, INADL, INAFM2, INCAI, INDO, INE1, INE2, INF y, INF2, ING1, ING3, ING4, ING5, INGX, INHA, INHBA, INHBA-AS1, INHBB, Inhibin B, Inhibin beta B, INO80, INO80B, INO80C, INO80D, INO80E, iNOS, INPPI, INPP4A, INPP4B, INPP5B, INPP5D, INPP5F, INPP5K, INPPL1, INS, Insl, INSC, INSIGI, INSL3, INSMI, INSR, Insulin, Integrin alpha 4 beta 1, Integrin alpha 4 beta 7, Integrin alpha 6, Integrin alpha-2, Integrin alpha2betal, Integrin alpha4betal, Integrin alpha4beta7, Integrin alpha-6, Integrin alpha6beta4, Integrin alpha-8, Integrin beta-1, Integrin aipi, integrin allbp3, Interleukin 21, Intestinal Alkaline Phosphatase, INTS10, INTS12, INTS4, INTS6, INTS7, INTS8, INTS9, INTU, Involucrin, INVS, IOT-10, IP-10, IP3R, IP6K1, IP6K2, IP6K3, IPCEF1, IPF1, IPMK, IPO13, IPO5, IPO5P1, IPO7, IPP, IPW, IQCA1, IQCB1, IQCD, IQCE, IQCG, IQCH, IQCK, IQGAP1, IQGAP2, IQGAP3, IQSEC1, IQUB, IR, IRAK2, IRAK3, IREB2, IRF1, IRF2, IRF2BP2, IRF2BPL, IRF3, IRF4, IRF5, IRF6, IRF7, IRF8, IRF9, IRG1, IRGM, IRGQ, IRS2, IRX1, IRX2, IRX3, IRX4, ISCA1, ISCA2, ISCU, ISG10, ISG15, ISG20, ISG20L2, isll, ISL2, Islet amyloid polypeptide, ISLET- 1, ISLR, ISLR2, ISM1, ISOCI, ISPD, IST1, ISX, ISY1, ISYNA1, ITA4, ITA6, ITB1, ITCH, ITCH-AS1, ITFG1, ITFG2, ITFG3, ITGA1, ITGA11, ITGA2, ITGA2B, ITGA3, ITGA4, ITGA5, ITGA6, Itga6 (CD49f), ITGA7, ITGA8, ITGA9, ITGAE, ITGAL, ITGAM, ITGAV, ITGAVB5, ITGAX, ITGB1, ITGB1BP1, ITGB2, ITGB2 rs3788142, ITGB2-AS1, ITGB3, ITGB3BP, ITGB4, ITGB5, ITGB6, ITGB7, ITGB8, ITGBL1, ITI, ITIH2, Itih3, ITIH4-AS1, ITIH5, ITK, ITLN1, ITLN2, ITM2A, ITM2B, ITM2C, ITPA, ITPK1, ITPK1-AS1, ITPKB, ITPKC, ITPR1, ITPR2, ITPRIP, ITSN1, ITSN2, Ivl, IVNS1ABP, IWS1, IYD, Izumolr, JADE1, JADE2, JADE3, JAG1, JAG2, Jagged- 1, JAGN1, JAK1, JAK2, JAK-2, JAK3, JAM2, JAM3, JAML, JARID1B, JAR.ID2, JAZF1, JCHAIN, J-chain, JDP2, JHDM1D-AS1, JMJD1C, JMJD4, JMJD6, JMJD7, JMJD7-PLA2G4B, JMY, JOSD1, JOSD2, JPH1, JPH2, JPH4, JPX, JSRP1, JTB, JUN, JUNB, JUND, JUP, jp, K10,75299833684.1K14, K15, K19, K5, K8, KALI, KALRN, KANK1, KANK2, KANK3, KANK4, KANSL1, KANSL1L, KANSL2, KARS, KAT2A, KAT2B, KAT5, KAT6A, KAT6B, KAT8, KATNAL1, KATNB1, KB-1208A12.3, KB-1507C5.4, KBTBD11, KBTBD13, KBTBD2, KBTBD6, Kca3.1 , KCC AT333 , KCMF 1 , Kcna 1 , KCNA3 , KCNA7, KCNAB 1 , KCNAB 1 - AS 1 , KCNAB2, KCNB1, KCND1, KCNE1, KCNE3, KCNE5, KCNF1, KCNH1, KCNH2, KCNH6, KCNH7, KCNH8, KCNIP2, KCNIP3, Kcnip4, KCNJ1, KCNJ10, KCNJ13, KCNJ14, KCNJ15, KCNJ16, KCNJ2, Kcnj3, KCNJ5, KCNJ6, KCNJ8, KCNK1, KCNK17, KCNK5, KCNK6, KCNK9, KCNMA1, KCNMB1, KCNMB2, KCNMB4, KCNN3, KCNN4, KCNQ1OT1, KCNQ2, KCNQ3, KCNQ4, KCNQ5, KCNRG, KCNS3, KCNT2, KCP, KCTD10, KCTD12, KCTD13, KCTD14, KCTD15, KCTD16, KCTD17, KCTD19, KCTD2, KCTD5, KCTD9, KDELC1, KDELC2, KDELR1, KDELR2, KDELR3, KDF1, KDM1A, KDM1B, KDM2A, KDM2B, KDM3A, KDM4A-AS1, KDM4B, KDM4C, KDM4D, KDM5A, KDM5B, KDM5C, KDM5D, KDM6A, KDM6B, KDM7A, KDR, KDSR, KEAP1, KEL, KERA, Keratin-1, Keratin-10, Keratin-13, Keratin-14, Keratin-15, Keratin-16, Keratin-18, Keratin-19, Keratin-2, Keratin-3, Keratin-5, Keratin-6, Keratin-7, Keratin-8, Keratins, Kfll, KHDC1, KHDC1L, KHDC3L, KHDC3L MII-1, KHDC3L MIL2, KHDC3L MIL3, KHDC3L MII-5, KHDC3L MIL6, KHDRBS1, KHDRBS2, KHDRBS3, Ki67, Ki-67, Ki-67+, KIAA0020, KIAA0087, KIAA0101, KIAA0125, KIAA0226, KIAA0226L, KIAA0319, KIAA0329, KIAA0355, KIAA0368, KIAA0408, KIAA0430, KIAA0513, KIAA0556, KIAA0586, KIAA0753, KIAA0754,KIAA0864, KIAA0895, KIAA0895L, KIAA0907, KIAA0922, KIAA0930, KIAA1024, KIAA1033, KIAA1109, KIAA1114, KIAA1143, KIAA1147, KIAA1161, KIAA1191,KIAA1211, KIAA1217, KIAA1244, KIAA1257, KIAA1324, KIAA1328, KIAA1377,KIAA1429, KIAA1456, KIAA1462, KIAA1467, KIAA1524, KIAA1549L, KIAA1551, KIAA1586, KIAA1598, KIAA1614, KIAA1656, KIAA1715, KIAA1751, KIAA1804,KIAA1919, KIAA1958, KIAA2012, KIAA2013, KIAA2026, KIDINS220, KIF11, KIF12, KIF13B, KIF15, KIF16B, KIF17, KIF18A, KIF19, KIF1A, KIF1B, KIF20B, KIF21A, KIF21B, KIF22, KIF23, KIF26B, KIF27, KIF2A, KIF2C, KIF3A, KIF3C, KIF4, KIF5B, KIF5C, KIF6, KIF9, KIFAP3, KIFC1, KIMI, KIN, Kin28, KIR, KIR2.1, KIR2DL1, KIR2DL1-2DS1, KIR2DL2, KIR2DL2-2DL3CD127, KIR2DL3, KIR2DL4, KIR2DL5, KIR2DS1, KIR2DS2, KIR2DS4, KIR2DS5, KIR3DL1, KIR3DL2, KIR3DL3, KIR3DP1, KIR3DS1, KIR3DX1, KIRREL2, KIRREL3, KIRS, KIT, KIZ, KL, KL6, KL-6, KL7, KL8, KLC1, KLC3, KLC4, Klfl,76299833684.1KLF10, KLF11, KLF12, KLF13, KLF17, KLF2, KLF3, KLF-3, KLF3-AS1, KLF4, KLF5, KLF6, KLF7, KLF8, KLF9, KLGR1, KLHDC1, KLHDC2, KLHDC3, KLHDC4, KLHDC7B, KLHDC8A, KLHDC8B, KLHDC9, KLHL1, KLHL11, KLHL13, KLHL14, KLHL15, KLHL18, KLHL2, KLHL20, KLHL21, KLHL22, KLHL23, KLHL24, KLHL28, Klhl3, KLHL31, KLHL32, KLHL35, KLHL36, KLHL41, KLHL5, KLHL6, KLHL7, KLHL8, KLK1, KLK2, KLK3, KLK6, KLKB1, KLRB1, KLRB1, Klrblc, KLRC1, KLRC2, KLRC3, KLRC4, KLRD1, Klrel, KLRF, KLRF1, KLRG1, KLRG2, KLRK1, KMO, KMT2A, KMT2B, KMT2C, KMT2E, KMT5C, KNCN, KNDC1, KNG1, KNG2A, KNG2D, KNSTRN, KNTC1, KPNA2, KPNA3, KPNA4, KPNA6, KPNA7, KPNB1, KPTN, KR2DS4, KRAS, KRBA2, KRBOX1, KRCC1, KREMEN1, KREMEN2, KRI1, KRIT1, KRP1, KRR1, KRT, KRT1, KrtlO, KRT12, KRT13, KRT14, KRT14, KRT15, KRT16, KRT17, KRT17P5, KRT18, Krtl9, KRT2, KRT20, KRT23, KRT25, KRT4, KRT5, KRT6, KRT6A, KRT6B, KRT6C, KRT7, KRT72, KRT73, KRT78, KRT8, KRT80, KRT81, KRT86, KRT9, KRTCAP2, KRY1, KSCNS3, KSR1, KTN1, KXD1, KYNU, L1CAM, L1TD1, L2HGDH, L3MBTL1, L3MBTL2, L3MBTL3, L5P1, LACC1, LACTB, LAD1, Laeverin, LAG3, LAG-3, LAGE3, LAIR1, LAIR2, LAMA, LAMA1, LAMA2, LAMA3, LAMA4, LAMA5, LAMB, LAMB1, LAMB2, LAMB3, LAMC1, LAMC2, Laminin subunit gamma-2, LAMP, Lampl, LAMP2, LAMP3, LAMP5, LAMTOR1, LAMTOR2, LAMTOR3, LAMTOR4, LAMTOR5, LANCL1, LANCL2, Langerin, LAP, LAP3, Laptm4a, LAPTM4B, LAPTM5, LARP6, LARP7, LARS, LAS IL, LASPI, LAT, LAT2, LATEXIN, LATS1, LATS2-AS1, LAX1, LAYN, LBH, LBP, LBR, LCA5, LCA5L, LCAT, LCK, LCMT1, LCMT2, LCN2, LCN8, LCOR, LCORL, LCP1, LCP2, LDB2, LDB3, LDH, LDHA, LDHAL6A, LDHB, LDHC, LDHD, LDLR, LDLRAD1, LDLRAD4, LDLRAP1, LDOC1, LDOC1L, LEAP2, LECT2, lectin, LEDGF, LEF1, LEF1-AS1, LEFT, LEFTY, LEFTY1, LEFTYA, LEKR1, LEMD1, LEMD1-AS1, LEMD2, LEMD3, LENG1, LENG8, LENG8-AS1, LEO1, Lep, Lepr, LEPRE1, LEPREL4, LEPROT, LEPROTL1, Leptin, LETMD1, Leu-12, Leu-2a, Leu-3a, Leu8, Leukemia inhibitory factor receptor, LFA1, LFA-1, LFA3, LFNG, LGALS1, LGALS12, LGALS16, LGALS2, LGALS3, LGALS3BP, LGALS4, LGALS7, LGALS7B, LGALS9, LGALS9C, LGI1, LGI2, LGI3, LGI4, LGMN, LGR4, LGR5, LGR6, LGSN, LHB, LHFP, LHFPL2, LHFPL3, LHFPL3-AS2, LHPP, LHX1, LHX2, LHX3, LHX5, Lhx6, LHX8, LHX9, LIAS, LIF, LIFR, LIFR (soluble), LIG1, LIG3, LIGHT, LILRA1, LILRA2, LILRA4, LILRA5, LILRA6, LILRB1, LILRB2, LILRB3, LILRB4, LILRB5, LIM2,77299833684.1LIMA1, LIMCH1, LIMD1, LIMD2, LIME1, LIMK1, LIMK2, LIMSI, LIMS2, LIMS3, LIMS3L, Lin, LIN2, LIN28, LIN28A, LIN28B, LIN41, LIN52, LIN7A, LIN7B, LINC00094,LINC00116, LINC00152, LINC00211, LINC00299, LINC00304, LINC00311, LINC00426, LINC00461, LINC00467, LINC00476, LINC00483, LINC00493, LINC00539, LINC00574, LINC00582, LINC00612, LINC00623, LINC00649, LINC00665, LINC00672, LINC00694, LINC00696, LINC00838, LINC00861, LINC00869, LINC00926, LINC00936, LINC00943,LINC00963, LINC00969, LINC00982, LINC00996, LINC00998, LINC01031, LINC01059, LINC01094, LINC01116, LINC01125, LINC01137, LINC01138, LINC01158, LINC01160, LINC01187, LINC01272, LINC01279, LINC01351, LINC01356, LINC01359, LINC01420, LINC01481, LINC01506, LINC01550, LINC01551, LINC01554, LINC01559, LINC01571,LINC01588, LINC01597, LINC02446, LINC-PINT, LING02, LING04, LINS1, LIPA, LIPF,LIPG, LIPH, LIPN, LITAF, Live-Dead, LIX1, LKAAEAR1, LLGL2, LLPH, LMAN1,LMAN2, LMAN2L, LMBR1, LMBR1L, LMBRD1, LMCD1, LMF1, LMF2, LMLN, LMNA,LMNB1, LMNB2, LMNTD1, LM01, LMO2, LMO3, LMO4, LMO7, LMOD3, LMP1,LMX1A, LMX1B, LNGFR, LNPEP, LNX1, LOC100129940, LOC100130357LOC100130476, LOC100130872, LOC100131089, LOC100131564, LOC100133161LOC100133445, LOC100190986, LOC100233209, LOC100288911, LOC100294145LOC100505549, LOC100505666, LOC100506302, LOC100506388, LOCI 00507600LOC100507639, LOC100996255, LOC101927204, LOC101927318, LOC101927746LOC101928100, LOC101928103, LOC101929497, LOC101929549, LOC102606465LOC102723968, LOC102724549, LOC102724661, LOC1027255328, LOC145783,LOC158960, LOC171391, LOC200772, LOC284454, LOC284551, LOC285972, LOC339524,LOC339803, LOC388312, LOC388780, LOC389831, LOC400657, LOC441081, LOC441601, LOC541471, LOC642776, LOC643201, LOC643733, LOC644172, LOC644961, LOC645638, LOC646214, LOC650226, LOC652276, LOC653786, LOC728392, LOC729732,LOH11CR2A, LONP1, LONP2, LONRF1, Lor, Loricrin, Lox, LOX1, LOX-1, LOXHD1, LOXL2, LOXL4, LPAL2, LPAR1, LPAR2, LPAR4, LPAR5, LPAR6, LPCAT1, LPCAT2, LPCAT4, LPGAT1, LPIN1, LPIN2, LPL, LPMAB-12, LPO, LPP, LPP-AS2, LPPR1, LPPR5, LPXN, LRAT, LRBA, LRCH1, LRCH2, LRCH4, LRG1, Lrg5, LRIF1, LRIG1, LRIG3, LRMP, LRP1, LRP10, LRP11, Lrplb, LRP2, LRP3, LRP4, LRP5, LRP5L, LRP8, LRPAP1, LRPPRC, LRRC10B, LRRC15, LRRC16A, LRRC17, LRRC18, LRRC2, LRRC23, LRRC25, LRRC26,78299833684.1LRRC27, LRRC32, LRRC34, LRRC36, LRRC38, LRRC3B, LRRC40, LRRC41, LRRC42, LRRC43, LRRC45, LRRC46, LRRC47, LRRC49, LRRC4C, LRRC57, LRRC58, LRRC59, LRRC6, LRRC61, LRRC69, LRRC71, LRRC73, LRRC74B, LRRC75A, LRRC75A-AS1, LRRC8A, LRRC8B, LRRC8C, LRRFIP1, LRRFIP2, LRRIQ1, LRRIQ3, LRRK1, LRRK2, LRRN1, LRRN3, LRRN4, LRRTM3, LRSAM1, LRTM1, LRWD1, Lsamp, LSAMP-AS1, LSD1, LSM1, LSM10, LSM11, LSM12, LSM14A, LSM14B, LSM2, LSM3, LSM4, LSM5, LSM6, LSM7, LSM8, LSP1, LSR, LSS, LST1, LTA, LTA4H, LT-alpha, LTB, LTB4R, LT- betaR, LTBP1, LTBP2, LTBP3, LTBP4, LTC4S, LTF, LTK, LTN1, LTV1, LUC7L, LUC7L2, LUC7L3, LUCAT1, LUM, LUN, LUZP1, LUZP2, LUZP4, LUZP6, Lxn, LylO8, Ly6a, Ly6a (Sca-1), Ly6A / E, Ly6c, Ly-6C, Ly6cl, Ly6c2, Ly6d, LY6E, LY6G, LY6G5B, LY6G5C, Ly6g6c, LY6G6D, LY6H, LY75, LY75-CD302, LY86, LY9, Ly-9, LY96, LYAR, Lybd, LYL1, Lyn, LYPD1, LYPD2, LYPD3, LYPD4, LYPD6B, LYPD8, LYPLA1, Lypla2, LYPLA2P2, LYPLAL1, LYRM1, LYRM2, LYRM4, LYRM5, LYRM7, LYRM9, LYS, Lysmd2, LYSMD3, Lysozyme, LYST, LYVE, LYVE1, LYVE-1, LYZ, LYZ1, Lyz2, LZH8, LZIC, LZTFL1, M1AP, M2A, M60, M6PR, MA4A1, MA4A2, MAATS1, MAB21L3, Mac 1, MAC1, Mac-1, Mac2, Mac-2, MAC3, MACC1, MACF1, MACRO, MACROD2, Macrophage galactose-type C-type lectin, MAD IL 1, MAD2L1, MAD2L2, MADCAM1, MADD, MADDAM, MAEA, MAEL, MAF, MAF1, MAFA, MAFB, MafF, MAFK, MAG, MAGE3, MAGEA11, MAGEA3, MAGE- A3, MAGEA4, MAGE-A4, MAGEA6, MAGEB1, MAGEBIO, MAGEB16, MAGEB2, MAGEB3, MAGEB6, MAGECI, MAGEC2, MAGED1, MAGED2, MAGEE 1, MAGEF1, MAGEH1, MAGI2-AS3, MAGI3, MAGOH, MAGT1, MAL, MAL2, MALAT1, MALL, MALT1, MAMDC2, MAMDC4, MAML1, MAML2, MAML3, Mania, MAN1A1, MAN1A2, MAN1B1-AS1, MANIC 1, MAN2A1, MAN2B1, MAN2C1, MANBA, MANEA-AS1, MANEAL, MANF, MANSC1, MAOA, MAOB, MAP, MAP10, MAP-120, MAP1A, MAP1B, MAP1LC3A, MAP1LC3B, MAP1LC3B2, MAP2, MAP2ab, MAP2K1, MAP2K2, MAP2K3, MAP2K5, MAP2K6, MAP2K7, MAP3K1, MAP3K11, MAP3K2, MAP3K3, MAP3K6, MAP3K7, MAP3K7CL, MAP3K8, MAP3K9, MAP4K1, MAP4K2, MAP4K4, MAP4K5, MAP6, MAP6D1, MAP7, MAP7D1, MAP7D2, MAP7D3, MAP9, MAPK1, MapklO, MAPK12, MAPK13, MAPK14, MAPK15, MAPK1IP1L, MAPK3, MAPK8, MAPK8IP1, MAPK8IP3, MAPKAP1, MAPKAPK2, MAPKAPK3, MAPKAPK5, MAPKAPK5-AS1, MAPKBP1, MAPRE1, MAPRE2, MAPRE3, MAPT, Marl, MARIO, MAR3, MAR5, MAR6,79299833684.1MAR7, MARCKS, MARCKSL1, MARCO, MARK1, MARK3, MARK4, MARVELD3, MASP1, MASP2, Mast cell tryptase, MAST3, MAST4, MASTL, MAT1A, MAT2B, MATER, MATH-2, MATK, MATN1-AS1, MATN2, Matn4, MAVS, MAX, MAZ, MB, MB2, MB21D1, MB21D2, MBD1, MBD2, MBD4, MBD5, MBD6, MBIP, MBLAC2, MBNL1, MBNL2, MBNL3, MBOAT1, MBOAT2, MBOAT7, MBP, MBTPS1, MBTPS2, MC, MCAB51, MCAM, MCC, MCCC1, MCCC2, MCCS, MCEE, MCEMP1, MCF2L2, MCHR2, MCIDAS, MCL1, Mcl-1, MCM10, MCM2, MCM3, MCM3AP, MCM3AP-AS1, MCM4, MCM5, MCM6, MCM7, MCMBP, MCMDC2, Mcmpt8, MCOLN1, MCOLN2, MCOLN3, MCP1, MCP-1, MCPH1, MCRS1, MCSP, Mctl, Mct4, MCTP1, MCTP2, MCTS1, MCU, MCUR1, MDFIC, MDGA1, MDGA2, MDH1, MDH1B, MDH2, MDK, MDM1, MDM2, MDM4, MDN1, MDR1, MDS2, ME, MEI, ME2, ME3, MEA1, MEAF6, MECOM, MECP2, MECR, MED1, MEDIO, MED12L, MED 13, MED13L, MED 14, MED15P9, MED 16, MED 17, MED 18, MED 19, MED20, MED22, MED23, MED24, MED25, MED26, MED27, MED28, MED29, MED30, MED31, MED4, MED6, MED7, MED8, MEF2A, MEF2B, MEF2C, MEF2D, MEFC2, MEFLIN, MEFV, MEG3, MEGF11, MEGF9, MEH, MEM, MEIKIN, MEIOB, MEIS1, MEIS2, MEIS3, Melan A, Melan-A, MELK, MEOX1, MEOX2, MEP1A, MEPE, MERTK, MESDC1, MESDC2, MESP1, MEST, MET, metalloproteinases, METAP1, METAP1D, METAP2, Meteorin, METRNL, METTL1, METTL13, METTL14, METTL15, METTL16, METTL17, METTL21A, METTL22, METTL23, METTL25, METTL2A, METTL2B, METTL5, METTL6, METTL7A, METTL7B, METTL8, METTL9, MEX3C, MF API, MFAP2, Mfap31, MFAP4, MFAP5, MFF, MFGE8, MFHAS1, MFI2, MFI2-AS1, MFN1, MFN2, MFNG, MFSD1, MFSD10, MFSD11, MFSD14A, MFSD2A, MFSD3, MFSD4, MFSD8, MFSD9, MGA, MGAM, MGARP, MGAT1, MGAT2, MGAT4A, MGAT4C, MGAT5, MGC 16275, MGC72080, MGEA5, MGL12, Mgl2, MGLL, mGluRl, mGluR5, MGMT, MGP, MGP35, MGRN1, MGST1, MGST2, MGST3, MHC class, MHC class I, MHC Class II, MHC2, MHCclass II, MHC-VP2, MHCII, MHC-II, MIA, MIA3, MIAT, MIATNB, MIB2, MICA, MICAL1, MICAL2, MICAL3, MICALL1, MICALL2, MICB, MICU2, Midi, MIDHP1, MID2, MIDN, MIEF1, MIEN1, MIER1, MIF, MIF4GD, MIF-AS1, MIIP, MILR1, MINA, Mini80, MINK1, MINOS1, MINOS1P1, MIPEPP3, MIPLA, MIR155, MIR155HG, MIR17HG, MIR181A1HG, MIR22HG, MIR3142HG, MIR3945HG, MIR4435-2HG, MIR4632, MIR497HG, MIR682, MIRLET7BHG, MIS, MIS18BP1, MISTI, MITD1, MITF, MITF P,80299833684.1Mitofilin, MixLl, MK167, MKI67, MKKS, MKL2, MKNK1, MKNK2, MKRN1, MKRN2, MKRN20S, Mkx, MLANA, MLC1, MLC2a, MLC2v, MLEC, MLF1, MLF2, MLH1, MLK7- AS1, MLL, MLLT1, MLLT10, MLLT11, MLLT3, MLLT4, MLLT4-AS1, MLLT6, MLPH, MLXIP, MLXIPL, MMAA, MMAB, MMACHC, MMADHC, MMD2, MME, MMGT1, MMP1, MMP11, MMP12, MMP13, MMP-13, MMP14, MMP15, Mmpl6, MMP19, MMP2, MMP23B, MMP24-AS1, MMP25-AS1, MMP28, MMP7, MMP8, MMP9, MMRN1, MMRN2, MMS22L, mMullerian inhibiting substance, MMU-MIR-703, MN1, MNAT1, MND1, MNDA, MNS1, MNT, MNX1, MNX1-AS1, MO57, MOAP1, MOB1A, MOB1B, MOB2, MOB3A, MOB3B, MOB4, MOBKL1B, MOBKL3, MOBP, MOCS3, MOG, MOGAT2, MOGAT3, MOGS, MOK, MORC1, MORC2, MORC3, MORF4L1, MORF4L2, MORN2, MORN3, MORN5, MOVIO, MOV10L1, MOXD1, MPC1, MPC2, MPDZ, MPEG1, MPG, MPHOSPH8, MPHOSPH9, MPL, MPLKIP, MPO, MPP1, MPP2, MPP5, MPP6, MPP7, MPPED1, MPPED2, MPRIP, MPST, MPV17, MPV17L, MPZ, MPZL1, MPZL3, MR1, MRAP2, MRAS, MRC1, MRC1L1, MRC2, MREG, MRFAP1, MRFAP1L1, MRGBP, MRI1, MRLN, MRO, MRP14, MRP-14, MRP2, MRPL1, MRPL10, MRPL11, MRPL12, MRPL13, MRPL14, MRPL15, MRPL16, MRPL17, MRPL18, MRPL19, MRPL20, MRPL21, MRPL23, MRPL24, MRPL27, MRPL28, MRPL3, MRPL32, MRPL33, MRPL34, MRPL36, MRPL37, MRPL39, MRPL40, MRPL41, MRPL43, MRPL44, MRPL47, MRPL48, MRPL49, MRPL51, MRPL52, MRPL53, MRPL54, MRPL55, MRPL57, MRPL9, MRPS11, MRPS12, MRPS15, MRPS16, MRPS17, MRPS18A, MRPS18B, MRPS2, MRPS21, MRPS24, MRPS25, MRPS26, MRPS27, MRPS28, MRPS30, MRPS31, MRPS33, MRPS34, MRPS35, MRPS36, MRPS5, MRPS6, MRPS7, MRPS9, MRS2, MRVI1, MRVI1-AS1, MS4A1, MS4A127, MS4A1A, MS4A2, MS4A3, MS4A4A, Ms4a4b, MS4A6A, MS4A7, MS4A8, MSANTD2, MSC, MSCA-1, MSC-AS1, MSEIS2, MSGN1, MSH2, MSH4, MSH6, MSI1, MSI2, MSL1, MSL3, Msln, MSMB, MSMO1, MSN, MSR1, MSRA, MSR-A, MSRB1, MSRB3, MST1, MST1P2, MSTN, MSX1, Mtl, MT1A, MT1E, MT1F, MT1G, MT1H, MT1HL1, MT1L, MT1M, MT1X, Mt2, MT2A, MT3, MT-3, MTA1, MTAP, MT-ATP6, MTCH1, MTCH2, MT-CO, MT-CO1, MT-CO2, MT-CO3, MT-CYB, MTDH, MTERF2, MTERF4, MTERFD1, MTERFD3, MTF1, MTF2, MTFMT, MTFP1, MTG, MTG1, MTG2, MTGENES, MTHFD1, MTHFD1L, MTHFD2, MTHFD2L, MTHFR, MTHFS, MTIF2, MTIF3, MTL5, MTM1, MTMR11, MTMR12, MTMR2, MTMR3, MTMR6, MTMR9, MT-ND, MT-ND1, MT-ND2, MT-ND3, MT-ND4, MT-ND4L,81299833684.1MTND4P15, MT-ND5, MT-ND6, mTOR, mTORCl, MTPN, MTRF1L, MTRNR2L1, MTRNR2L12, MTRNR2L2, MTRNR2L6, MTRNR2L8, MTRNR2L9, MTSS1, MTSS1L, MTTP, MTURN, MTUS1, MTX1, MTX2, MTX3, MUC, MUC1, MUC13, MUC1318, MUC15, MUC16, MUC 16, MUC2, MUC20, MUC21, MUC3A, MUC3B, MUC4, MUC5, MUC5AC, MUC5B, MUC6, MUC8, Mucin, MUCL1, MUM1, MUS81, Musashi-1, Musashi-2, MUTYH, MVB12A, MVB12B, MVD, MVK, MVP, Mxl, MX1S, MX2, MXD1, MXD3, MXD4, MXI1, MXRA5, MXRA7, MXRA8, MYADM, MYB, MYBL1, MYBL2, MYBPC3, MYBPH, MYBPHL, MYC, MYC-1, MYCBP, MYCBP2, MYCBPAP, MYCHNSCC, MYCL, MYCL1, MYCN, MYCNOS, MYCT1, MYD88, MYDGF, MYEF2, Myelin basic protein, Myelin protein zero, Myeloperoxidase, MYE0V2, MYF5, MYF6, MYG, MyH, MYH1, MYH10, MYH11, MYH15, MYH2, MYH3, MYH6, MYH7, MYH9, MYL1, MYL1+, MYL12A, MYL12B, MYL2, MYL4, MYL6, MYL7, MYL9, MYLIP, MYLK, MYLK3, MYLPF, MYNN, MYO 10, MYO15B, Myol8a, MYO18B, MYO19, MYO1A, MYO1B, MYO1C, MYOID, MYO1E, MYO IF, MYO1G, MYO3A, MYO3B, MYO5A, MYO5B, MYO5C, MYO6, MYO7A, MYO7B, MYO9B, MYOC, MYOCD, MYOD, Myodl, MYOF, MYOG, MYOG+, myogenin, MYOMI, MYOM2, MYOM3, Myosin Heavy Chain, MYPOP, MYSM1, MYST3, MYT1, MYT1L, MZB1, MZF1, MZF1-AS1, MZT1, MZT2A, MZT2B, N4BP1, N4BP2, N4BP2L1, N4BP2L2, N4BP3, NAA10, NAA15, NAA20, NAA30, NAA35, NAA38, NAA40, NAA50, NAA60, NAAA, NAALAD2, NAALADL1, Naaladl2, NAAOG, NAB1, NABP1, NABP2, NACA, NACA2, NACC1, NACC2, NADK, NADPH, NADSYN1, NAE1, NAGA, NAGS, NAIP, NALP9, NAMPT, NANOG, NANOS1, NANOS2, NANOS3, NANS, NAP1L1, NAP1L4, NAP1L5, NAP1L6, NAPA, NAPB, NAPEPLD, NAPRT, NAPSA, NARF, NARS, NARS2, NASP, NAT 14, NATD1, Natriuretic peptide B, Natural cytotoxicity receptors, NAVI, NAV2, NAV3, NBAS, NBEA, NBEAL1, NBEAL2, NBN, NBPF1, NBPF10, NBPF12, NBPF19, NBPF8, NBR1, NBT, NCAD, N-cadherin, N-cadherin, NCALD, NCAM, NCAM1, NCAM-1, Ncam2, NCAMs, NCAN, NCAPD3, NCAPG, NCAPH, NCAPH2, NCBP1, NCBP2, NCBP2-AS2, NCBP3, NCCRP1, NCDN, NCEH1, NCF1, NCF1B, NCF1C, NCF2, NCF4, NCK1, NCK1-AS1, NCK2, NCKAP1L, NCKAP5, NCL, NCLN, NCOA1, NCOA3, NCOA4, NCOA5, NCOA7, NCOR1, NCOR2, NCR1, NCR2, NCR3, NCR3LG1, NCRUPAR, NDC1, NDC80, NDE1, NDEL1, NDFIP1, NDFIP2, NDN, NDNF, NDRG1, NDRG2, NDRG4, NDST1, NDST2, NDUFA1, NDUFA10, NDUFA11, NDUFA12, NDUFA13, NDUFA2, NDUFA3,82299833684.1NDUFA4, NDUFA4L2, NDUFA5, NDUFA6, NDUFA7, NDUFA9, NDUFAB I, NDUFAF2, NDUFAF3, NDUFAF4, NDUFAF6, NDUFB I, NDUFB I 0, NDUFB I I, NDUFB2, NDUFB3, NDUFB4, NDUFB5, NDUFB6, NDUFB7, NDUFB8, NDUFB9, NDUFC2, NDUFC2- KCTD14, NDUFS2, NDUFS3, NDUFS4, NDUFS5, NDUFS6, NDUFS7, NDUFS8, NDUFVI, NDUFV2, Ndufv3, NE, NEAT1, NEB, NEBL, NEC1, NECAB1, NECAB2, NECAB3, NECAP1, NECAP2, Nectin-4, NEDD1, NEDD4L, NEDD8, NEDD9, NEEL, NEFL, NEFM, NEGRI, NEIL1, NEIL2, NEIL3, NEK1, NEK10, NEK11, NEK2, NEK3, NEK4, NEK5, NEK6, NEK7, NEK8, NEK9, NELFB, NELFCD, NELFE, NELLI, NELL2, NEMF, NEMP2, NEO1, Nes, Nestin, NET1, NETO1, NETO2, NETs, NEU1, NEW, NeuN, NEURL, NEURL1, NEURL4, NeuroD, NEUROD1, NEUROD2, NEUROD4, NEUROD6, Neurofilament heavy protein (NF-H), Neurofilament medium protein (NF-M), Neurofilament protein, NEUROG1, NEUROG3, Neurogenin- 1, Neurogenin-2, Neurogenin-3, Neuroglycan-C, Neurogranin, Neuron-specific enolase, Neuropilin-2, NEXN, NF, NF1, NF2, NF AMI, NFASC, NF AT, NFAT5, NFATc, NFATcl, NFATC2, NFATC2IP, NFATC3, NFATC4, NFE2, Nfe212, NFE2L3, NFE4, NFIA, NFIA-AS1, NFIA-AS2, NFIB, NFIC, NFIL3, NFIX, NF-kappa-B, NFKB1, NFKB2, NFKBIA, NFKBIB, NFKBID, NFKBIE, NFKBIZ, NFS1, NFU1, NFX1, NFYB, NFYC-AS1, NG2, NG2 proteoglycan, NGAL, NGB, NGDN, NGEF, NGF, NGFR, NGFRAP1, NGK7, NGLY1, NGN2, NGN3, NGP, NGRN, NHE3, NHLH1, NHLH2, NHLRC3, NHLRC4, NHP2, NHP2L1, NHSL1, NHSL2, NIACR1, NIBP, Nicalin, NICN1, NIDI, NID2, NIF3L1, NIFK, NIM1K, NIN, NINJ1, NINJ2, NIP7, NIPA1, NIPAL1, NIPAL3, NIPAL4, NIPBL, NIPSNAP3A, NIT2, NK1.1, NKAIN2, NKAIN3, NKAIN4, NEAP, NKAPL, NKD1, NKG2A, NKG2C, NKG2D, NKG2DLs, NKG7, NKH1, NKEC3, NKIRAS1, NKP30, NKP44, NKP46, NKp80, NK-T, NKTR, NKX2.1, Nkx2.2, NKX2.5, NKX2-1, NKX2-2, NKX2-5, NKX3.1, NKX31, NKX3-1, NKX6.1, NKX6-1, NKX6-2, NLE1, NLGN1, NLGN3, NLN, NLRC3, NLRC4, NLRP1, NLRP11, NLRP12, NLRP14, NLRP2, NLRP3, NLRP4, NLRP5, NLRP7, NLRP9, NM_003293, NM_014274, NM_017616, NM_021941, NMB, NMBR, NMD3, NMDA-NR1, NMD ARI, NMDAR2B, NME1, NME2, NME3, NME4, NME5, NME6, NME7, NMI, N-MICG, NMNAT1, NMRAL1, NMRK1, NMT1, NMT2, NMU, NMUR1, NNAT, NNMT, NNT, NO Al, N0B1, NOBOX, NOC2L, NOC3L, NOC4L, NODI, N0D2, NODAL, NOG, Noggin, NOGO, NOGOA, NOL11, NOL12, NOL4L, NOL6, NOL7, NOL8, NOL9, NOLC1, N0M1, N0M01, N0M03, NONO, NOPIO, NOP14, NOP16, NOP56, NOP58,83299833684.1norrin, NOS1, NOS2, Nos3, NOSIP, NOSTRIN, NOTCH1, NOTCH2, NOTCH2NL, NOTCH3, NOTCH4, NOTUM, NOV, N0VA1, N0X1, N0X4, N0XA1, Np63, Npas3, NPAT, NPB, NPC1, NPC2, NPFF, NPHP1, NPHP3, NPHP3-ACAD11, NPHS1, NPHS2, NPIPA1, NPIPA2, NPIPA5, NPIPB15, NPIPB3, NPIPB5, NPIPB6, NPIPB9, NPL, NPM1, NPM1P37, NPM2, NPNT, NPPA, NPPB, NPPC, NPR1, Npr3, NPRL2, NPRL3, NPTN, NPTN-IT1, NPTX1, NPTX2, NPTXR, NPTXs, NPW, NPY, NPY2R, NQO1, NR0B1, NR0B2, NR1D1, NR1D2, NR1H2, NR1H4, NR1I2, NR2B1, NR2C1, NR2C2AP, NR2E1, NR2E3, NR2F1, NR2F1-AS1, NR2F2, NR2F2-AS1, NR3C1, NR3C2, NR4A1, NR4A2, NR4A3, NR5A1, NR5A2, NR6A1, NRAP, NRARP, NRAS, NRBF2, NRBP1, NRBP2, NRCAM, NRDC, NRDE2, NREP, NRF2, NRG1, Nrg2, NRG4, NRGN, NRIP1, NRIP2, NRIP3, NRK, NRL, NRN1, NRP1, NRP-1, NRP2, NRSFS, NRXN1, NRXN3, NRXNs, NSA2, NSCL2, NSD1, NSF, NSG1, NSMAF, NSMCE1, NSMCE2, NSMCE3, NSMCE4A, NSRP1, NSUN2, NSUN4, NSUN5, NSUN6, NSUN7, NT5A, NT5C, NT5C2, NT5C3A, NT5C3B, NT5DC1, NT5DC2, NT5DC3, NT5E, NT5E (CD73), NT5M, NTAN1, NTF3, NTHL1, NTM, NTMT1, NTN1, NTN4, NTNG1, NTNG2, NTPCR, NTRK1, NTRK2, NTRK3, NTS, NUAK2, NUB1, NUBP2, NUCB1, NUCB2, NUCKS1, Nucleostemin, NUDC, NUDCD2, NUDT1, NUDT10, NUDTI 1, NUDT14, NUDT16, NUDT16L1, NUDT21, NUDT22, NUDT4, NUDT5, NUDT6, NUDT7, NUDT8, NUDT9, NUF2, NUFIP1, NUFIP2, NUGGC, NUMA1, NUMB, NUMBL, NUP107, NUP133, NUP153, NUP160, NUP210, NUP210L, NUP214, NUP35, NUP37, NUP43, NUP50, NUP50- AS1, NUP54, NUP88, NUP93, NUP98, NUPR1, Nurrl, NUS1, NUSAP1, NUTF2, NUTM1, NUTM2B-AS1, NVL, NWD1, NXF1, NXF2, NXF2B, NXF3, NXN, NXNL1, NXPE3, NXPH1, NXPH4, NXT1, NXT2, NYAP2, NYNRIN, 04, 0ARD1, 0AS1, 0AS2, 0AS3, OASL, OAT, 0AZ1, 0BFC1, 0BP2A, 0BSL1, Occludin, 0CEL1, 0CIAD1, 0CIAD2, OCLN, OCN, OCSTAMP, OC-STAMP, OCTI, 0CT2, 0CT3, OCT3 / 4, 0CT4, 0CT4A, 0CT4B, 0CT6, 0DC1, 0DF2, 0DF2L, 0DF3B, 0FD1, 0GF0D3, OGFR, 0GFRL1, OGGI, OGN, OGT, 0IP5, 0IT3, 0LA1, OLAH, Olfactory marker protein, 0LFM2, 0LFM3, 0LFM4, 0LFML1, 0LFML2B, 0LFML3, Olig 1, Olig 2, Olig 3, 0LIG1, 0LIG2, Olig2-C, 0LIG3, OLMALINC, 0LR1, 0MA1, OMG, 0NECUT1, 0NECUT2, 00SP1, 00SP2, 0PA1, 0PA3, OPALIN, OPCML, 0PHN1, OPN, 0PN1LW, 0PN1MW, 0PN1SW, 0PN3, 0PRM1, OPTN, OR4N3P, OR7E156P, OR7E37P, OR8B3, 0RAI1, 0RAI2, 0RC4, 0RC6, 0RM1, 0RM2, 0RMDL1, 0RMDL2, 0RMDL3, 0S9, OSBPLIO, OSBPLIO-ASI, 0SBPL11, 0SBPL1A, 0SBPL2,84299833684.10SBPL3, 0SBPL5, 0SBPL6, 0SBPL7, 0SBPL8, OSCAR, OSER1, OSER1-AS1, OSGEP, OSGIN1, OSM, Osmr, OSP, OSR1, OSR2, OST4, OSTC, osteocalcin, Osteopontin, Osterix, OSTF1, OSTN, OSX, OTC4, OTOP2, 0TUB1, 0TUD1, 0TUD4, 0TUD5, 0TUD6A, OTUD6B-AS1, 0TUD7A, 0TUD7B, OTULIN, 0TX1, 0TX2, OV6, OV-6, Ovastacin, 0VGP1, 0V0L1, 0V0L2, OVOS2, 0X40, OX40L, 0XA1L, OXCT1, 0XLD1, 0XNAD1, OXPHOS, 0XR1, OXSR1, OXTR, P27, P2RX1, P2RX3, P2RX4, P2RX5, P2RX5-TAX1BP3, P2RX7, P2RX7B, P2RY1, P2RY10, P2RY11, P2RY12, P2RY13, P2RY14, P2RY6, P2RY8, P2X7, P2X7R, P2Y12, P3H1, P3H2, P3H3, P3H4, P4HA1, P4HA2, P4HA2-AS1, P4HB, P4HTM, P501S, P63, p73, P75, p75 Neurotrophin R, P75ntr, PA24, PA2G4, PAAF1, PABPC1, PABPC1L, PABPC1P2, PABPC3, PABPC4, PABPN1, PACAP, PACRG, PACS1, PACS2, PACSIN1, PADI1, PADI2, PADI4, PADI6, PAF1, PA-FABP, PAFAH1B1, PAFAH1B2, PAFAH1B3, PAFAH2, PAG1, PAGE1, PAGE2, PAGE2B, PAGE5, PAH, PAICS, PAIP1, PAIP2, PAIP2B, PAK1, PAK2, PAK4, PALB2, PALD1, PALLD, PALM2, PALM2-AKAP2, PALMD, PAM, PAMR1, PAN2, PAN3, PanCK, PAN-CK, Pancytokeratin, pan-cytokeratin, PANK2, pan-keratin, PANX2, Pan-ANp63, PAOX, PAPD4, PAPD5, PAPD7, PAPL, PAPLN, PAPOLA, PAPOLG, PAPPA2, PAPSS1, PAPSS2, PAQR3, PAQR4, PAQR6, PAQR8, PARD3, Pard3b, PARD6B, PARG, PARK2, PARK7, PARE, PARM1, PARP1, PARP10, PARP12, PARP14, PARP15, PARP16, PARP6, PARP8, PARTI, PARVG, PASD1, PASK, Patched, PATE2, PATL1, PATL2, PAWR, PAX1, Pax2, PAX3, PAX4, PAX5, PAX-5, PAX6, Pax-6, PAX7, PAX8, PAX9, PAXBP1, PAXIP1-AS2, PBCS, PBDC1, PBK, PBLD, PBOV1, PBRM1, PBSM11, PBX1, PBX3, PBX4, PBXIP1, PCA1, PCA2, P-cadherin, Pcanwas, PCAT19, PCBD2, PCBP1, PCBP2, PCBP4, PCCB, PCD1, PCDH1, PCDH11X, PCDH11Y, PCDH15, PCDH17, PCDH18, PCDH20, PCDH7, PCDH8, PCDH9, PCDHGA5, PCED1A, PCED1B, PCED1B-AS1, PCF11, PCGF3, PCGF5, PCGF6, PCGR2A, PCID2, PCIF1, Pckl, PCK2, PCLAF, PCM1, PCMT1, PCMTD1, PCMTD2, PCNA, PCNP, PCNT, PCNX, PCNXL4, PCOLCE, PCOLCE2, PCP2, PCP4, PCPP260, PCSK1, PCSK1N, PCSK5, PCSK6, PCSK7, PCSK9, PCX3CR1, PCYOX1, PCYOX1L, PCYT2, PD1, PD-1, PD1-L1, PD1-L2, PD2, PDAC, PDAP1, Pdcl, PDCD1, PDCD10, PDCD11, PDCD1LG2, PDCD2, PDCD4, PDCD4-AS1, PDCD5, PDCD6, PDCD6IP, PDCD6IPP2, PDCD7, PDCL, PDCL2, PDCL3, PDDC1, PdelOa, PDE1A, PDE1B, PDE1C, PDE2A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE4DIP, PDE5, PDE5A, PDE5H, PDE6A, PDE6B, PDE6C, PDE6D, PDE6G, PDE6H, PDE7A, PDE7B,85299833684.1PDE8A, PDE8B, PDE9A, PD-ECGF, PDFGRA, PDGDRA, PDGF, Pdgfa, PDGF-A, PDGF- AA, PDGFB, PDGFC, PDGFD, PDGFR, PDGFR- 0, PDGFR a, PDGFRa, PDGFR-alpha, PDGFRB, PDGFR-beta, PDGFRL, PDGFRa, PDGFR-a, PDGFRa , PDGFRa / 0, PDGFR0, PDGFR-0, PDGRB, PDHA1, PDHB, PDHX, PDIA2, PDIA3, PDIA4, PDIA6, PDIK1L, PDK1, PDK2, PDK3, PDK4, PDL1, PDL-1, PD-L1, PDL1-PDL2, PDL2, PD-L2, PDLIM1, PDLIM2, PDLIM3, Pdlim4, PDLIM5, PDLIM7, PDLM3, PDP1, PDP2, PDPK1, PDPN, PDPR, PDRG1, PDS5A, PDS5B, PDSS2, PDX1, PDXDC1, PDXDC2P, PDXK, PDXP, PDYN, PDZD11, Pdzd2, PDZD3, PDZD8, PDZK1, PDZK1IP1, PDZRN3, PEA15, PEA15A, PEAR1, PEBP1, PECAM, PECAM1, PECAM-1, PECAM128, PECR, PEF1, PEG10, PEG3, PELI1, PELI2, PELN, PEMT, Penk, PEP 19, PEPD, Pepsinogen C, pepsinogen-I, PERI, PER3, Perforin, Perilipin, Perilipin-2, periostin, Peripherin, peroxiredoxin-6, PERP, Peryl 2, PET1, PET 100, PET117, PEX11A, PEX13, PEX14, PEX16, PEX19, PEX2, PEX26, PEX3, PEX6, PF4, pfcSNPs, PFDN1, PFDN2, PFDN4, PFDN5, PFDN6, PFKFB2, PFKFB3, PFKFB4, PFKL, PFKP, PFLT3, PFN1, PFN2, PFN4, PGA3, PGA4, PGA5, PGAM1, PGAM5, PGC, PGC-1- alpha, PGD, PGDS, PGE, PGE2-R, PGF, pGFAP, PGK1, PGLS, PGLYRP1, PGLYRP4, PGM1, PGM2, PGM2L1, PGM3, PGM5, PGM5P2, PGP, PGP9.5, PGPEP1, PGPEP1L, pGR, PGRMC1, PGRMC2, PGS1, PHACTR1, PHACTR2, PHACTR3, PHACTR4, PHAX, PHB, PHB2, PHC1, PHC2, PHC3, PHEX, PHF1, PHF10, PHF11, PHF12, PHF13, PHF14, PHF19, PHF20, PHF20L1, PHF21A, PHF21B, PHF23, PHF24, PHF3, PHF5A, PHF6, PHF7, PHF8, PHGDH, PHIP, PHKA2, PHKA2-AS1, PHKB, Phkgl, PHKG2, PHLDA1, PHLDA2, PHLDA3, PHLDB1, PHLDB2, PHLPP1, PHLPP2, PHOSPHO1, PHOSPHO2, PHOSPHO2- KLHL23, PHOX2A, PHOX2B, PHPT1, PHTF1, PHTF2, PHYHIPL, PHYKPL, PI15, PI16, PI3, PI4K2B, PI4KA, PI4KB, PIANP, PIAS2, PIC ALM, PID1, PIEZO 1, PIEZO2, PIFO, PIG6B, PIGC, PIGH, PIGK, PIGM, PIGO, PIGP, PIGQ, PIGR, PIGT, PIGU, PIGV, PIGW, PIGX, PIH1D1, PIH1D2, PIH1D3, PIK3AP1, PIK3C2A, PIK3C2B, PIK3C3, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIK3IP1, PIK3R1, PIK3R3, PIK3R5, PIK3R6, PILRA, PILRB, PIM1, PIM2, PIM3, PIN1, PIN4, PINK1-AS, PINX1, PIP, PIP4K2A, PIP5K1A, PIP5K1B, PIP5K1C, PIP5KL1, PIPOX, PIR, PISD, PIT-1, PITHD1, PITPNA, PITPNB, PITPNC1, PITPNM1, PITPNM2, PITRM1, PITX1, PITX2, Pitx3, PIWIL1, PIWIL2, PIWIL4, PJA1, PJA2, PK-6102, pKARMA, PKC, PKC-alpha, PKCzeta, PKD1, PKD1L2, PKD1L3, PKDCC, PKHD1L1, PKIB, PKIG, PKM, PKM2, PKN1, PKP1, PKP2, PKP3, Pkp4, PLA2G12A, PLA2G15, PLA2G16,86299833684.1PLA2G1B, PLA2G2A, PLA2G4C, PLA2G4F, PLA2G5, PLA2G6, PLA2G7, PLAA, PLAC1, PLAC8, PLAC9, PLAG1, PLAGL1, PLAGL2, PLAP, PLAT, platelet-derived growth factor(PDGF)receptor, PLAU, Plaur, PLBD1, PLBD2, PLCB1, PLCB2, PLCB4, PLCD1, Plcel, PLCG1, PLCG1-AS1, PLCG2, Plcll, PLCL2, PLCXD2, PLCXD3, PLD1, PLD2, PLD3, PLD4, PLD5, PLD6, PLEC, PLEK, PLEK2, PLEKHA1, PLEKHA2, PLEKHA3, PLEKHA4, PLEKHA5, PLEKHA6, PLEKHB1, PLEKHF1, PLEKHF2, PLEKHG1, PLEKHG2, PLEKHG3, PLEKHG4B, PLEKHG5, PLEKHG6, PLEKHG7, PLEKHH1, PLEKHH2, PLEKHJ1, PLEKHM2, PLEKH01, PLEKHO2, PLEKHS1, PLET1, PLGRKT, PLIN, PLIN2, PLIN3, PLIN5, PLK1, PLK2, PLK3, PLK4, PLLP, pLMP2, PLN, PLOD1, PLOD2, PLOD3, PLP, PLP+, PLP1, PLP2, PLPP1, PLPP3, PLPP5, PLPPR3, PLPPR5, PLRG1, PLS1, PLS3, PLSCR1, PLSCR5, PLTP, PLVAP, PLXDC1, PLXDC2, PLXNA2, PLXNA4, PLXNB1, PLXNC1, PLXND1, PLZF, PMAIP1, PMC A, PMCA2, PMCH, PMEL, Pmel-1, PMEPA1, PMF1, PMF1-BGLAP, PML, PMM1, PMM2, PMo, PMP2, PMP22, PMPCA, PMPCB, PMS1, PMS2, PMS2L2, PMS2P5, PMVK, PN1, PNCK, PNECs, PNISR, PNKP, PNLDC1, PNLIP, PNLIPRP1, PNLIPRP2, PNMA1, PNMA2, PNMAL1, PNMT, PNN, PNO1, PNOC, PNP, PNPLA2, PNPLA3, PNPLA4, PNPLA6, PNPLA7, PNPLA8, PNPT1, PNRC1, PNRC2, POC1B, POC5, Podocalyxin, Podoplanin, PODXL, PODXL-1, POF1B, POFUT2, POGK, POGLUT1, POLA2, POLB, POLD2, POLD4, POLDIP2, POLE3, POLE4, POLG, POLH, POLI, POLK, POLL, POLM, POLN, POLQ, POLR1C, POLR1D, POLR1E, POLR2A, POLR2B, POLR2C, POLR2D, POLR2E, POLR2F, POLR2G, POLR2H, POLR2I, POLR2J, POLR2J2, POLR2J3, POLR2J4, POLR2K, POLR2L, P0LR2M, POLR3B, POLR3D, POLR3E, POLR3G, POLR3GL, POLR3K, P0M121, POM121C, POM121L8P, POMC, P0MGNT1, P0MGNT2, POMP, POMT1, POMT2, POMZP3, PON1, PON2, PON3, POP4, POP5, POP7, POPDC2, POPDC3, POR, POSTN, POTI, POTEF, POU1F1, POU2AF1, POU2F2, POU2F3, POU3F1, POU3F2, POU3F3, POU4F1, POU4F2, POU5F1, POU5F1B, POU5F2, POU6F2, POXDL, PP, PP1CB, pp65, PP7080, PPA1, PPA2, PPAN, PPAP2A, PPAP2B, PPAP2C, PPAPDC1B, PPARA, PPARG, PPARgamma, PPARGC1A, PPARy, PPBP, ppCT16-25, PPDPF, PPEF2, PPFIA1, PPFIA2, PPFIA3, PPFIBP1, PPFIBP2, PPHLN1, PPIA, Ppib, PPIC, PPID, PPIE, PPIF, PPIG, PPIH, PPIL2, PPIL3, PPIL6, PPIP5K2, PPL, PPM1A, PPM1B, PPM1D, PPM1F, PPM1G, PPM1H, PPM1J, PPM1K, PPM1M, PPM1N, PPME1, PPOX, PPP1CA, PPP1CB, PPP1CC, PPP1R10, PPP1R11, PPP1R12A, PPP1R12B, PPP1R12C,87299833684.1PPP1R13B, PPP1R13L, PPP1R14A, PPP1R14B, PPP1R14C, PPP1R15A, PPP1R15B, PPP1R16A, PPP1R16B, PPP1R17, PPP1R18, PPP1R1B, PPP1R1C, PPP1R2, PPP1R35, PPP1R36, PPP1R37, PPP1R3B, PPP1R3C, PPP1R3G, PPP1R42, PPP1R7, PPP1R8, PPP1R9A, PPP1R9B, Ppp2ca, PPP2R1A, PPP2R2A, PPP2R2B, PPP2R2D, PPP2R3A, PPP2R3B, PPP2R3C, PPP2R5A, PPP2R5C, PPP2R5D, PPP2R5E, PPP3CA, PPP3CB, PPP3CC, PPP4C, PPP4R2, PPP4R3A, PPP4R3B, PPP4R4, PPP5C, PPP6C, PPP6R1, PPP6R2, PPRG, PPT1, PPWD1, PPY, PQBP1, PQLC2, PQLC3, PRADC1, PRAF2, PRAM1, PRAME, PRAP1, Praxl, PRBP, PRC1, PRCC, PRCD, PRCH1, PRCP, PRDM1, PRDM14, PRDM2, PRDM4, PRDM9, PRDX1, PRDX2, PRDX3, PRDX4, PRDX5, Prdx6, PRE, PREFI, PRELID1, PRELID2, PRELID3B, PRELP, PREP, PREPL, PREXI, Prex2, PRF, PRF1, PRF2, PRF4, PRF5, PRF6, PRF7, PRF8, PRF9, PRG2, PRG4, PRICKLEI, Prickle2, PRICKLE2-AS3, PRIM1, PRIM2, PRK2, PRKAA1, PRKAA2, PRKAB1, PRKACA, PRKACB, PRKAG1, PRKAG2, PRKAG2- AS1, PRE AR I A, PREAR I B, PRKAR2A, PRKAR2B, PRKCA, PRKCB, PRKCD, PRKCDBP, PRKCE, PRKCH, PRKCQ, PRKCQ-AS1, PRKCSH, PRKD1, PRKD2, PRKD3, PRKDC, PRKG1, PRKG2, PRKRIP1, PRKRIR, PRKRIRP3, PRKX, PRKXP1, PREY, PRL, PRLHR, PRLR, PRM1, PRM2, PRM3, PRMT1, PRMT2, PRMT6, PRMT9, PRND, Prnp, PRNT3, PR0B1, Procr, ProC-R, PRODH, PR0DH2, PROK2, PR0M1, Prominin 2, Prominin- 1, PROP1, properdin, PRORY, PROS1, Prostate specific antigen, proteases, PR0X1, Prox-1, PROX2, PRPF18, PRPF19, PRPF3, PRPF31, PRPF38A, PRPF38B, PRPF39, PRPF4, PRPF40A, PRPF4B, PRPF6, PRPF8, PRPH, PRPRC, PRPS1, PRPS2, PRPSAP1, PRPSAP2, PRR11, PRR13, PRR14, PRR15, PRR15L, Prrl8, PRR27, PRR29, PRR4, PRR5, PRR5- ARHGAP8, PRR5L, PRR7, PRR7-AS1, PRR9, PRRC2B, PRRC2C, PRRT2, PRRT3, PRRX1, PRSS, PRSS1, PRSS12, PRSS16, PRSS2, PRSS21, PRSS22, PRSS23, PRSS27, PRSS3, PRSS35, PRSS36, PRSS3P2, PRSS50, PRSS57, PRSS8, PRTG, PRTN3, Prune2, PRX, Prxxl, PS, PSA, PSA-NCAM, PSAP, PSAT1, PSCA, PSD, PSD3, PSD4, PSD95, PSEN1, PSEN2, PSENEN, PSIP1, PSMA, PSMA1, PSMA2, PSMA3, PSMA3-AS1, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB6, PSMB7, PSMB8, PSMB8-AS1, PSMB9, PSMC1, PSMC2, PSMC3, PSMC4, PSMC5, PSMC6, PSMD1, PSMD10, PSMD11, PSMD12, PSMD13, PSMD14, PSMD2, PSMD3, PSMD4, PSMD5-AS1, PSMD6, PSMD7, PSMD8, PSMD9, PSME1, PSME2, PSME4, PSMF1, PSMG2, PSMG3, PSMG3-AS1, PSMG4, PSORS1C2, PSPC1, PSPN, PSTK, PSTPIP1, PSTPIP2, PTAFR,88299833684.1PTAR1, PTBP1, PTBP2, PTBP3, PTCH, Ptchl, PTCH2, PTCHD1, PTCRA, PTDSS1, PTEN, PTF1A, PTGDR, PTGDR2, PTGDS, PTGER2, Ptger3, PTGER4, PTGER4P2-CDK2AP2P2, PTGES, PTGES2, PTGES3, PTGES3L, PTGFR, PTGFRN, PTGIR, PTGIS, PTGR1, PTGS1, PTGS2, PTH1R, PTK2, PTK2B, PTK6, PTK7, PTKN2, PTMA, PTMS, PTN, PT0V1, PTOV1- AS2, PTP4A1, PTP4A2, PTP4A3, PTPDC1, PTPLAD1, PTPLAD2, PTPMT1, PTPN1, PTPN11, PTPN12, PTPN13, PTPN14, PTPN2, PTPN21, PTPN22, PTPN4, PTPN6, PTPN7, PTPN9, PTPRA, PTPRB, PTPRC, PTPRCAP, PTPRE, PTPRF, PTPRG, PTPRG-AS1, PTPRJ, PTPRK, PTPRM, PTPRN2, PTPRO, PTPRR, PTPRS, PTPRT, PTPRU, PTPRZ1, PTRF, PTRH1, PTRHD1, PTS, PTTG1, PTTG1IP, PTX3, PU. l, PU1, PUF60, PUM1, PUM2, PUM3, PURA, PURB, PUS3, PUS7L, PVALB, pVIPR, PVLAP, PVR, PVRIG, PVRL1, PVRL2, PVRL3, PVRL4, PVT1, PWARSN, PWP1, PWRN1, PWWP2A, PWWP2B, PXDC1, PXDN, PXK, PXMP4, PXN, PXT1, PYCARD, PYCR1, PYCR2, PYCRL, PYGB, PYGL, PYGO2, PYHIN1, PYR0XD1, PYROXD2, PYURF, PYY, PZP, PaS, QARS, QAS3, QDPR, Qk, QKI, QKI-5, QPCT, QPCTL, QPRT, QRFPR, QRICH1, QRSL1, QSER1, QSOX1, QSOX2, QTRT1, R3HCC1, R3HCC1L, R3HDM4, RAB10, RAB11A, RABI IB, RAB11FIP1, RAB11FIP2, RAB11FIP4, RABB, RAB14, RABIS, RAB17, Rabl8, RAB1A, RAB1B, RAB20, RAB21, RAB23, RAB24, RAB25, RAB27A, RAB27B, RAB28, RAB29, RAB2A, RAB30, RAB31, RAB32, RAB33A, RAB34, RAB35, RAB37, RAB38, RAB3A, RAB3B, RAB3C, RAB3D, RAB3GAP1, RAB3GAP2, RAB3IL1, RAB3IP, RAB40A, RAB40B, RAB41, RAB42, RAB44, RAB4A, RAB4B, RAB5A, RAB5B, RAB5C, RAB6A, RAB7A, Rab7b, RAB7L1, RAB8A, RAB8B, RAB9A, RAB9B, RABAC1, RABEP1, RABEP2, RABEPK, RABGAP1, RABGAP1L, RABGGTA, RABL2A, RABL2B, RABL3, Rael, RAC2, RACGAP1, RACK1, RADI, RAD17, RAD18, RAD21, RAD21L1, RAD23A, RAD23B, RAD50, RAD51, RAD51AP1, RAD51AP2, RAD51-AS1, RAD51C, RAD51D, RAD51L3-RFFL, RAD54L2, RAD9A, RAD9B, RADIL, RAE1, RAET1E, RAFI, Raftlin, RAG, RAG1, RAG2, RAI14, RALA, RALB, RALBP1, RALGAPA1, RALGAPA2, RALGDS, RALGPS2, RALY, RALY- AS1, RALYL, RAMP1, RAMP2, RAMP2-AS1, RAMP3, RAN, Ran2, RANBP1, RANBP10, RANBP17, RANBP3, RANBP6, RANGRF, RANK, RANTES, RAP1, RAP1A, RAP1B, RAP1GAP, RAP1GAP2, RAP1GDS1, RAP2A, RAP2B, RAP2C, RAPGEF1, RAPGEF4, RAPGEF5, RAPGEF6, RAPH1, RARA, RARB, RARG, RARRES1, RARRES2, RARRES3, RARS, RASA1, RASA2, RASA3, RASA4, RASA4B, Rasal2, RASAL2-AS1, RASAL3,89299833684.1RASD1, RASEF, RASGEF1A, RASGEF1B, RASGEF1C, RASGRF1, RASGRF2, RASGRP1, RASGRP2, RASGRP3, RASGRP4, RASIP1, RASL10A, RASL11B, RASL12, RASSF1, RASSF2, RASSF3, RASSF4, RASSF5, RASSF6, RASSF7, Rassf8, RAVER2, RAX, RAX2, RB, RBI, RB1CC1, RBBP4, RBBP5, RBBP6, RBBP7, RBBP8, RBCK1, RBFOX1, RBFOX2, RBFOX3, RBKS, RBL1, RBL2, RBM, RBM10, RBM12, RBM14, RBM15, RBM17, RBM19, RBM20, RBM22, RBM23, RBM24, RBM25, RBM26, RBM26-AS1, RBM27, RBM28, RBM3, RBM33, RBM34, RBM38, RBM39, RBM4, RBM41, RBM42, RBM44, RBM46, RBM47, RBM48, RBM4B, RBM5, RBM6, RBM7, RBM8A, RBMS1, RBMS2, RBMS3, RBMX, RBMX2, RBMXL1, RBP1, RBP2, RBP4, RBP7, RBPJ, RBPMS, RBPMS2, RBSN, RBTN3, RBX1, RC3H1, RC3H2, RCAN2, RCAN3, RCBTB1, RCBTB2, RCC1, RCC2, RCE1, RCHY1, RCL1, RCN1, Rcn2, RCN3, RCOR1, RCOR3, RCSD1, RCVRN, RDGFRB, RDH10, RDH5, RDX, RECI 14, REC8, Recoverin, RECQL, REDD1, REDD2, REEP1, REEP2, REEP4, Reep5, REEP6, REGIA, REGIB, REG3A, REG3G, REG4, REL, RELA, RELB, RELL1, RELN, RELT, REN, Reni, Renin receptor, REP15, REPIN1, REPSI, REPS2, RER1, RERE, REREP3, RERG, Rergl, REST, RET, RETN, Retnla, retnlb, RETS AT, REV3L, REXI, REXO1, REXO1L1P, REXO2, REXO4, RFC1, RFC2, RFC3, RFD7, RFESD, RFFL, RFK, RFPL1, RFPL1S, RFPL3, RFPL4B, RFTN1, RFTN2, RFWD3, RFX2, RFX3-AS1, RFX4, RFX5, RFX6, RFX7, RFXANK, RFXAP, RG9MTD2, RGAG1, RGAG4, RGCC, Rgll, RGL4, RGMA, RGMB, RGN, RGP4, RGR, RGS1, RGS10, RGS12, RGS13, RGS14, RGS16, RGS19, RGS2, RGS20, RGS22, RGS3, RGS5, RGS7, RGS9, RHBDD1, RHBDD2, Rhbdfl, RHBDF2, Rhbg, RHCE, RHCG, RHEB, RHEBL1, RHNO1, RHO, RHO A, RHOB, RHOBTB2, RHOC, RHOD, Rhodopsin, RHOF, RHOG, RHOH, RHO J, RHOQ, RHOT1, RHOT2, RHOXF1, RHPN1, RHPN2, RIBCI, RIBC2, RIC1, RIC3, RIC8A, RICTOR, RIF1, RIIAD1, RILPL2, RIMKLA, RIMS2, RIMS3, RIN2, RIN3, RING1, RINL, RINT1, RIOK1, RIOK3, RIPK1, RIPK2, RIPK3, RIPPLY1, RIT1, RIT2, RITA1, RLBP1, RLF, RMDN2, RMDN3, RMI2, RMND1, RMND5A, RMRP, RNA CD19, RNA PNOC, RNASE 1, RNASE2, RNASE3, RNASE4, RNASE6, RNASEH1, RNASEH1-AS1, RNASEH2A, RNASEH2B, RNASEH2C, RNASEK, RNASEL, RNASET2, RND2, RND3, RNF10, RNF103, RNF103-CHMP3, RNF11, RNF111, RNF113A, RNF114, RNF115, RNF125, RNF126, RNF128, RNF13, RNF130, RNF135, RNF138, RNF139, RNF139-AS1, RNF14, RNF141, RNF144B, RNF145, RNF149, RNF152, RNF157, RNF166, RNF167, RNF168, RNF170, RNF181, RNF182, RNF183,90299833684.1RNF185, RNF186, RNF187, RNF19A, RNF19B, RNF20, RNF207, RNF212, RNF212B, RNF213, RNF214, RNF216P1, RNF219, RNF220, RNF24, RNF25, RNF31, RNF32, RNF34, RNF38, RNF40, RNF41, RNF43, RNF44, RNF5, RNF6, RNF7, RNFT1, RNGTT, RNH1, RNLS, RNMT, RNMTL1, RNPC3, RNPEP, RNPEPL1, RNPS1, RNU, RNU6-2, RNU6-645P, RNXN2, R0B01, ROBO2, ROBO3, ROBO4, ROCK1, ROCK2, R0M1, R0M01, ROPN1L, ROR gamma, ROR gamma T, ROR1, ROR1-AS1, ROR2, RORA, RORA-AS1, ROR-alpha, RORB, RORC, RORgt, RORyT, ROS, ROS1, RP1, RP11-104L2E3, RP11-105N14.1, RP11- 1070N10.3, RP11-10L12.4, RP11-1100L3.8, RP11-12601.6, RP11-138A9.1, RP11-138A9.2, RP11-166P13.4, RP11-16E12.2, RP11-179A10.1, RP11-18H21.1, RP11-210M15.2, RP11- 215P8.3, RP11-222K16.2, RP11-255M2.3, RP11-25K19.1, RP11-266K4.9, RP11-290F5.1, RP11-291B21.2, RP11-295P9.13, RP11-298J20.3, RP11-302B13.5, RP11-307N16.6, RP11- 315120.1, RP11-325F22.2, RP11-326C3.15, RP11-347P5.1, RP11-354E11.2, RP11-35612.4, RP11-356J5.12, RP11-373D23.3, RP1-137K24.1, RP11-386G11.10, RP11-387A1.5, RP11- 398K22.12, RP11-412D9.4, RP11-426C22.5, RP11-431M7.3, RP11-449D8.1, RP11-455F5.5, RP11-47311.5, RP11-47L3.1, RP11-488C13.5, RP11-488L18.10, RP11-489E7.4, RP11- 48B3.3, RP11-493L12.4, RP11-500C11.3, RP11-501 J20.5, RP11-51J9.5, RP11-520H11.1, RP11-521B24.3, RP11-531F16.4, RP11-533E19.5, RP11-536K7.5, RP11-539I5.1, RP11- 539L10.2, RP11-542M13.3, RP11-544A12.8, RP11-635N19.1, RP11-65M17.3, RP11- 660L16.2, RP11-73E17.2, RP11-7306.3, RP11-763B22.4, RP11-796E2.4, RP11-83A24.2, RP11-93615.1, RP1-276N6.2, RP1-28O10.1, RP13-143G15.4, RP2, RP3-395M20.12, RP3- 395M20.8, RP3-508I15.10, RP4-539M6.22, RP4-706G24.1, RP4-728D4.2, RP5-1028K7.2, RP5-1085F17.3, RP5-1171110.5, RP5-1180E21.5, RP5-887A10.1, RP5-940J5.9, RP6- 149D17.1, RP6-159A1.4, RPA1, RPA2, RPA3, RPA4, RPAIN, RPAP2, RPARP-AS1, RPE, RPE65, RPF1, RPF2, RPGR, RPGRIP1, RPGRIP1L, RPH3AL, RPIA, RPL10, RPL10A, RPL10A-PS1, RPL10L, RPL11, RPL12, RPL13, RPL13A, RPL13P5, RPL14, RPL14-PS1, RPL15, RPL17, RPL18, RPL18A, RPL18-PS1, RPL19, RPL21, RPL21P44, RPL22, RPL22L1, RPL23, RPL23A, RPL23AP53, RPL23AP7, RPL23AP82, RPL24, RPL26, RPL27, RPL27A, RPL28, RPL29, RPL3, RPL30, RPL31, RPL32, RPL32P3, RPL34, RPL35, RPL35A, RPL36, RPL36A, RPL36AL, RPL36A-PS1, Rpl36-ps3, RPL37, RPL37A, RPL38, RPL38-PS2, RPL39, RPL39L, RPL4, RPL41, RPL5, RPL5-PS1, RPL6, RPL7, RPL7A, RPL7L1, RPL7P52, RPL8, RPL9, RPL9-PS6, RPLPO, RPLP0P2, RPLP1, RPLP2, RPLP2-PS1, RPN2, RPP25, RPP25L,91299833684.1RPP38, RPPH1, RPRD1B, RPRM, RPS10, RPS1O-PS1, RPS11, RPS12, RPS13, RPS13-PS1, RPS14, RPS15, RPS15A, RPS16, RPS17, RPS17L, RPS18, RPS18P9, RPS19, RPS19BP1, RPS19-PS11, RPS19-PS3, RPS19-PS7, RPS2, RPS20, RPS21, RPS23, RPS24, RPS24-PS2, RPS24-PS3, RPS25, RPS26, RPS27, RPS27A, RPS27L, RPS28, RPS29, RPS3, RPS3A, RPS4X, RPS4XP16, RPS4Y1, RPS4Y2, RPS5, RPS6, RPS6KA1, RPS6KA2, RPS6KA3, RPS6KA5, RPS6KA6, RPS6KB1, RPS6KB2, RPS6KC1, RPS7, RPS8, RPS9, RPSA, RPSAP58, RPSAP9, RPSA-PS1O, RPSA-PS4, R-PTP-gamma, RPUSD2, RPUSD3, RQCD1, RRAD, RRAGA, RRAGB, RRAGC, RRAGD, RRAS2, RRBP1, RREB1, RRM1, RRM2, RRM2B, RRN3, RRNAD1, RRP12, RRP15, RRP7A, RRP7B, RRP8, RRP9, RRS1, RRTM2, rs75712673, rs75862629, RSAD1, RSAD2, RSBN1L, RSF1, RSG13, RSL1D1, RSL24D1, RSPH1, RSPH4A, RSPH9, RSPO1, RSPO2, RSPO3, RSPRY1, RSRC1, RSRC2, RSRP1, RSU1, RTCA, RTCB, RTDR1, RTF1, RTFDC1, RT-ICB, RTKN, RTKN2, RTN1, RTN2, RTN3, RTN4, RTP1, RTP4, RTP5, RTTN, RUFY1, RUFY3, RUNDC1, RUNDC3B, RUNX1, RUNX1T1, RUNX2, RUNX3, RUVBL1, RUVBL2, RWDD1, RWDD2A, RWDD2B, RWDD4, RXFP1, RXRA, RXRB, RXRG, RYBP, RYK, RYR1, RYR2, RYR3, SI 00, S-100, SI 00 protein, S100A, S100A1, S100A10, S100A11, S100A12, S100A1210, S100A13, S100A14, S100al6, S100A2, S100A4, S100A6, S100A7, S100A8, S100A8 / A9, S100A9, S100A9, SIOOB, S100-B, SlOO-beta, SlOObeta., S100G, SI OOP, S100PBP, SIOOB, S100Z, SlOOp, S104B, S1PR1, S1PR2, Slpr3, S1PR4, S1PR5, S22, SAA1, SAA2, SAA2-SAA4, SAA3, SAA3P, SAA4, SAAL1, SAC3D1, SACM1L, SACS, SAFB, SAFB2, SAG, SAGE1, SALL1, SALL2, SALL3, SALL4, SAMD12, SAMD13, SAMD15, SAMD3, Samd4, SAMD4A, SAMD4B, SAMD7, SAMD9, SAMD9L, SAMHD1, SAMM50, SAMSN1, SAP, SAP18, SAP25, SAP30, SAP30BP, SAP30L- AS1, SAR1A, SAR1B, Saraf, SARDH, SARM1, SARS, SARS2, SART1, SASH1, SASH3, SASS6, SAT1, SAT2, SATB1, SATB2, SAV1, SAXO2, SBDS, SBDSP1, SBF1, SBF2-AS1, SBK1, SBNO1, SBNO2, SBS3, SBSN, SBSPON, SC5D, SCA-1, Sca-1, SCAF1, SCAF11, SCAF4, SCAMP1-AS1, SCAMP2, SCAMP3, SCAMP5, SCAND1, SCAND2P, SCAP, SCAPER, SCARA5, SCARB1, SCARB2, SCARF 1, SCARF2, SCARNA2, SCARNA9, scavenger receptor A, scavenger receptor Bl, SCCPDH, SCD, sCD163, Scd2, SCD5, SCEL, SCF, SCFD1, SCG2, SCG3, SCG5, SCGB1A, SCGB1A1, SCGB1A1, SCGB1B2P, SCGB2A1, SCGB2A2, SCGB3A1, SCGB3A2, SCGN, SCIMP, SON, SCIP, Sclerostin, SCLT1, SCML1, SCML2, SCML4, SCN11A, SCN1A, SCN1B, SCN2A, SCN2B, SCN3A, SCN4B, SCN5A,92299833684.1SCN7A, SCN9A, SCNN1A, Scnnlb, SCNN1D, SCNN1G, SCNNA1, SC01, SCO2, SCP2, SCP3, SCPEP1, SCRG1, SCRN1, SCRN2, SCRN3, SCT, SCTR, SCUBE2, SCUBE3, Sex, SCXA, SCYL2, SDAD1, SDC1, SDC127, SDC2, SDC3, SDC4, SDCBP, SDCCAG3, SDCCAG8, SDE2, SDF1, SDF2, SDF2L1, SDF4, SDHA, SDHAF2, SDHAF3, SDHAF4, SDHB, SDHC, SDHD, SDK2, SDPR, SDS, SDSL, SEC11A, SEC11C, SEC13, SEC14L1, SEC14L2, SEC14L4, SEC14L5, SEC22A, SEC22C, SEC23A, SEC23B, SEC23IP, SEC24A, SEC24B, SEC24C, SEC31A, SEC61A1, SEC61A2, SEC61B, SEC61G, SEC62, SEC63, SECISBP2, SECISBP2L, SECTM1, SEH1L, SEIL, SEL1L, SEL1L3, SELE, SELENBP1, SELENOP, Selk, SELL, SELM, SELP, SELPLG, SELS, SELT, SEMA3C, SEMA3D, SEMA3E, SEMA3G, SEMA4A, SEMA4B, SEMA4F, SEMA5A, SEMA6A, Sema6d, SEMA7A, SENCR, SENP1, SENP2, SENP5, SENP6, SENP7, SEP1, SEP11, SEP 15, SEP2, SEP3, SEP4, Sep6, SEP7, SEP9, SEPN1, SEPPI, SEPTI', SEPT6', SEPW1, SERBP1, SERCA, SERF1A, SERF2, SERGEF, SERINCI, SERINC2, SERINC3, SERINC5, Serotonin receptor 1A, Serotonin transporter, SERP1, SERPINA1, SERPINA11, SERPINA3, Serpina3n, SERPINA4, SERPINA5, SERPINA9, SERPINB1, SERPINB13, SERPINB2, SERPINB3, SERPINB4, SERPINB5, SERPINB6, SERPINB7, SERPINB8, SERPINB9, SERPINC1, SERPINE1, SERPINE2, SERPINF1, Serpingl, SERPINH1, SERPINI2, SERTAD1, SERTAD2, SERTAD4-AS1, SERTM1, sE-selectin, SESN1, SESN3, SESTD1, SET, SET2D, SETBP1, SETD1B, SETD2, SETD3, SETD4, SETD5, SETD8, SETD9, SETDB2, SETX, SEZ6L, SEZ6L2, SF1, SF-1, SF3A1, SF3A2, SF3A3, SF3B1, SF3B2, SF3B3, SF3B4, SF3B5, SF3B6, SFI1, SFMBT1, SFMBT2, SFN, SFPQ, SFPR4, SFR1, SFRP1, SFRP1, SFRP2, sFRP-2, SFRP3, SFRP4, SFRS7, SFSWAP, SFT2D1, SFT2D2, SFTA3, SFTPA, SFTPA1, SFTPA2, SFTPB, SFTPC, SFTPD, SFXN1, SFXN3, SFXN5, SGCA, SGCB, Sgcd, SGCG, SGCZ, SGF29, SGIP1, SGK1, SGK2, SGK3, SGK494, SGMS1, SGMS1-AS1, SGMS2, SGOL1, SGOL2, SGPL1, SGPP1, SGSH, SGSM1, SGSM3, SGTB, SH2B2, SH2B3, SH2D1A, SH2D1B, SH2D2A, SH2D3A, SH2D3C, SH2D4A, SH3BGRL, SH3BGRL3, SH3BP1, SH3BP2, SH3BP4, SH3BP5, SH3BP5-AS1, SH3D19, SH3GL1, SH3GL1P1, SH3GL2, SH3GL3, SH3GLB1, SH3KBP1, SH3PXD2A, SH3PXD2B, SH3RF1, SH3TC1, SH3TC2, SH3YL1, SHANK2, SHANK3, SHARP1, SHARPIN, SHC1, SHC4, SHCBP1, SHCBP1L, SHD, SHE, SHFM1, SHISA2, SHISA3, SHISA4, Shisa5, Shisa6, SHISA8, SHISA9, SHKBP1, SHMT2, SHOC2, SH0X2, SHPK, SHPRH, SHQ1, SHR00M1, Shroom3, SHR00M4, SH-SY5Y, SHTN1, SI, SIAH1,93299833684.1SIAH2, SIAH3, Side population, SIDT1, SIDT1-AS1, SIDT2, SIG, SIGIRR, Siglec 8, Siglec H, SIGLEC1, SIGLEC10, Siglec-10, SIGLECH, SIGLEC14, SIGLEC15, SIGLEC16, SIGLEC17P, Siglec2, SIGLEC3, SIGLEC5, SIGLEC6, SIGLEC7, SIGLEC8, Siglec-8, SIGLEC9, Siglec-9, Siglecg, Siglech, SIGMAR1, Sik3, SIKE1, SIL1, SIMC1, SIN3A, SIN3B, SIPA1, SIPA1L1, SIPA1L2, SIPA1L3, SIRPA, SIRPB1, SIRPB2, SIRPG, SIRPa, SIRT1, SIRT2, SIRT3, SIRT5, SIRT7, SIT1, SIVA1, SIX1, SIX2, SIX3, SIX3-AS1, SIX4, SKA2, SKA3, SKAP, SKAP1, SKAP2, SKI, SKIDA1, SKIL, SKIV2L, SKIV2L2, SKP1, SKP2, SL00A8, SL00A9, SLA, SLA1C3, SLA2, SLAIN1, SLAIN2, SLAMF1, SLAMF6, SLAMF7, SLAMF8, SLAMF9, Sian, SLBP, SLC10A3, SLC10A4, SLC11A1, SLC12A1, SLC12A2, SLC12A3, SLC12A5, SLC12A6, SLC12A7, SLC13A1, SLC13A2, SLC13A3, SLC13A4, SLC13A5, SLC14A1, SLC14A2, SLC15A1, SLC15A2, SLC15A3, SLC15A4, SLC16A1, SLC16A2, SLC16A3, SLC16A5, SLC16A6, SLC16A7, SLC16A8, SLC16A9, SLC17A, SLC17A3, SLC17A5, SLC17A6, Slcl7a7, SLC18A1, SLC18A2, SLC18A3, SLC19A3, SLC1A1, SLC1A2, SLC1A3, SLC1A4, SLC1A6, SLC20A1, SLC22A16, SLC22A17, SLC22A18, SLC22A20, SLC22A3, SLC22A4, SLC22A5, Slc22a6, SLC22A7, SLC22A8, SLC22A9, SLC23A2, SLC24A1, SLC24A3, SLC24A4, SLC25A1, SLC25A10, SLC25A11, SLC25A12, SLC25A14, SLC25A15, SLC25A16, SLC25A18, SLC25A20, SLC25A22,SLC25A23, SLC25A26, SLC25A29, SLC25A3, SLC25A31, SLC25A32, SLC25A34,SLC25A36, SLC25A37, SLC25A38, SLC25A39, SLC25A4, SLC25A42, SLC25A46,SLC25A5, SLC25A5-AS1, SLC25A6, SLC26A2, SLC26A3, SLC26A4, SLC26A6, SLC26A7, SLC26A8, SLC27A2, SLC27A3, SLC27A5, SLC27A6, SLC28A2, SLC28A3, SLC29A1, SLC29A3, SLC29A4, SLC2A1, SLC2A11, SLC2A12, SLC2A13, SLC2A14, SLC2A3, SLC2A4, SLC2A4RG, Slc2a5, SLC2A6, SLC2A8, SLC30A10, SLC30A3, SLC30A5, SLC30A7, SLC30A8, SLC31A1, SLC31A2, SLC32A1, SLC33A1, SLC34A1, SLC34A2, SLC34A3, SLC35A1, SLC35A2, SLC35A3, SLC35A4, SLC35A5, SLC35B2, SLC35B3, SLC35B4, SLC35C2, SLC35D1, SLC35D2, SLC35E1, SLC35E2, SLC35E2B, SLC35E3, Slc35fl, SLC35F2, SLC35F3, SLC35F5, SLC35F6, SLC35G1, SLC35G2, SLC36A4, SLC37A1, SLC37A2, SLC37A3, SLC37A4, SLC38A1, SLC38A10, SLC38A2, SLC38A3, SLC38A4, SLC38A5, SLC38A7, SLC38A8, SLC39A1, SLC39A10, SLC39A11, SLC39A12, Slc39al4, SLC39A4, SLC39A5, SLC39A6, SLC39A7, SLC39A8, SLC39A9, SLC3A2, SLC3A3, SLC40A1, SLC41A1, SLC41A2, SLC41A3, SLC43A1, SLC43A2, SLC43A3,94299833684.1SLC44A1, SLC44A2, SLC44A4, SLC45A1, SLC45A2, SLC45A3, SLC46A3, SLC47A1, SLC4A1, SLC4A10, SLC4A11, SLC4A1AP, SLC4A2, SLC4A3, SLC4A4, SLC4A5, SLC4A7, SLC4A8, SLC4A9, SLC50A1, SLC51B, SLC52A3, SLC5A12, Slc5a2, SLC5A3, SLC5A5, SLC5A7, SLC5A9, SLC6A1, SLC6A10P, SLC6A11, SLC6A14, SLC6A19, SLC6A20, SLC6A3, SLC6A4, SLC6A6, SLC6A8, SLC6A9, SLC7A1, SLC7A10, SLC7A11, SLC7A11- AS1, SLC7A13, SLC7A14, SLC7A2, SLC7A3, SLC7A4, SLC7A5, SLC7A5P2, SLC7A6, SLC7A6OS, SLC7A7, SLC7A8, SLC7A9, SLC8A1, SLC8A1-AS1, SLC8B1, Slc9a3, SLC9A3R1, SLC9A3R2, SLC9A4, SLC9A6, SLC9A7, SLC9A7P1, SLC9A8, SLC9A9, SLC9B1, SLC01B3, SLC01C1, SLCO2A1, SLCO2B1, SLCO3A1, SLCO4A1, SLCO4C1, SLCO5A1, SLCO6A1, SLF1, SLFN11, SLFN12L, SLFN13, SLFN5, SLIRP, SLIT1, Slit2, SLIT3, SLITRK1, SLITRK2, SLITRK5, SLITRK6, SLK, SLMAP, SLM02, SLPI, Sispl, SLTM, SLU7, Slug, SLX1A, SLX4IP, SM22a, SMA, SMA5, SMActin, SMAD1, SMAD2, SMAD3, SMAD4, SMAD5, Smad6, SMAD7, SMAD9, SMAGP, SMAP1, SMAP2, SMARCA1, SMARCA2, SMARCA4, SMARCA5, SMARCAD1, SMARCB1, SMARCC1, SMARCC2, SMARCD1, SMARCD2, SMARCD3, SMARCE1, SMC1A, SMC1B, SMC2, SMC3, SMC4, SMC5, SMC6, SMCHD1, SMC04, SMCR5, SMDT1, SMEK1, SMEK3P, SMG1, SMG5, SMG6, SMG7-AS1, SMG8, SMG9, SMI32, SMIM1, SMIM10L1, SMIM11, SMIM13, SMIM14, SMIM15, SMIM19, SMIM22, SMIM24, SMIM3, SMIM4, SMIM7, SMIM8, SMKR1, SMN1, SMN2, SMNDC1, SMO, SMOC1, SMOC2, SMOC-2, smooth muscle myosin heavy chain, Smooth muscle a-2 actin, Smoothelin, Smoothened, SMOX, SMPD1, SMPD2, SMPD3, SMPD4, Smpdl3a, SMPDL3B, SMS, SMTN, SMU1, SMYD1, SMYD2, SMYD3, SMYD4, SNA, SNAI1, SNAI2, SNAI3, Snail, snail 1, Snail- 1, SNAP23, SNAP25, SNAP29, SNAP47, SNAP91, SNAPCI, SNAPC2, SNAPC3, SNAPC4, SNAR-C3, SNAR-C4, SNAR-E, SNAR-F, SNAR-G1, Snca, SNCG, SND1, SNED1, SNF8, SNHG1, SNHG12, SNHG15, SNHG16, SNHG17, SNHG19, SNHG21, SNHG3, SNHG5, SNHG6, SNHG7, SNHG8, SNHG9, SNIP1, SNN, SNORA7B, SNRK, SNRNP200, SNRNP25, SNRNP40, SNRNP70, SNRPA, SNRPA1, SNRPB, SNRPB2, SNRPC, SNRPD1, SNRPD2, SNRPD3, SNRPE, SNRPF, SNRPG, SNRPN, SNTA1, SNTB1, SNTB2, SNTG2, SNTN, SNUB, SNURF, SNURF-SNRPN, SNW1, SNX1, SNX10, SNX11, SNX13, SNX14, SNX16, SNX17, SNX18, SNX2, SNX20, SNX21, SNX22, SNX24, SNX25, SNX27, SNX29, SNX29P2, SNX3, SNX30, SNX33, SNX5, SNX7, SNX8, SNX9, SOAT1, SOAT2, SOBP, SOC2, SOCS1,95299833684.1S0CS2, S0CS3, S0CS4, S0CS6, S0CS7, S0D1, SOD2, SOFAT, SOGA3, SOHLH1, SOHLH2, SOLH, Solute carrier family 30, Somatostatin, SON, Sorbsl, Sorbs2, SORBS3, SORCS2, SORD, SORL1, SORT1, S0S2, SOST, SOSTDC1, SOWAHD, SOX, SOX1, SOX- 1, SOXIO, SOX11, SOX12, SOX13, SOX15, SOX17, SOX18, SOX2, Sox-2, SOX21, SOX2- OT, SOX3, SOX30, SOX4, SOX5, SOX6, SOX8, SOX9, SOX9, SP, SP100, SP110, SP140, SP140L, SP2, SP2-AS1, SP3, SP4, SP5, SP7, SP8, SP9, SPA17, SPACA3, SPACA4, SPACA6P, SPAG1, SPAG16, SPAG17, SPAG5, SPAG5-AS1, SPAG6, SPAG7, SPAG8, SPAG9, SPANXA2-OT1, SPARC, SPARC19, SPARCL1, SPATA13, SPATA16, SPATA17, SPATA18, SPATA2, SPATA21, SPATA22, SPATA3, SPATA33, SPATA4, SPATA5, SPATA6, SPATA6L, SPATA7, SPATC1L, SPATS 1, SPATS2, SPATS2L, SPC25, SPCS1, Spcs2, SPCS3, SPDEF, SPDL1, SPDYA, SPECC1, SPECC1L, SPEF1, SPEF2, SPERT, SPESP1, SPG20, SPG21, SPG7, SPI1, SPIB, Spi-B, SPIC, SPICE1, SPIDR, SPIN1, SPIN3, SPIN4, SPINK1, SPINK2, SPINK4, Spink5, Spink8, SPINT2, SPIRE1, SPIRE2, SPLI, SPN, SPNS2, SPNS3, SPO11, SPOCD1, SPOCK1, SPOCK2, SPOCK3, SPON1, SPON2, SPOP, SPOPL, Spot 35 protein, SPP1, SPP2, SPPI, SPPL2A, SPR, SPRED1, SPRED2, SPRR1A, SPRR1B, SPRR2, SPRR2A, SPRR3, SPRTN, SPRY1, SPRY2, SPRY4, SPRYD7, SPSB3, SPTAN1, SPTBN1, SPTBN2, SPTBN5, SPTLC1, SPTLC3, SPTSSA, SPTSSB, SPTY2D1, SQLE, SQRDL, SQSTM1, SRA1, SRBD1, Src, SRCAP, SRCIN1, SRD5A1, SRD5A3, Srebfl, SREK1, SREK1IP1, SRF, SRFBP1, SRGAP1, SRGAP28, SRGAP3, SRGN, SRI, SRM, SRP14, SRP14-AS1, SRP19, SRP54, SRP68, SRP72, SRP72P2, SRP9, SRPK1, SRPK2, SRPR, SRPRA, SRPRB, SRPX, SRPX2, SRR, SRRM1, SRRM2, SRRM2-AS1, SRRM4, SRRT, SRSF1, SRSF10, SRSF11, SRSF12, SRSF2, SRSF3, SRSF4, SRSF5, SRSF6, SRSF7, SRSF8, SRSF9, SRXN1, SS18, SS18L1, SS18L2, SSB, SSBP1, SSBP2, SSBP3, SSBP4, SSC, SSC4D, SSC-A, SSEA1, SSEA-1, SSEA-3, SSEA4, SSEA-4, SSEA-5, SSFA2, SSH1, SSH2, s-SHM, SSNA1, SSPN, SSR1, SSR2, SSR3, SSR4, SSRP1, SSSCA1, SST, SST2, SSTR1, SSTR2, SSTR5-AS1, SSU72, SSUH2, SSX2IP, SSX3, STB, STM, ST2, ST20, ST20-AS1, ST2L, ST3GAL1, ST3GAL2, ST3GAL4, ST3GAL5, ST3GAL6, ST6GAL1, ST6GAL2, ST6GALNAC1, ST6GALNAC2, ST6GALNAC3, ST6GALNAC4, ST6GALNAC6, ST8SIA1, ST8SIA4, STAB1, STAB2, Stabilin-1, Stabilin-2, STAC2, STAC3, STAG1, STAG2, STAG3, STAG3L1, STAG3L2, STAG3L3, STAG3L4, STAG3L5P-PVRIG2P-PILRB, Stage Specific Embryonic Antigens, STAM, STAMBP, STAMBPL1, STAP1, STAR, STARD10, START) 13,96299833684.1STARD13-AS, STARD3, STARD3NL, STARD4, STARD5, STARD6, STARD7, STARD8, STARD9, STAT1, STAT2, STAT3, STAT4, STAT5, STAT5a, STAT5b, STAT6, STATH, Stathmin 1, STAU1, STAU2, STAU2-AS1, STC1, STEAP1, STEAP1B, STEAP3, STEAP4, STELLA, Stem cell factor, sTIL, STIM1, STIM2, STIP1, STK10, STK11, STK11IP, STK16, STK17A, STK17B, STK24, STK25, STK26, STK31, STK32A, STK32B, STK33, STK36, STK38, STK39, STK4, STK40, STK4-AS1, STMN1, STMN2, STMN3, STMN4, STMND1, STOM, STOML1, STOML2, STOML3, STON2, STOX1, STPG1, STRA13, STRA6, STRA8, STRADB, STRAP, Stratifin, STRBP, STRC, STRIP1, STRIP2, STRN3, STRN4, STRO-1, STT3A, STT3B, STUB1, STX10, STX11, STX16, STX17, STX18, STX2, STX3, STX4, STX5, STX6, STX7, STX8, STXBP2, STXBP3, STXBP4, STXBP5, STXBP5-AS1, STXBP5L, STXBP6, STYK1, STYXL1, SUB1, SUCLA2, SUCLG1, SUCLG2, SUCNR1, SUCO, SUDS3, SUGCT, SUGP2, SUGT1, SULF1, SULF2, SULT1A1, SULT1B1, SULT1C2, SULT1E1, SULT2A1, SULT2B1, SUMF1, SUMF2, SUMO1, SUMO2, SUMO3, SUN2, SUN3, SUOX, SUPT16H, SUPT20H, SUPT3H, SUPT4H1, SUPT5H, SUPT7L, SURF1, SURF2, SURF4, SURF6, Surfactant protein A, Surfactant protein B, Surfactant protein C, Surfactant protein D, survivin, SUSD1, SUSD2, SUSD3, SUSD4, SUSD6, SUV39H2, SUZ12, SUZ12P, SV2, SV2B, SVEP1, SVIL, SVIL-AS1, SVIP, SVOPL, SWAP70, SWT1, SYAP1, SYBU, SYCE1, SYCE2, SYCE3, SYCN, SYCP1, SYCP2, SYCP2L, SYCP3, SYDE2, SYF2, SYK, SYN1, SYN3, Synapsin, Synapsinl, Synaptophysin, SYNCRIP, syndecan-1, SYNE1, SYNE2, SYNE3, SYNGAP1, SYNGR1, SYNGR2, SYNGR3, SYNGR4, SYNJ1, SYNJ2, SYNM, SYNPO, Synpo2, SYNPO2L, SYNPR, SYNRG, SYP, SYPL1, SYS1, SYT1, SYT10, SYT11, SYT13, SYT16, SYT17, SYT2, SYT4, SYT6, SYT7, SYTL1, SYTL2, SYTL3, SYTL4, SYVN1, SZRD1, T, TAB1, TAC1, TAC3, TACC1, TACC2, TACC3, TACI, TACO1, TACR1, TACSD2, TACSTD2, TADA2B, TADA3, TAF1, TAF10, TAF11, TAF12, TAF13, TAF15, TAFIA, TAF1B, TAF1D, TAF2, TAF3, TAF4B, TAF5, TAF5L, TAF6L, TAF7, TAF7L, TAF8, TAF9, TAGAP, TAGLN, TAGLN2, TAGLN3, TALI, TAL2, TALDO1, TANCI, TANC2, TANG06, TANK, TAOK1, TAOK3, TAPI, TAP2, TAPBP, TAPBPL, TAPT1, TARBP 1, TARDBP, TARP, TARS, TARS2, TARSL2, TAS1R3, TASP1, TAT, TATDN1, TATDN2, TATDN3, tau, TAX1BP1, TAX1BP3, TAZ, TBC1D1, TBC1D10A, TBC1D10C, TBC1D12, TBC1D13, TBC1D14, TBC1D15, TBC1D16, TBC1D17, TBC1D19, TBC1D2, TBC1D22A-AS1, TBC1D22B, TBC1D23, TBC1D25, TBC1D28, TBC1D2B, TBC1D3, TBC1D30, TBC1D31,97299833684.1TBC1D32, TBC1D4, TBC1D5, TBC1D8, TBC1D8B, TBC1D9, TBCA, TBCB, TBCC, TBCCD1, TBCD, TBET, T-bet, TBK1, TBL1XR1, TBP, TBPL1, TBPL2, TBR1, TBR2, TBX1, TBX10, TBX18, TBX19, TBX2, TBX20, TBX21, TBX-21, TBX3, TBX5, TBX6, TBXA2R, TBXAS1, TBXT, TC2N, TCAF2, TCAP, TCEA1, TCEA3, TCEAL1, TCEAL2, TCEAL3, TCEAL4, TCEAL5, TCEAL8, TCEANC2, TCEB1, TCEB2, TCEB3, TCERG1, TCF1, TCF-1, TCF12, TCF15, TCF19, Tcf21, Tcf-21, TCF25, TCF3, TCF4, TCF7, TCF7L1, TCF7L2, Tcfcp211, TCIRG1, TCL18, TCL1A, TCL1B, TCL6, TCN1, TCOF1, TCP1, TCP11, TCP11L1, TCP11L2, TCR, TCR alpha / beta, TCR gamma / delta, TCR V0, TCR a, TCR 0, TCR y, TCR y / 5, TCR 8, TCRA, TCRalpha / beta, TCRD, TCRG, TCRgd, Tcrg-V6, TCRB, TCRVa72, TCRvalpha24, TCRvbetal l, TCRa, TCRa0, TCR0, TCR0 VJ, TCRyS, TCTA, TCTEX1D1, TCTEX1D2, TCTEX1D4, TCTN1, TCTN2, TCTN3, TDG, TDGF1, TDGF1P3, TDO2, TDP1, TDRD1, TDRD3, TDRD5, TDRD6, TDRD9, TDRKH, TDRP, TdT, TEAD1, TEAD2, TEAD4, TEC, TECPR1, TECPR2, TECR, TEF, TEFM, TEK, TEKT1, TEKT2, TEKT3, TEKT4, TEKT4P2, TEKT5, TELO2, Telomerase Inhibitors, TEM1, TEM7, TEM8, TEMRA, Tenascin C, TENM1, TENM4, Teri 19, TERFI, TERF2, TERF2IP, Terminal deoxynucleotidyltransferase, TERT, TES, TESC, Tesmin, TESPA1, TET1, TET2, TET3, Tetraspanin-7, TEX101, TEX11, TEX12, TEX14, TEX15, TEX19, TEX19.1, TEX2, TEX264, TEX30, TEX9, TF, TFAM, TFAP2A, TFAP2B, TFAP2C, TFAP2a, TFAP4, TFAPC2, TFB1M, TFCP2L1, TFDP1, TFDP2, TFDP3, TFE3, TFEB, TFEC, TFF1, Tff2, TFF3, TFG, Tfhl, Tfhl 7, Tfh2, TFIP11, TFPI, TFPI2, TFR, TFR2, TFRC, TG, TGFA, TGFB1, TGFB2, TGFB3, TGF- beta, TGFBI, TGFBR1, TGFBR2, TGFBR3, TGF-a, TGF0, TGF-01, TGF02, TGF-02, TGF0I, TGIF1, TGIF2, TGLN, TGM1, TGM2, TGM3, TGM7, Tgolnl, TGOLN2, TGS1, TH, Th 17, THAD A, THAP1, THAP10, THAP11, THAP2, THAP5, THAP7, THAP9-AS1, THBD, THBS1, THBS2, THBS3, Thbs4, THC, THEM4, THEM6, THEMIS, THEMIS2, THNSL1, THOC2, THOC3, THOC5, THOC6, THOC7, THRA, THRA1 / BTR, THRAP3, THRB, Thrombomodulin, THRSP, THSD1, THSD1P1, Thsd4, THSD7A, THTPA, THU1, THUMPD1, THUMPD3, THUMPD3-AS1, THY1, THY1 (CD90), THYN1, TIA1, TIA-1, TIAL1, TIAM1, TIBI, TICAM1, TIE1, TIE-1, TIE1 (soluble), TIE2, TIE-2, TIFA, TIGD1, TIGD6, TIGIT, TIM- 1, TIM3, TIM-3, Tim4, Timd4, TIMD-4, TIMELESS, TIMM10, TIMM10B, TIMM13, TIMM17A, TIMM17B, TIMM23, TIMM50, TIMM8A, TIMM8B, TIMM9, TIMP1, TIMP2, TIMP3, TIMP4, TINAGL1, TINF2, TIP ARP, TIPARP-AS1, TIPIN, TIPRL, TIRAP, TJAP1,98299833684.1TJP1, TJP2, TJP3, TK1, TKFC, TKT, TKTL1, TLCD1, TLCD2, TLDC1, TLDC2, TLE1, TLE2, TLE3, TLE4, TLE6, TLK1, TLK2, TLL1, TLL2, TLN1, TLN2, TLR1, TLR10, TLR2, TLR-2, TLR3, TLR-3, TLR4, TLR6, TLR7, TLR8, TLR9, TLRs, TM2D1, TM2D3, TM4SF1, TM4SF18, TM4SF19, TM4SF19-TCTEX1D2, TM4SF20, TM4SF4, TM6SF1, TM7SF2, TM7SF3, TM7SF4, TM9SF1, TM9SF2, Tm9sf3, TMA16, TMA7, TMBIM1, TMBIM4, Tmbim6, TMC3, TMC5, TMC6, TMC7, TMC8, TMCC1, Tmcol, TMCO3, TMED1, TMED10, TMED2, TMED3, TMED4, TMED9, TMEFF2, TmemlOO, TMEM101, TMEM106A, TMEM106B, TMEM106C, TMEM107, TMEM108, TMEM109, TMEM11, TMEM116, TMEM119, TMEM120, TMEM120B, TMEM123, TMEM126A, TMEM128, TMEM130, TMEM131, TMEM132A, TMEM132B, TMEM132C, TMEM133, TMEM134, TMEM135, TMEM136, TMEM141, TMEM144, TMEM14A, TMEM14B, TMEM14C, TMEM151B, TMEM154, TMEM156, TMEM160, TMEM161A, TMEM161B-AS1, TMEM163, TMEM165, TMEM167A, TMEM167B, TMEM168, TMEM17, TMEM170A, TMEM170B, TMEM171, TMEM173, TMEM174, TMEM175, TMEM176A, TMEM176B, TMEM177, TMEM178A, Tmeml78b, TMEM179B, TMEM18, TMEM181, TMEM183A, TMEM184B, TMEM185B, TMEM19, TMEM190, TMEM192, TMEM198B, TMEM2, TMEM200A, TMEM201, TMEM204, TMEM205, TMEM206, Tmem207, TMEM208, TMEM212, TMEM213, TMEM215, TMEM216, TMEM218, TMEM220-AS1, TMEM222, TMEM230, TMEM231, TMEM232, TMEM233, TMEM234, TMEM236, TMEM237, TMEM241, TMEM243, TMEM246, TMEM248, TMEM249, TMEM25, TMEM254, TMEM254-AS1, TMEM255A, TMEM255B, TMEM256, TMEM258, TMEM261, TMEM263, TMEM30A, TMEM33, TMEM37, TMEM38A, TMEM39B, TMEM41A, TMEM42, TMEM43, TMEM44, TMEM45A, TMEM45B, Tmem47, TMEM50A, TMEM51, TMEM52, TMEM52B, TMEM56, TMEM57, Tmem59, TMEM59L, TMEM61, TMEM63A, TMEM64, TMEM67, TMEM69, TMEM70, TMEM71, TMEM80, TMEM86B, TMEM87A, TMEM88, TMEM8A, TMEM90A, TMEM91, TMEM97, TMEM98, TMEM99, TMEM9B, TMEPAI, TMF1, TMG2, T-MICG, TMIGD1, TMIGD2, TMIGD3, TMMN1, TMOD1, TMOD3, TMP1, TMPO, TMPRSS1 IB, TMPRSS1 ID, TMPRSS11E, TMPRSS13, TMPRSS2, TMPRSS3, TMPRSS7, TMSB1O, TMSB15A, TMSB15B, TMSB4X, TMTC1, TMTC3, TMUB1, TMUB2, TMX1, TMX2, TMX4, TNAP, TNC, TNF, TNFAIP2, TNFAIP3, TNFAIP6, TNFAIP8, TNFAIP8L1, TNFAIP8L2, TNFAIP8L3, TNF-alpha, TNF-beta, TNFR1, TNFR2, TNFRFA1, TNFRFB2, TNF-RI,99299833684.1TNFRSF10A, TNFRSF1OB, TNFRSF1OC, TNFRSF11A, TNFRSF12A, TNFRSF13B, TNFRSF13C, TNFRSF14, TNFRSF16, TNFRSF17, TNFRSF18, TNFRSF19, TNFRSF1A, TNFRSF1B, TNFRSF21, TNFRSF25, TNFRSF4, TNFRSF8, Tnfrsf9, TNFSF1O, TNFSF11, TNFSF12, TNFSF13, TNFSF13B, TNFSF14, TNFSF15, TNFSF3, TNFSF4, TNFSF5, TNFSF8, TNFSRF18, TNFSRF4, TNFSRF9, TNFa, TNF-a, TNIK, TNIP1, TNIP2, TNIP3, TNK2, TNKS, TNKS2, TNKS2-AS1, TNMD, TNNC2, TNNI1, TNNI2, TNNI3, TNNT2, TNP1, TNPO3, TNR, TNRC6A, TNRC6B, TNRC6C, TNS1, TNS2, TNS3, TNS4, TNXIP, TOBI, TOB2, TOE1, TOMI, TOM1L2, Tomato, TOMM20, TOMM22, TOMM34, T0MM5, T0MM7, TONSL, TOPI, TOP1MT, TOP2, TOP2A, TOP2B, TOP3A, TOPAZ 1, TOPBP 1, TOPORS, TOPORS-AS1, TOR1A, TOR1AIP1, TOR1AIP2, TOR1B, TOR2A, TOR3A, Tox, TOX2, TOX3, TOX4, TP53, TP53BP1, TP53BP2, TP53I11, TP53I13, TP53I3, TP53INP1, TP53TG1, TP53TG3D, TP53TG5, TP63, TP63 low, TP63, TP73, TPBS2, TPCN1, TPD52, TPD52L1, Tpdpa, TPGS1, TPGS2, TPH1, TPI1, TPM1, TPM2, TPM3, TPM3P9, TPM4, TPMT, TPO, TPP1, TPP2, TPPP, TPPP3, TPR, Tprgl, TPSAB1, TPSAB2, TPSAP1, TPSB2, TPSD1, TPST1, TPST2, TPT1, TPT1-AS1, TPTE, TPTE2P1, TPTEP1, TPX2, TRA, TRA-1- 60, TRA-l-60(R), TRA- 1-81, TRA-2-49, TRA-2-54, TRA2A, TRA2B, TRABD, TRABD2A, TRAC, TRADD, TRAF1, TRAF2, Traf2DN, TRAF3, TRAF3IP1, TRAF3IP2, TRAF3IP3, TRAF4, TRAF-4, TRAF5, TRAF6, TRAFD1, TRAIL, TRAIL-R1, TRAIP, TRAK1, TRAM1, TRAM2, TRANK 1, Transferrin, transglutaminase-2, TRAP, TRAP1, TRAPPCI, TRAPPC10, TRAPPCI 1, TRAPPC2, TRAPPC2B, TRAPPC2L, TRAPPC2P1, TRAPPC3, TRAPPC4, TRAPPC5, TRAPPC6A, TRAPPC6B, TRAPPC8, TRAT1, TRAV1-2, TRAV1-2, TRAV1- 2 / TRAJ12, TRAV1-2 / TRAJ20, TRAV1-2 / TRAJ33, TRBC1, TRBC2, TRBV23-1, TRBV29-1, TRD, TRDC, TRDMT1, TRDV2, Trdv4, TREH, TREM1, TREM2, TREML1, TRERF1, TRG- AS1, TRGC, TRGC1, TRGC2, TRGs, TRGV10, TRGV2, TRGV9, TRHDE, TRIAPI, TRIBI, TRIB2, TRIL, TRIM, TRIM11, TRIM14, TRIM16, TRIM2, TRIM21, TRIM23, TRIM24, TRIM25, TRIM26, TRIM27, TRIM28, TRIM29, TRIM3, TRIM31, TRIM32, TRIM33, TRIM36, TRIM37, TRIM38, TRIM39, TRIM4, TRIM41, TRIM44, TRIM47, TRIM50, TRIM52, TRIM52-AS1, TRIM54, TRIM55, TRIM56, TRIM58, TRIM6, TRIM61, TRIM62, TRIM63, TRIM65, TRIM66, TRIM69, TRIM7, TRIM71, TRIM72, TRIM74, TRIM77, TRIM8, TRIML2, TRIO, TRIP 10, TRIP11, TRIP 12, TRIP 13, TRIQK, TRMO, TRMT1, TRMT10A, TRMT10B, TRMT10C, TRMT112, TRMT1L, TRMT2A, TRMT44, TRMT6, TRMU,100299833684.1TRNAU1AP, TROAP, TROP2, TROP2, Troponin T, TROVE2, TROY, TRP1, TRP-1, TRP2, TRP63, TRPC1, TRPC3, TRPC4AP, TRPC5, TRPC5OS, TRPC6, TRPC7, TRPM1, TRPM2,TRPM4, TRPM5, Trpm6, TRPM7, TRPS1, TRPT1, TRPV2, Trpv4, Trpv5, TRPV6, TRRAP, Trypsin, tryptase, Tryptophan hydroxylase, TSACC, Tsapn7, TSC1, TSC2, TSC-22, TSC22D1, TSC22D1-AS1, TSC22D2, TSC22D3, TSC22D4, TSEN15, TSEN54, TSFM, TSG101, TSGA10, TSHR, TSHZ1, TSHZ2, TSHZ3, TSIX, TSLP, TSN, TSNARE1, TSNAX,TSNAXIP1, TSP, TSPAN1, TSPAN12, TSPAN13, TSPAN14, TSPAN15, TSPAN17, TSPAN18, TSPAN19, TSPAN3, TSPAN32, TSPAN33, Tspan4, TSPAN5, TSPAN6, TSPAN7, TSPAN8, TSPAN9, TSPO, TSPYL1, TSPYL2, TSPYL4, TSPYL5, TSPYL6, TSR1, TSR2, TSR3, TSSC1, TSSC4, TSSK6, Tst, TSTA3, TSTD1, TSTD3, TTBK2, TTC1, TTC12, TTC13,TTC14, TTC16, TTC17, TTC18, TTC19, TTC21A, TTC21B, TTC23, TTC23L, TTC24,TTC25, TTC26, TTC27, TTC28, TTC28-AS1, TTC3, TTC30A, TTC32, TTC33, TTC37,TTC38, TTC39A, TTC39B, TTC39C, TTC39C-AS1, TTC40, TTC7A, Ttc8, TTC9C, TTF1,TTF-1, TTK, TTLL1, TTLL3, TTLL5, TTLL6, TTLL7, TTLL9, TTN, TtnISO, TTP A, TTP AL,TTR, TTTY14, TTTY15, TTYH1, TTYH2, TTYH3, TUB1A1, TUBA1A, TUBA1B, TUBA1C, TUB A3 C, TUBA3D, TUBA3E, TUBA3FP, TUBA4A, TUBA4B, TUBA8, TUBB, TUBB1, Tubb2a, TUBB2B, TUBB3, TUBB4, TUBB4A, TUBB4B, TUBB4Q, TUBB6, TUBB8, TUBD1, TUBE1, TUBG1, TUBG2, TUBGCP2, TUBGCP3, TUBGCP4, TUC4, TUFM, TUFT1, TUJ, Tuj l, TULIP1, TULP4, TUSC7, TWF2, Twist, TWIST1, Twist-1, TWIST2, TWISTNB, TWSG1, TXK, TXLNA, TXLNB, TXLNGY, TXN, TXN2, TXNDC11, TXNDC12, TXNDC15, TXNDC16, TXNDC17, TXNDC5, TXNDC9, TXNIP, TXNL1, TXNRD1, TYK2, TYMP, TYMS, TYMSOS, type IV collagen, TYR, TYROBP, Tyrosine hydroxylase, TYRP1, TYRP2, TYSND1, TYW1, TYW3, TYW5, U2AF1, U2AF1L4, U2AF2, U2SURP, U66061.39, UACA, UAP1, UAP1L1, UBA2, UBA3, UBA5, UBA52, UBA6, UBAC2, UBALD2, UBAP1, UBAP2L, UBASH3B, UBB, UBC, UBD, UBE2B, UBE2C, UBE2D1, UBE2D2, UBE2D3, UBE2D4, UBE2E1, Ube2e2, UBE2E3, UBE2F, UBE2G1, UBE2G2, UBE2I, UBE2J1, UBE2J2, UBE2L3, UBE2L6, UBE2M, UBE2MP1, UBE2N, UBE2Q1, UBE2Q2, UBE2Q2L, UBE2Q2P1, UBE2S, UBE2T, UBE2U, UBE2V1, UBE2V2, UBE2W, UBE2Z, UBE3A, UBE3C, UBE3D, UBE4B, UBIAD1, UBL3, UBL5, UBL7, UBLCP1, UBN1, UBN2, UBOX5, UBQLN1, UBQLN2, UBR1, UBR4, UBR5, UBTD1, UBTD2, UBTF, UBXN1, UBXN10, UBXN11, UBXN2A, UBXN2B, UBXN4, UBXN6,101299833684.1UCB(s), UCHL, UCHL1, UCHL3, UCHL5, UCKL1, UCKL1-AS1, UCP1, UCP2, UFC1, UFD1L, UFL1, UFM1, UGCG, UGDH, UGDH-AS1, UGGT1, UGGT2, UGP2, UGP85, UGT1A9, UGT2A1, UGT2B15, UGT2B4, UGT2B7, UGT3A1, UGT3A2, UGT8, UHMK1, UHRF1, UHRF1BP1, UHRF1BP1L, UHRF2, UIMC1, UKBGS, ULBP1, ULK1, ULK2, ULK3, ULK4, UMAD1, UMOD, UMPS, UNCI 19, UNC119B, UNC13C, UNC13D, UNC45A, UNC50, UNC5B, UNC5B-AS1, UNC5C, UNC80, UNCX, UNE2C, UNG, UNK, UNKL, UNQ6494, Up3kb, uPAR, UPB1, UPF2, UPF3A, UPF3B, UPK1A, UPK1B, UPK2, UPK3A, Upk3b, UPK3BL, UPP1, UPRT, UQCC1, UQCC2, UQCR10, UQCR11, UQCRB, UQCRC1, Uqcrc2, UQCRFS1, UQCRH, UQCRHL, UQCRQ, URB1-AS1, URB2, URGCP, URU, URM1, UROD, uroplakin II, Uroplakin III, uroplakins, UROS, USB1, USE1, USF2, USF3, USMG5, USO1, USP1, USP10, USP11, USP12, USP13, USP14, USP15, USP16, USP18, USP2, USP20, USP22, USP24, USP28, USP3, USP30, USP30-AS1, USP31, USP32P2, USP33, USP34, USP36, USP37, USP38, USP3-AS1, USP4, USP40, USP42, USP43, USP46, USP47, USP48, USP49, USP51, Usp53, USP54, USP6, USP6NL, USP7, USP8, USP9X, USP9Y, UST, Uteroglobin, UTF1, UTP14A, UTP14C, UTP15, UTP23, UTP6, UTRN, UTS2, UTS2B, UTUC, UVRAG, UVSSA, UXS1, UXT, V1N1, VAC14, VAChT, Valpha24-Jalphal8 TCR, VAMP1, VAMP2, VAMP4, VAMP5, VAMP7, VAMP8, VAPA, VARS, VASA, VASH1, VASH2, VASN, VASP, VAT1, VAT1L, VAV1, VAV2, VAV3, VAV3-AS1, VBP1, VCAM, VCAM1, VCAM-1, VC AN, VCL, VCP, VCPKMT, VCX, VCX2, VCX3A, VCX3B, VDAC1, VDAC2, VDAC3, VDR, VEcad, VE-cad, VE-cadheri, VE-cadherin, VEFGB, VEGF, VEGF Rl, VEGF R2, VEGF R3, VEGF A, VEGFB, VEGFC, VEGFR, VEGFR-1, VEGFR2, VEGFR-2, VEGFR2 / KDR, VEGFR3, VEGFR-3, VEGFR3 / FLT4, ven, VENTX, VEPH1, Vesicular acetylcholine transporter, VE-Statin, VEZF1, VEZT, VG5Q, VGAT, VGF, VGLL1, VGLL4, vGLUTl, VGLUT2, VHF, VHL, VIL1, VIL2, Villin-1, VIM, VIM1, VIM-AS1, vimentin, Vimp, VIP, VIPR1, VIPR2, VISTA, VIT, VK0RC1, VLA2, VLA3, VLA4, VLA5, VLA6, VLDLR, VMAT1, VMF, VM01, VMP1, VMRS, VN1R10P, VNN1, VNN2, VNN3, von Willebrand factor, VOPP1, Votch3, VPREB1, VPREB3, VPS11, VPS13A, VPS13B, VPS13C, VPS13D, VPS16, VPS26A, VPS26B, VPS28, VPS29, VPS33A, VPS35, VPS36, VPS37A, VPS37B, VPS39, VPS45, VPS4A, VPS4B, VPS51, VPS53, VPS54, VPS9D1, VRK1, VRK3, VRTN, VSIG1, VSIG10, VSIG4, VSIR, VSNA, VSNL1, VSTM1, VSTM2A, VSTM2B, VSTM4, VSX1, VSX2, VTCN1, VTI1A, VTI1B, VTN, VTRNA1-1, Vwal, VWA3A, VWA3B,102299833684.1VWA5A, VWA7, VWA9, VWC2, VWDE, VWF, VWF rs73049469, Va24, Va7.2, V , V 11, Vy9, Vyb, V61, V62, WAC, WAC-AS1, WAPL, WARS, WARS2, WAS, WASF1, WASF2, WASF3, WASH1, WASH3P, WBP1, WBP11, WBP2, WBP4, WBP5, WBSCR16, WBSCR22, WBSCR27, WDFY1, WDFY2, Wdfy3, WDFY3-AS2, WDFY4, WDHD1, WDPCP, WDR1, WDR11, WDR13, WDR16, WDR17, WDR19, WDR20, WDR27, WDR3, WDR31, WDR33, WDR34, WDR35, WDR37, WDR38, WDR4, WDR41, WDR43, WDR45, WDR45B, WDR46, WDR47, WDR5, WDR52, WDR53, WDR54, WDR55, WDR5B, WDR61, WDR62, WDR63, WDR66, WDR69, WDR70, WDR73, WDR74, WDR76, WDR78, WDR83, WDR83OS, WDR86-AS1, WDR89, WDR90, WDR91, WDR92, WDR93, WDSUB1, WDYHV1, WEE1, WEE2, WFDC1, Wfdcl7, WFDC2, WFDC21P, WFDC3, WFIKKN1, WFS1, WHAMM, WHAMMP3, WHRN, WHSCI, WHSC1L1, WIBG, WIFI, WIPF1, WIPF2, WIPF3, WIPI1, WIPI2, WISP2, WLS, WNK1, Wnk4, WNT10A, WNT11, WNT16, WNT2, WNT2B, WNT3, WNT4, WNT5A, WNT5B, WNT6, WNT7A, WNT7B, WRAP73, WRB, WSB1, WSB2, WSCD1, WSCD2, Wtl, WT-1, WTAP, WWOX, WWP1, WWP2, WWTR1, XAB2, XAF1, XBP1, XBP-1, XCL1, XCL2, XCR1, XDH, XIAP, Xllla, XIRP2, XK, XKR9, XPA, XPB1, XPC, XPNPEP1, XPNPEP2, XPO1, XPO5, XPOT, XRCC2, XRCC4, XRCC5, XRCC6, XRN1, XRN2, XXbac-BPG13B8.10, XYLT2, YAF2, YAP, YAP1, YARS, YARS2, YBEY, YBX1, YBX2, YBX3, YDJC, YEATS2, YEATS4, YES1, YIF1A, YIPF2, YIPF3, YIPF4, YIPF5, YJEFN3, YKL40, YKL-40, Yml, YME1L1, YPEL1, YPEL2, YPEL3, YPEL5, YRDC, YTHDC1, YTHDC2, YTHDF1, YTHDF2, YTHDF3-AS1, YWHAB, YWHAE, YWHAG, YWHAH, YWHAQ, YWHAZ, YY1, YY2, ZADH2, ZAK, ZAN, ZAP70, ZAR1, ZBBX, ZBED2, ZBED4, ZBED5, ZBED5-AS1, ZBED9, ZBP1, ZBTB1, ZBTB10, ZBTB11, ZBTB11- AS1, ZBTB16, ZBTB17, ZBTB18, ZBTB2, ZBTB20, ZBTB21, ZBTB24, ZBTB25, ZBTB32, ZBTB33, ZBTB38, ZBTB39, ZBTB4, ZBTB43, ZBTB44, Zbtb46, ZBTB7A, ZBTB8A, ZBTB8B, ZBTB8OS, ZC2HC1A, ZC2HC1B, ZC3H11A, ZC3H12A, ZC3H12D, ZC3H13, ZC3H14, ZC3H15, ZC3H18, ZC3H3, ZC3H6, ZC3H7A, ZC3H8, ZC3HAV1, ZCCHC10, ZCCHC11, ZCCHC14, ZCCHC17, ZCCHC2, ZCCHC24, ZCCHC6, ZCCHC7, ZCCHC9, ZCRB1, ZCWPW1, ZCWPW2, ZDBF2, ZDHHC1, ZDHHC12, ZDHHC13, ZDHHC15, ZDHHC17, ZDHHC18, ZDHHC20, ZDHHC21, ZDHHC24, ZDHHC3, ZDHHC4, ZDHHC6, ZDHHC7, ZDHHC8, ZDHHC8P1, ZDHHC9, ZEB1, Zeb-1, ZEB2, ZEB2-AS1, Zebrin II, ZER1, ZFAND1, ZFAND2A, ZFAND2B, ZFAND3, ZFAND5, ZFAND6, ZFAS1, ZFAT,103299833684.1ZFC3H1, ZFHX2, ZFHX3, ZFHX4, ZFP14, ZFP36, ZFP36L1, ZFP36L2, ZFP36L3, ZFP37, ZFP41, ZFP42, ZFP618, ZFP64, Zfp706, ZFP90, ZFP91, ZFPL1, ZFR, ZFR2, ZFX, ZFY, ZFYVE16, ZFYVE21, ZFYVE26, ZFYVE27, ZFYVE28, ZG16, ZG16B, ZGLP1, ZHX1, ZHX2, ZHX3, ZIC1, ZIC2, ZIC3, ZIC4, ZIM2, ZKSCAN1, ZKSCAN2, ZKSCAN3, ZKSCAN4, ZKSCAN8, ZMAT1, ZMAT2, ZMAT3, ZMAT5, ZMIZ1, ZMYM1, ZMYM2, ZMYM3, ZMYM5, ZMYM6NB, ZMYND10, ZMYND11, ZMYND12, ZMYND8, ZNF1O1, ZNF106, ZNF107, ZNF114, ZNF117, ZNF12, ZNF121, ZNF124, ZNF131, ZNF133, ZNF135, ZNF136, ZNF138, ZNF140, ZNF141, ZNF142, ZNF143, ZNF148, ZNF154, ZNF155, ZNF16, ZNF169, ZNF184, ZNF185, ZNF195, ZNF205, ZNF207, ZNF208, ZNF215, ZNF217, ZNF22, ZNF222, ZNF224, ZNF23, ZNF230, ZNF234, ZNF236, ZNF24, ZNF25, ZNF250, ZNF251, ZNF254, ZNF256, ZNF260, ZNF263, ZNF264, ZNF266, ZNF267, ZNF273, ZNF274, ZNF275, ZNF276, ZNF277, ZNF280A, ZNF280B, ZNF280C, ZNF281, ZNF286A, ZNF286B, ZNF292, ZNF296, ZNF3, ZNF302, ZNF316, ZNF317, ZNF318, ZNF320, ZNF321P, ZNF322, ZNF326, ZNF33O, ZNF331, ZNF33B, ZNF34, ZNF343, ZNF346, ZNF35O, ZNF354A, ZNF354C, ZNF362, ZNF365, ZNF366, ZNF367, ZNF37A, ZNF382, ZNF383, ZNF385A, ZNF385B, ZNF385D, ZNF394, ZNF395, ZNF397, ZNF398, ZNF407, ZNF410, ZNF417, ZNF426, ZNF428, ZNF429, ZNF43, ZNF430, ZNF433, ZNF436, ZNF440, ZNF441, ZNF444, ZNF445, ZNF451, ZNF454, ZNF461, ZNF462, ZNF468, ZNF469, ZNF473, ZNF483, ZNF486, ZNF488, ZNF490, ZNF493, ZNF5O3, ZNF5O3-AS1, ZNF506, ZNF507, ZNF511, ZNF512, ZNF514, ZNF516, ZNF518A, ZNF519, ZNF521, ZNF525, ZNF526, ZNF527, ZNF528, ZNF532, ZNF540, ZNF541, ZNF546, ZNF549, ZNF551, ZNF554, ZNF555, ZNF556, ZNF561, ZNF562, ZNF563, ZNF569, ZNF57, ZNF571, ZNF574, ZNF576, ZNF581, ZNF582, ZNF585A, ZNF585B, ZNF586, ZNF587, ZNF587B, ZNF589, ZNF592, ZNF593, ZNF595, ZNF600, ZNF605, ZNF606, ZNF608, ZNF609, ZNF620, ZNF621, ZNF622, ZNF625, ZNF626, ZNF628, ZNF638, ZNF639, ZNF641, ZNF644, ZNF652, ZNF655, ZNF662, ZNF664, ZNF665, ZNF667, ZNF667-AS1, ZNF669, ZNF674, ZNF681, ZNF682, ZNF683, ZNF684, ZNF688, ZNF692, ZNF696, ZNF700, ZNF701, ZNF703, ZNF704, ZNF706, ZNF708, ZNF710, ZNF711, ZNF713, ZNF714, ZNF716, ZNF721, ZNF728, ZNF729, ZNF737, ZNF740, ZNF747, ZNF749, ZNF75A, ZNF76, ZNF761, ZNF763, ZNF764, ZNF766, ZNF773, ZNF776, ZNF784, ZNF785, ZNF786, ZNF789, ZNF79, ZNF791, ZNF793, ZNF799, ZNF8OO, ZNF804B, ZNF8O8, ZNF815P, ZNF816A, ZNF816-ZNF321P, ZNF827, ZNF829, ZNF83, ZNF83O, ZNF831,104299833684.1ZNF836, ZNF841, ZNF843, ZNF860, ZNF862, ZNF865, ZNF883, ZNF90, ZNF91, ZNF92, ZNFX1, ZNHIT1, ZNHIT2, ZNHIT3, ZNRD1, ZNRF1, ZNRF3, ZNRF3-AS1, Z01, ZO-1, ZO- 2, ZP1, ZP2, ZP3, ZP4, ZPBP, ZPBP2, ZPR1, ZRANB2, ZRANB3, ZSCAN10, ZSCAN16- AS1, ZSCAN18, ZSCAN22, ZSCAN26, ZSCAN29, ZSCAN30, ZSCAN9, ZSWIM1, ZSWIM3, ZSWIM5, ZSWIM6, ZSWIM8, ZUFSP, ZWINT, ZYGI 1 A, ZYX, ZZEF1, a2pi Integrin, a2pihi, a4p7, aActinin, a-actinin, a-catenin, a-MHC, aSMA, a-SMA, a-smooth muscle actin, ATP1A2, a- TUBULIN, APOE, P-catenin, P-catenin, P-HCG, P-III-Tubulin, P- MHC, P-Tubulin III, y-catenin, EOME, TOP2A, or a comination thereof. This list of markers is collectively referred to as “Marker List I”.IL Methods of Using

[0130] The fibroblast cells and / or fibroblast-derived materials of the disclosure may be used in treatment, prevention and / or studying or modeling any disease or disorder. In some aspects, the methods include administering any of the fibroblast cells and / or fibroblast-derived materials disclosed herein. Also disclosed herein are the fibroblast cells and / or fibroblast-derived materials disclosed herein for use in the manufacture of a medicament for the treatment of any disease or symptom.

[0131] For example, the fibroblast cells and / or fibroblast-derived materials may be administered into a subject having any or suspected to have any of the disorders encompassed herein. Following administration, the subject can have increased survival rate and or alleviation or amelioration of one or more symptoms or conditions, diminishment of extent of a disorder or disease, stabilization of state of disease, prevention of development of a disorder or disease, prevention of spread of a disorder or disease, delay or slowing of disorder or disease progression, delay or slowing of onset of a disorder or disease, amelioration or delay of a disorder or disease state, and remission (whether partial or total). A single cell population may be used, or at least two or more cell populations may be used. For example, a first cell population may include any of the fibroblasts disclosed herein and a second cell population may include any of the second cell types disclosed herein, including immune cells of any kind. The first cell population may be administered concurrently with the second population or sequentially in any order. In some aspects, the first cell population may be premixed with the second cell population prior to administration. Administration may be intravenous, intraarterial, subcutaneous, intraperitoneal,105299833684.1intramuscular, intrathymic, perithymic, articular, renal subcapsular, hepatic, injection into the bone marrow, or the like.

[0132] In an aspect, a therapeutically effective amount of the fibroblast cells and / or fibroblast-derived materials is administered in a single dose or various dose.

[0133] In an aspect, the method for treating or preventing the disease or disorder may include one or more additional therapies. Non-limiting examples of additional therapies can include chemotherapy, radiation therapy, androgen deprivation therapy, antibody therapeutics, cell therapies, immunotherapy of any kind, immune activation therapy, checkpoint blockade therapy, immune suppression, leuikoablative therapy, lymphodepletion therapy, immune tolerogenic therapy, pain therapy, or the like, or any combination thereof. The administration of the fibroblast cells and / or fibroblast-derived materials may occur concurrently with the additional therapy or sequentially.

[0134] In some aspects, a cancer is targeted. A cancer can be from In some aspects, the cancer originated in tissue from bladder, blood, bone, bone marrow, brain, breast, colon, esophagus, duodenum, small intestine, large intestine, colon, rectum, anus, gum, head, kidney, liver, lung, nasopharynx, neck, ovary, pancreas, prostate, skin, stomach, testis, tongue, or uterus in the patient. A cancer can comprise aids-related non-Hodgkin’s lymphoma, activated B-cell like-diffuse large b cell lymphoma (ABC DLBCL), acute B lymphoblastic leukemia, acute lymphoblastic leukemia (ALL), acute monocytic leukemia, acute myeloid leukemia, acute T lymphoblastic leukemia, acute leukemia, adenocarcinomas of the stomach and the gastroesophageal junction, adenoid cystic carcinoma, adenosquamous carcinoma, adrenal neuroblastoma, alveolar cell carcinoma, ampullary cancer, anaplastic large cell lymphoma, anaplastic thyroid cancer, anaplastic thyroid carcinoma, angioimmunoblastic T-cell lymphomas, angiosarcoma, astroblastoma, astrocytoma, B cell type malt lymphoma, B-acute lymphoblastic leukemia, B-cell lymphoma, B-cell malignancies, B-lymphoblastic leukemia, Barrett’s esophagus, basal cell carcinoma, biliary tract cancer, bladder cancer, bone cancer, brain cancer, breast cancer, breast cancer (circulating), CNS primitive neuroectodermal tumor, castrationresistant prostate cancer, central nervous system cancer, cervical cancer, cervical cancer and cervical intraepithelial neoplasia, cervical squamous cell carcinoma, cervical squamous cell carcinoma and endocervical adenocarcinoma, cholangiocarcinoma, cholangiolocellular carcinoma, chondrosarcoma, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic106299833684.1pancreatitis, clear cell renal cell carcinoma, clear-cell renal cell carcinoma, colon cancer, colorectal cancer, colorectal cancer (circulating), colorectal cancer liver metastasis, colorectum cancer, combined hepatocellular and intrahepatic cholangiocarcinoma, combined hepatocellular carcinoma and cholangiocarcinoma, corticotroph tumor, cutaneous squamous cell carcinoma, cutaneous T cell lymphoma, cutaneous epithelioid angiomatous nodule, cutaneous perivascular epithelioid cell tumor, cutaneous 76 T cell lymphoma, diffuse glioma, diffuse intrinsic pontine glioma, diffuse large B-cell lymphoma, ductal breast carcinoma, ductal carcinoma in situ, early T-cell progenitor acute lymphoblastic leukemia, early-onset colorectal cancer, endometrial cancer, endometrial tumour, ependymoma, epithelioid sarcoma-like (pseudomyogenic) hemangioendothelioma, epithelioid sarcoma-like hemangioendothelioma, epithelioid soft tissue tumor, esophageal adenocarcinoma, esophageal cancer, esophageal squamous cell carcinoma, metastatic melanoma, Ewing’s sarcoma, extra-mammary Paget’s disease, extrahepatic cholangiocarcinoma, familial platelet disorder with a predisposition to myeloid malignancy, fibroid, fibrosarcoma, follicular lymphoma, fusiform cerebral aneurysms, gallbladder cancer, gallbladder adenocarcinoma, gallbladder carcinoma, gastric adenocarcinoma, gastric cancer, gastric cancer (circulating), gastric adenocarcinoma of fundic-gland type, gastrointestinal cancer, gastrointestinal stromal tumor, gastrointestinal tumor, germ cell tumor, germinal center B-cell like-diffuse large B cell lymphoma (GCB DLBCL), giant cell tumor (circulating), glioblastoma, glioma, gonadoblastoma, granular cell tumor, granulosa cell tumor, head and neck squamous cell carcinoma, head and neck cancer, hepatobiliary tumor, hepatoblastoma, hepatocellular cancer, hepatocellular carcinoma, hepatosplenic T-cell lymphoma, high-grade serous carcinoma of uterine adnexa, high-grade serous ovarian cancer, Hodgkin’s lymphoma, human papillomaviruses (HPV)-related cancers, hydatidiform mole, hypophysoma, infantile hemangiomas, inflammatory leiomyosarcoma, intestinal cancer, intracranial aneurysm, intracranial germinoma, intracranial meningioma, intraductal papillary neoplasm, intrahepatic cholangiocarcinoma, invasive breast cancer, invasive micropapillary carcinoma, Kaposi’s sarcoma, kidney cancer, Langerhans’ cell histiocytosis, large B cell lymphoma, laryngeal squamous cell carcinoma, larynx cancer, leiomyoma, leiomyosarcoma, lentigo maligna melanoma, leukemia, lipoma, liposarcoma, liver cancer, low-grade glioma, lung adenocarcinoma, lung cancer, lung carcinoid, lung carcinoma, lung squamous cell carcinoma, lung tumour, lymphangioleiomyomatosis, lymphoma, malignant epithelial neoplasm, malignant107299833684.1insulinoma, malignant mesothelioma, malignant peripheral nerve sheath tumor, malignant melanoma, malignant tenosynovial giant cell tumor, mantle cell lymphoma, medulloblastoma, melanoma, melanoma (circulating), meningioma, merkel cell carcinoma, metaplastic breast carcinoma, metastatic breast cancer, metastatic colorectal cancer, metastatic urothelial carcinoma, microphthalmia-associated transcription factor family aberration-associated renal cell carcinoma, mucoepidermoid carcinoma, mucinous tubular and spindle cell carcinoma, multiple myeloma, mycosis fungoides, myeloma, nasopharyngeal cancer, nasopharyngeal carcinoma, natural killer cell lymphoma, nephroblastoma, neuroblastoma, neuroendocrine prostate cancer, neuroendocrine tumor, neuroepithelial tumors with patz-1 fusions, nonHodgkin’s lymphoma, non-clear renal cell carcinoma, non-small cell lung cancer, non-small cell lung cancer (circulating), nodular lymphocyte predominant Hodgkin lymphoma, nodal B-cell lymphoma, norfollicular lymphoma tumoral, esophageal cancer, esophageal squamous cell carcinoma, oligodendroglioma, oral cancer, oral squamous cell carcinoma, oropharyngeal cancer, osteosarcoma, ovarian adenocarcinoma, ovarian cancer, ovarian teratocarcinoma, ovarian clear cell carcinoma, pancreatic cancer, pancreatic ductal adenocarcinoma, pancreatic ductal carcinoma, pancreatic adenocarcinoma, pediatric cancer, papillary thyroid carcinoma, papillary neoplasm, peritoneal carcinomatosis, peripheral T-cell lymphoma, pheochromocytoma, pituitary adenoma, pituitary neuroendocrine tumor, pituicytoma, pleural tumor, primary central nervous system lymphoma, primary cutaneous B cell lymphoma, primary lung cancer, primary mediastinal B-cell lymphoma, prostate cancer, prostate cancer (circulating), pulmonary sarcomatoid carcinoma, rectal cancer, recurrent renal cell carcinoma, renal cell carcinoma, renal clear cell carcinoma, renal carcinoma, retinoblastoma, rhabdoid tumor, rhabdomyosarcoma, salivary gland tumor, sarcoma, Sezary syndrome, serous ovarian cancer, small bowel adenocarcinoma, small cell lung cancer, small bowel adenocarcinoma (SB A), small cell carcinoma of the bladder, small intestine adenocarcinoma, soft tissue sarcoma, solid tumor, spindle cell oncocytoma, spitz nevi, squamous cell carcinoma, squamous cell carcinomas, squamous cell carcinoma (SCC), stage 1 hpv-positive head and neck squamous cell carcinoma (HNSCC), stomach cancer, synovial sarcoma, systemic sclerosis, testicular germ cell tumor, testicular germ cell tumor (circulating), teratocarcinoma, thoracic aortic aneurysm, thyroid cancer, tongue cancer, tongue squamous cell carcinoma, triple-negative breast cancer, tumor vessels, T-cell acute lymphoblastic leukemia, T-cell lymphoma, T-cell leukemia, T-108299833684.1cell / histiocyte-rich large B-cell lymphoma (TCRLBCL), urothelial carcinoma, uveal melanoma, undefined, underlying hematologic malignancy, undifferentiated pleomorphic sarcoma, unspecified epithelial ovarian cancer, uterine leiomyoma, uterine sarcomas, vulvar squamous cell carcinoma, pan-cancer, or a combination thereof.

[0135] Having described the disclosure in detail, it will be apparent that modifications, variations, and equivalent aspects are possible without departing from the scope of the disclsoure defined in the appended claims. Furthermore, it should be appreciated that all examples in the present disclosure are provided as non-limiting examples.EXAMPLES

[0136] The following non-limiting examples are provided to further illustrate aspects of the disclosure disclosed herein. It should be appreciated by those of skill in the art that the techniques disclosed in the examples that follow represent approaches that have been found to function well in the practice of the disclosure, and thus can be considered to constitute examples of modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific aspects that are disclosed and still obtain a like or similar result without departing from the spirit and scope of the disclosure.Example 1

[0137] In aspects of the disclosure, an individual is determined to be in need of therapy for a medical condition. The type of medical condition may reflect a need for a specific type of engineered fibroblasts and / or engineered fibroblast-derived materials. As one example, an individual with a particular type of cancer in which cancer cells are located in a particular tissue or organ is in need of therapy that can target the particular tissue or organ. As a result, fibroblasts and / or fibroblast-derived materials are tailored by specific engineering to include, remove, or modify one or more markers in Marker List I such that the administered therapy will target the tissue and / or organ of interest. The individual is then administered a therapeutically effective amount of the engineered fibroblasts and / or engineered fibroblast-derived materials and is monitored for amelioration of one or more symptoms of the medical condition.109299833684.1

[0138] Although the present disclosure and its advantages have been described in detail, it should be understood that various changes, substitutions, and alterations can be made herein without departing from the spirit and scope of the disclosure as defined by the appended claims. Moreover, the scope of the present application is not intended to be limited to the particular aspects of the process, machine, manufacture, composition of matter, means, methods and steps described in the specification. As one of ordinary skill in the art will readily appreciate from the disclosure of the present disclosure, processes, machines, manufacture, compositions of matter, means, methods, or steps, presently existing or later to be developed that perform substantially the same function or achieve substantially the same result as the corresponding aspects described herein may be utilized according to the present disclosure. Accordingly, the appended claims are intended to include within their scope such processes, machines, manufacture, compositions of matter, means, methods, or steps.REFERENCES

[0139] All patents, patent applications, publications of patent applications, and other material, such as articles, books, specifications, publications, documents, things, and / or the like, referenced herein are hereby incorporated herein by this reference in their entirety for all purposes, excepting any prosecution file history associated with same, any of same that is inconsistent with or in conflict with the present document, or any of same that may have a limiting effect as to the broadest scope of the claims now or later associated with the present document. By way of example, should there be any inconsistency or conflict between the description, definition, and / or the use of a term associated with any of the incorporated material and that associated with the present document, the description, definition, and / or the use of the term in the present document shall prevail.1. Gomes, R.N., F. Manuel, and D.S. Nascimento, The bright side of fibroblasts: molecular signature and regenerative cues in major organs. NPJ Regen Med, 2021. 6(1): p. 43.2. Briigger, M.D. and K. Basler, The diverse nature of intestinal fibroblasts in development, homeostasis, and disease. Trends Cell Biol, 2023.110299833684.13. Ushakumary, M.G., M. Riccetti, and A.T. Perl, Resident interstitial lung fibroblasts and their role in alveolar stem cell niche development, homeostasis, injury, and regeneration. Stem Cells Transl Med, 2021. 10(7): p. 1021-1032.4. Maity, P., et al., Persistent JunB activation in fibroblasts disrupts stem cell niche interactions enforcing skin aging. Cell Rep, 2021. 36(9): p. 109634.5. Cialdai, F., C. Risaliti, and M. Monici, Role of fibroblasts in wound healing and tissue remodeling on Earth and in space. Front Bioeng Biotechnol, 2022. 10: p. 958381.6. Morsing, M., et al., Fibroblasts direct differentiation of human breast epithelial progenitors. Breast Cancer Res, 2020. 22(1): p. 102.7. Cavagnero, K. J. and R.L. Gallo, Essential immune functions of fibroblasts in innate host defense. Front Immunol, 2022. 13: p. 1058862.8. Davidson, S., et al., Fibroblasts as immune regulators in infection, inflammation and cancer. Nat Rev Immunol, 2021.9. Wang, J. Y. and J. A. Doudna, CRISPR technology: A decade of genome editing is only the beginning. Science, 2023. 379(6629): p. eadd8643.10. Olguin-Martinez, E., B.E. Ruiz-Medina, and P. Licona-Limon, Tissue-Specific Molecular Markers and Heterogeneity in Type 2 Innate Lymphoid Cells. Front Immunol, 2021. 12: p. 757967.11. Liu, W., et al., Targeted regulation of fibroblast state by CRISPR-mediated CEBPA expression. Respir Res, 2019. 20(1): p. 281.12. Matjusaitis, M., et al., Reprogramming of Fibroblasts to Oligodendrocyte Progenitorlike Cells Using CRISPR / Cas9-Based Synthetic Transcription Factors. Stem Cell Reports, 2019. 13(6): p. 1053-1067.I l l299833684.1

Claims

CLAIMSWhat is claimed is:

1. A method of engineering fibroblasts, fibroblast-like cells, fibroblast-derived materials, stem cells, or stem cell-derived materials, comprising the step of adding, removing, and / or modifying one or more surface markers, or tissue-specific antigen bound thereto, on the respective fibroblasts, fibroblast-like cells, fibroblast-derived materials or fibroblast fragments, stem cells, or stem cell-derived materials, said markers selected from the group consisting of the markers in Marker List I, to thereby migrate to or target one or more specific tissues and / or one or more organs ofinterest with the engineered fibroblasts, fibroblast-like cells, fibroblast-derived materials, stem cells, or stem cell-derived materials.

2. The method of claim 1, wherein one or more markers are removed from the fibroblasts, fibroblast-like cells, fibroblast-derived materials, stem cells, or stem cell-derived materials.

3. The method of claim 1, wherein one or more markers are added to the fibroblasts, fibroblast-like cells, fibroblast-derived materials, stem cells, or stem cell-derived materials.

4. The method of claim 1, wherein one or more markers of the fibroblasts, fibroblast-like cells, fibroblast-derived materials, stem cells, or stem cell-derived materials are modified.

5. The method of claim 1, wherein the engineering step comprises use of CRISPR / CAS9, novel Cas Nucleases (NCN), CasMINI, Cas-CLOVER, Prokaryotic Argonautes (NgAgo), Zinc Finger Nucleases (ZFNs), and / or Transcription activator-Like Effector Nucleases (TALENs).

6. The method of claim 1, wherein the process is in vivo.

7. The method of claim 1, wherein the process is in vitro.

8. The method of claim 1, wherein the fibroblasts, fibroblast-like cells, fibroblast-derived materials, stem cells, or stem cell-derived materials are autologous with respect to an individual.112299833684.

19. The method of claim 1, wherein the fibroblasts, fibroblast-like cells, fibroblast-derived materials, stem cells, or stem cell-derived materials are allogeneic with respect to an individual.

10. The method of claims 1, wherein the fibroblasts, fibroblast-like cells, fibroblast-derived materials, stem cells, or stem cell-derived materials are xenogeneic with respect to an individual.

11. The method of claim 1, wherein the fibroblasts, fibroblast-like cells, fibroblast-derived materials, stem cells, or stem cell-derived materials are syngeneic with respect to an individual.

12. The method of claim 1, wherein the fibroblast-derived material comprises exosomes from fibroblasts.

13. The method of claim 12, wherein the exosomes derive from the engineered fibroblasts.

14. The method of claim 13, further comprising the step of collecting exosomes from the engineered fibroblasts.

15. The method of claim 1, wherein the fibroblast-derived material comprises organoids comprising fibroblasts, optionally wherein the organoids are spheroids.

16. The method of claim 1, wherein the fibroblast-derived material comprises organoids comprising the engineered fibroblasts, optionally wherein the organoids are spheroids.

17. The method of claim 16, further comprising the step of generating organoids from the engineered fibroblasts.

18. The method of claim 1, wherein the fibroblast-derived material comprises fibroblast cells separated from organoids comprising fibroblasts.

19. The method of claim 18, wherein the organoids are generated from the engineered fibroblasts.113299833684.

120. The method of claim 19, further comprising the step of generating the organoids from the engineered fibroblasts.

21. The method of claim 1, wherein the fibroblast-derived material comprises lysate from fibroblasts.

22. The method of claim 1, wherein the fibroblast-derived material comprises lysate from the engineered fibroblasts.

23. The method of claim 22, further comprising the step of generating the lysate from the engineered fibroblasts.

24. The method of claim 1, wherein the fibroblast-derived material comprises conditioned media from culture of fibroblasts.

25. The method of claim 24, wherein the conditioned media is from culture of the engineered fibroblasts.

26. The method of claim 25, further comprising the step of generating the conditioned media from the engineered fibroblasts.

27. The method of claim 1, wherein the fibroblast-derived material comprises apoptotic bodies from fibroblasts.

28. The method of claim 27, wherein the fibroblast-derived material comprises apoptotic bodies from the engineered fibroblasts.

29. The method of claim 28, further comprising the step of generating the apoptotic bodies from the engineered fibroblasts.

30. The method of claim 1, wherein the one or more markers is associated with liver, lung, thymus, intestines, kidney, and / or brain tissue or organs.114299833684.

131. The method of claim 1, further comprising the step of administering the engineered fibroblasts, fibroblast-like cells, fibroblast-derived materials, stem cells, or stem cell-derived materials to an individual in need thereof.

32. The method of claim 31, further comprising the step of administering one or more type of immune cells or derivative agents thereof to an individual in need thereof.

33. The method of claim 32, wherein the immune cells are T cells, natural killer cells, natural killer T cells, dendritic cells, macrophages, B cells, monocytes, or a mixture thereof.

34. The method of claim 31, wherein the engineered fibroblasts, fibroblast-like cells, fibroblast-derived materials, stem cells, or stem cell-derived materials are administered topically, intravenously, subcutaneously, intraperitoneally, and / or intrathecally.

35. The method of claim 31, wherein the engineered fibroblasts, fibroblast-like cells, fibroblast-derived materials, stem cells, or stem cell-derived materials are administered into any tissue or organ of interest.

36. The method of claim 31, wherein the engineered fibroblasts, fibroblast-like cells, fibroblast-derived materials, stem cells, or stem cell-derived materials are administered locally.

37. The method of claim 36, wherein the engineered fibroblasts, fibroblast-like cells, fibroblast-derived materials, stem cells, or stem cell-derived materials are administered by injection.

38. The method of claim 31, wherein the engineered fibroblasts, fibroblast-like cells, fibroblast-derived materials, stem cells, or stem cell-derived materials are administered systemically.

39. The method of claim 31, wherein the administering results in modulation of the expansion and proliferation of pathogenic immune cells in the individual.115299833684.

140. The method of claim 31, wherein the administering is into the blood stream or tissue or organ of interest of the individual.

41. The method of claim 31, wherein the administering is to a tissue or organ of interest of the individual using a biologic or other material-encapsulating device to assist in protection and / or dispersion of clinical benefits to the individual.

42. The method of claim 41, wherein the biologic or other material-encapsulating device comprises organic biomaterial.

43. The method of claim 41, wherein the biologic or other material-encapsulating device comprises alginate, agarose, collagen, and chitosan.

44. The method of claim 41, wherein the material-encapsulating device comprises one or more synthetic polymers.

45. The method of claim 44, wherein the one or more synthetic polymers comprises polyethylene glycol (PEG), poly(lactic-glycolic acid) (PLGA), poly(lactic acid) (PLA), poly(glycolic acid (PGA), or a combination thereof.

46. The method of claim 31, wherein said administering results directly or indirectly in the modulation of expression of pathogenic levels of cytokines, chemokines, and / or growth factors.

47. The method of claim 31, wherein said administering results directly or indirectly in the epigenetic reprogramming of localized fibroblasts and / or non-fibroblast cells associated with the targeted tissue or organ of interest.

48. The method of claim 31, wherein the fibroblasts and / or fibroblast-derived materials are activated with one or more agents and optionally one or more types of immune cells or derivative agent(s) thereof.

49. The method of claim 48, wherein the fibroblasts and / or fibroblast-derived materials are activated upon ex vivo treatment with one or more cytokines, one or more chemokines, one or116299833684.1more growth factors, one or more epigenetic modifiers, scRNA. microRNA, RNAi, or a combination thereof.

50. The method of claim 31, wherein the administering results directly or indirectly in enabling the activation and / or migration of localized stem cell niches to replace pathogenetic fibroblasts or other targeted tissue-specific or organ-specific cells.

51. The method of claim 31, wherein the administering utilizes one or more adjuvants with the engineered fibroblasts, fibroblast-like cells, fibroblast-derived materials, stem cells, or stem cell-derived materials.

52. The method of claim 51, wherein the administering directly or indirectly activates the immune system of the individual.

53. The method of claim 51, wherein the one or more adjuvants are chemical -based, viral - based, and / or bacterial-based.

54. The method of claim 51, wherein the adjuvant is selected from the group consisting of a mineral adjuvant, emulsion adjuvant, polymeric adjuvant, saponin, derivative of the complement system, cytokine, a bacterial -derived adjuvant, and a combination thereof.

55. The method of claim 31, further comprising administering encapsulated RNA, microRNA, and / or RNAi to the individual.

56. The method of claim 55, wherein the RNA, microRNA, or RNAi is directed to a transcription factor, cytosolic protein, and / or nuclear protein.

57. The method of claim 55, wherein the encapsulation is by lipids, nano-particles, glycolipids, membranes, or a combination thereof.

58. The method of claim 31, wherein the administering directly or indirectly results in locally activate tissue regeneration.117299833684.

159. An engineered fibroblasts, fibroblast-like cells, fibroblast-derived materials, stem cells, or stem cell-derived materials, produced according to the method of any one of claims 1-58.

60. A method of treating a disease or disorder in an individual, comprising the step of administering the engineered fibroblasts, fibroblast-like cells, fibroblast-derived materials, stem cells, or stem cell-derived materials from claim 59.

61. The method of claim 60, wherein the disease comprises cancer.118299833684.1